

**MFT TRUST FORMULARY****Manchester University**  
NHS Foundation Trust

	<b>BNF Chapter</b>
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

**Version 9.12 (December 2024)**

Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

## Formulary status definitions

**Formulary** (OK to be prescribed - but after any 1<sup>st</sup> or 2<sup>nd</sup> line options)

1<sup>st</sup> line formulary (when there are few formulary options, this is the 1<sup>st</sup> choice)

2<sup>nd</sup> line formulary (when there are few formulary options, this is the 2<sup>nd</sup> choice)

Where there is no preferred 1<sup>st</sup> line agent provided, the drug choice appears in alphabetical order.

1<sup>st</sup> line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



## PCT Red/Amber/Green classifications



### Adult RAG, DNP & Grey list Paediatric RAG, DNP & Grey list

#### Red

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

#### Amber

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP). [See here for a list of GMMMG approved SCPs.](#)

#### Green

Drugs that are suitable for initiation and ongoing prescribing within primary care.

#### Green

specialist initiation

Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

#### Green

following specialist recommendation

Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

**Do Not Prescribe:** DNP

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

**Grey:** Grey

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

**Unlicensed:** U

Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be highlighted in the template as follows: drug name<sup>U</sup>

### MMC Medicines Management Committee decision tables

Summary of Product Characteristics

Blueteq Enabled Forms

British National Formulary (BNF)

Controlled Drug

British National Formulary for Children (BNFC)

High Cost Medicine

NICE guidance

Payment by Results high cost excluded drug

**NOT STOCKED** Not routinely stocked, can be ordered if existing patient supply is exhausted

## PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY 

GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Paediatric **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

## Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (**No password required**)

British National Formulary for Children (**No password required**)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

# Section 1: Gastro-Intestinal System

Supported by the  
(click here)



## 1.1 Dyspepsia & gastro-oesophageal reflux disease

1.1.1 Antacids & Simeticone

1.1.2 Compound Alginates & Proprietary Indigestion Preparations

## 1.2 Anti-spasmodics & other drugs altering gut motility

Antimuscarinics

Other Antispasmodics

Motility Stimulants

## 1.3 Antisecretory drugs & mucosal protectants

1.3.1 H<sub>2</sub>-Receptor Antagonists

1.3.3 Chelates & Complexes

1.3.5 Proton Pump Inhibitors

## 1.4 Acute diarrhoea

1.4.2 Antimotility Drugs

## 1.5 Chronic bowel disorders

1.5.1 Aminosalicylates

1.5.2 Corticosteroids & Enemas

1.5.3 Drugs Affecting the Immune Response

Advanced therapies (biologic and targeted synthetic treatments)

## 1.6 Laxatives

1.6.1 Bulk-forming Laxatives

1.6.2 Stimulant Laxatives

1.6.3 Faecal Softeners

1.6.4 Osmotic Laxatives

1.6.5 Bowel Cleansing Preparation

1.6.6 Peripheral opioid-receptor antagonists

1.6.7 Other drugs used in constipation

## 1.7 Local preparations for anal & rectal disorders

1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids

1.7.4 Management of anal fissures

## 1.9 Drugs affecting intestinal secretions

1.9.1 Drugs affecting biliary composition & flow

1.9.2 Bile acid sequestrants

1.9.4 Pancreatin

## 1.10 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines

**GASTRO / ENDOSCOPY** - medicine & prescribing policies / guidelines (MFT Policy Hub)

**ADULT** - medicine & prescribing policies / guidelines (MFT Policy Hub)

**PAEDIATRIC** - medicine & prescribing policies / guidelines (MFT Policy Hub)

**NEONATAL** - medicine & prescribing policies / guidelines (MFT Policy Hub)

[Non-formulary Conversion Table](#)

## NICE Guidance

**Biosimilar Medicines (KTT15)**

**Faecal Incontinence (CG49)**

**Irritable Bowel Syndrome (CG61)**

**Diarrhoea and vomiting in children under 5 (CG84)**

**Constipation in children and young people (CG99)**

**Acute upper GI bleeding (CG141)**

**Dyspepsia and gastro-oesophageal reflux disease (CG184)**

**Coeliac disease: recognition, assessment and management (NG20)**

**Crohn's disease: management (NG129)**

**Ulcerative colitis: management (NG130)**

**Ulcerative colitis (acute exacerbations) - infliximab (TA163)**

**Crohn's disease - infliximab & adalimumab (TA187)**

**Constipation (women) - prucalopride (TA211)**

**Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)**

**Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)**

**Naloxegol for treating opioid induced constipation (TA345)**

**Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)**

**Obeticholic acid for treating primary biliary cholangitis (TA443)**

**Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)**

**Tofacitinib for moderately to severely active ulcerative colitis (TA547)**

**Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)**

**Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)**

**Naldemedine for treating opioid-induced constipation (TA651)**

**Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)**

**Filgotinib for treating moderately to severely active ulcerative colitis (TA792)**

**Teduglutide for treating short bowel syndrome (TA804)**

**Ozanimod for treating moderately to severely active ulcerative colitis (TA828)**

**Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)**

**Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)**

**Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)**

**Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)**

**Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)**

**Risankizumab for treating moderately to severely active ulcerative colitis (TA998)**

**Elafibranor for previously treated primary biliary cholangitis (TA1016)**

## GMMM Formulary

Formulary Homepage

Chapter 1: Gastro-Intestinal system (v8.5 Dec-24)

GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List

GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 1.1 Dyspepsia & gastro-oesophageal reflux disease



### 1.1.1 Antacids & Simeticone

#### Aluminium & Magnesium Containing Antacids

##### Co-magaldrox

195/220 suspension<sup>SF</sup>



**1<sup>st</sup> line use**

##### Magnesium trisilicate

suspension



#### Simeticone alone (activated dimeticone)

##### Simeticone

DNP

Infacol® 40mg/mL liquid



**RESTRICTED**  
**Paediatric use only**

#### 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

##### Alginate raft-forming oral suspensions<sup>SF</sup>

DNP

suspension



## 1.2 Anti-spasmodics & other drugs altering gut motility



### Antimuscarinics

#### Hyoscine butylbromide

tablets; injection



MHRA Drug Safety Update (Feb-17): Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease

#### Glycopyrronium bromide (Glycopyrrolate)

Green

(Robinul®, Sialanar®) tablets; injection; oral solution; cream



### Other Antispasmodics

#### Mebeverine hydrochloride

135mg tablets

1<sup>st</sup> line use

#### Peppermint oil

capsules



#### Alverine citrate with simeticone

SimAlvia® 60mg/300mg capsules



### Motility Stimulants

#### Metoclopramide

10mg tablets (see also section 4.6)

1<sup>st</sup> line use

MHRA (Aug-13): Metoclopramide: risk of neurological adverse effects

#### Domperidone

Green

10mg tablets (see also section 4.6)

Use where 1<sup>st</sup> line unsuitable

MHRA Drug Safety Update (Dec19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects

MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects

## 1.3 Antisecretory drugs & mucosal protectants



### 1.3.1 H<sub>2</sub>-receptor antagonists

#### Famotidine

Green

20mg; 40mg tablets

MMC BNF emc

#### Ranitidine

150mg; 300mg tablets

  
BNF emc


### 1.3.3 Chelates & Complexes

#### Sucralfate

Green

1g tablets; oral suspension

  
MMC BNF emc

#### Bismuth subsalicylate (*Pepto-Bismol*®)

262.5mg chewable tablets

  
MMC BNF emc

**RESTRICTED**  
Adults, H. Pylori eradication regime

### 1.3.5 Proton Pump Inhibitors

#### Omeprazole

10mg; 20mg; 40mg capsules; 40mg infusion

  
BNF emc

#### Lansoprazole

15mg &amp; 30mg capsules; 15mg &amp; 30mg orodispersible tablets

  
MMC BNF emc

**RESTRICTED**  
tablets - enteral feeding tubes /  
dysphagia

#### Esomeprazole

40mg infusion

  
MMC BNF emc

**RESTRICTED**  
PPI indicated / enteral route not  
available/appropriate

MHRA (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice

MHRA Drug Safety Update (Sep-15): Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus

**Other PPIs are not available at this Trust**



# 1.4 Acute diarrhoea



## 1.4.2 Antimotility Drugs

### Loperamide hydrochloride

DNP

2mg capsules; 1mg/5mL syrup<sup>SF</sup>



**1<sup>st</sup> line use**

### Codeine phosphate

15mg; 30mg & 60mg tablets



**RESTRICTED**  
Adults - high output stomas

### Teduglutide



Revestive ® injection



**RESTRICTED** Gastro. Consultants  
only in line with NICE TA804

# 1.5 Chronic bowel disorders



## 1.5.1 Aminosalicylates

### Mesalazine

Green

tablets; M/R tablets; M/R granules; enema; foam enema; suppositories



**PRESCRIBE BY BRAND NAME**

### Balsalazide sodium

750mg capsules



## 1.5.2 Corticosteroids & Enemas

### Prednisolone

5mg tablets



**1<sup>st</sup> line use**

### Budesonide (*Budenofalk*®)

3mg capsules; rectal foam



### Budesonide (*Jorveza*®)

Green

1mg orodispersible tablets



**RESTRICTED**  
Adults - eosinophilic esophagitis

### Budesonide

Green

3mg CR capsules



**RESTRICTED**  
Adults - Gastro. Consultants only

### Hydrocortisone

foam enema



### Short chain fatty acid (SCFA) enema



Nutricol® / Prulab Pharma enema

MMC

**RESTRICTED**  
Adults - Gastro. Consultants only

## 1.5.3 Drugs Affecting the Immune Response

### Azathioprine

Amber

tablets; oral solution (see also sections 8.2.1; 10.1.3 & 13.5.3)



**1<sup>st</sup> line use**

### Ciclosporin (oral and I.V. preparations)

Amber

capsules; infusion; oral solution (see also section 8.2.2)



### Mercaptopurine

Amber

tablets; oral suspension (see also section 8.1.3)



### Methotrexate (s/c and oral preparations)

Amber

tablets; injection; oral solution (see also section 10.1.3)



MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions

MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing

### Advanced therapies (*biologic and targeted synthetic treatments*)

### Adalimumab

Red

££

injection (see also sections 10.1.3, 11.4.2 & 13.5.3)



**RESTRICTED** Gastro. Consultants for IBD as per NICE

MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely

### Infliximab

Red

££

infusion (see also sections 10.1.3 & 13.5.3)



**RESTRICTED** Gastro. Consultants for IBD as per NICE

MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely

### Etrasimod

Red

££

*Velsipity*® tablets



**RESTRICTED** Gastro. Consultants in line with NICE TA956

### Filgotinib

Red

££

*Jyseleca*® 100mg; 200mg tablets (see also section 10.1.3)



**RESTRICTED** Gastro. Consultants for Ulcerative colitis as per NICE

MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality

### Golimumab

Red

££

injection (see also section 10.1.3)



**RESTRICTED** Gastro. Consultants for IBD as per NICE

MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely

### Mirikizumab
































































Red

££

*Omvo*® injection; infusion



**RESTRICTED** Gastro. Consultants in line with NICE TA925

<p><b>Ozanimod</b>                         Zeposia® capsules       </p>	<p><b>RESTRICTED</b> Gastro. Consultants in line with NICE TA828</p>
<p><b>Risankizumab</b>                         Skyrizi® 75mg; 150mg injection (see also section 13.5.3)       </p>	<p><b>RESTRICTED</b>                      Specialist use only in line with NICE TA888 / TA998</p>
<p><b>Tofacitinib</b>                         tablets (see also section 10.1.3)       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality                      MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies                      MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of VTE and of serious and fatal infections                      MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing</p>	
<p><b>Upadacitinib</b>                         MR tablet (see also sections 10.1.3 and 13.5.3)       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE TA856 / TA905</p>
<p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality</p>	
<p><b>Ustekinumab</b>                         Stelara® injection (see also sections 10.1.3 &amp; 13.5.3)       </p>	<p><b>RESTRICTED</b> Gastro. Consultants as per NICE</p>
<p><b>Ustekinumab</b>                         Wezenla® injection (see also sections 10.1.3 &amp; 13.5.3)       </p>	<p><b>RESTRICTED</b> Gastro. Consultants as per NICE / <b>NOT</b> ulcerative colitis</p>
<p><b>Vedolizumab</b>                         infusion       </p>	<p><b>RESTRICTED</b> Gastro. Consultants for IBD as per NICE</p>
<p><b>ICAM-1 Inhibitor</b></p>	
<p><b>Alicaforsen</b>                         enema      </p>	<p><b>RESTRICTED</b>                      Gastro. Consultants only - pouchitis</p>

## 1.6 Laxatives



### 1.6.1 Bulk-forming Laxatives

#### Ispaghula husk

3.5g sachets

1<sup>st</sup> line use

### 1.6.2 Stimulant Laxatives

#### Docusate sodium

capsules; oral solution

1<sup>st</sup> line use

#### Senna

DNP

tablets; oral solution

1<sup>st</sup> line use

MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use

#### Bisacodyl

tablets; suppositories



MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use

#### Glycerol

suppositories



#### Sodium picosulfate

oral solution



MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use

#### Co-danthramer

oral suspension



**RESTRICTED**  
Adults, Palliative Care only

#### Co-danthrusate

oral suspension



**RESTRICTED**  
Adults, Palliative Care only

### 1.6.3 Faecal Softeners

#### Arachis oil

enema



### 1.6.4 Osmotic Laxatives

#### Lactulose

DNP

oral solution

1<sup>st</sup> line use

#### Macrogols (Polyethylene glycols)

DNP

sachets



2<sup>nd</sup> / 3<sup>rd</sup> line use Rehab patients /  
paediatrics

#### Phosphates (Rectal)

128mL enema



#### Sodium citrate (Rectal)

450mg micro-enema



### 1.6.5 Bowel Cleansing Preparations

NPSA RRR (Feb-09): Reducing risk of harm from oral bowel cleansing solutions

#### Sodium picosulfate with magnesium citrate

Picolax® oral powder

1<sup>st</sup> line use

#### Macrogols (Klean-Prep® & Moviprep®) oral powder

oral powder



### 1.6.6 Peripheral opioid-receptor antagonists

#### Methylnaltrexone bromide

injection



**RESTRICTED**  
Adults, Palliative Care only

#### Naldemedine

Green

200 microgram tablets



**RESTRICTED**  
Adults only in line with TA651

#### Naloxegol

Green

12.5mg; 25mg tablets



**RESTRICTED**  
Adults only in line with TA345

**1.6.7 Other drugs used in constipation****Prucalopride**

Green

1mg; 2mg tablets

NICE MMC BNF emc

**RESTRICTED - Adult women, Gastro.  
Consultants only****Linaclootide**

Green

290 micrograms capsules

MMC BNF emc

**RESTRICTED - 3<sup>rd</sup> line use Adults  
Gastro. Consultants only**

# 1.7 Local preparations for anal & rectal disorders



## 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids

**Anusol®**

DNP

ointment



**Proctosedyl®**

ointment



**Scheriproct®**

ointment; suppositories



## 1.7.4 Management of anal fissures

**Glyceryl trinitrate**

Rectogesic® 0.4% ointment



**1<sup>st</sup> line for anal fissure**

**Diltiazem hydrochloride**

**U** Green

2% cream; ointment



# 1.9 Drugs affecting intestinal secretions



## 1.9.1 Drugs affecting biliary composition & flow

<p><b>Ursodeoxycholic acid</b></p> <p>150mg tablets</p> <p><b>MMC</b> <b>BNF</b> <b>emc</b></p>	<p><b>1<sup>st</sup> line use</b></p>
<p><b>Obeticholic acid</b></p> <p><b>Red</b> <b>££</b></p> <p>Ocaliva® 5mg; 10mg tablets</p> <p><b>PbR X</b> <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>blueiq</b></p>	<p><b>RESTRICTED</b> Hepatology Consultants only 2<sup>nd</sup> line per TA443</p>
<p><b>Elafibranor</b></p> <p><b>Red</b> <b>££</b></p> <p>Iqirvo® 80mg tablets</p> <p><b>PbR X</b> <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>blueiq</b></p>	<p><b>RESTRICTED</b> Hepatology Consultants only as per TA1016</p>
<h2>1.9.2 Bile acid sequestrants</h2>	
<p><b>Colestyramine</b></p> <p><b>Green</b></p> <p>powder 4g sachet (see also section 2.12)</p> <p><b>BNF</b> <b>emc</b></p>	<p><b>1<sup>st</sup> line use</b></p>
<p><b>Coesevelam hydrochloride</b></p> <p><b>Green</b></p> <p>625mg tablets (see also section 2.12)</p> <p><b>MMC</b> <b>BNF</b> <b>emc</b></p>	<p><b>RESTRICTED</b> adults. Gastro &amp; Lipid Clinic Consultants only</p>
<h2>1.9.4 Pancreatin</h2>	
<p><b>Pancreatin</b></p> <p><b>Green</b></p> <p>capsules</p> <p><b>BNF</b> <b>emc</b></p>	<p><b>NOT STOCKED</b></p>

# 1.10 Miscellaneous preparations



## Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 8.4, 10.4 & 13.14)



**RESTRICTED**  
2<sup>nd</sup> line rescue therapy





# Non-Formulary Items



<p><b>Darvadstrocel</b> DNP Alofisel® 5 million cells/mL injection</p>	<p>NICE MMC emc</p>	<p><b>REJECTED in line with NICE TA556</b></p>
<p><b>Dicycloverine hydrochloride</b> DNP</p>	<p>BNF emc</p>	<p><b>in line with GMMMG</b></p>
<p><b>IQoro</b> DNP Neuromuscular training device</p>		<p><b>in line with GMMMG</b></p>
<p><b>Lubiprostone</b> DNP capsules</p>	<p>NICE MMC emc</p>	<p><b>Discontinued Jan-19</b></p>
<p><b>OTC haemorrhoid preparations</b> DNP</p>	<p>BNF emc</p>	<p><b>in line with GMMMG</b></p>
<p><b>Racecadotril</b> DNP capsules; granules for oral suspension; tablets</p>	<p>NICE BNF emc</p>	<p><b>in line with GMMMG</b></p>
<p><b>Rifaximin</b> DNP 200mg tablets (see also section 5.1.7)</p>	<p>NICE MMC BNF emc</p>	<p><b>in line with GMMMG for Traveller's diarrhoea</b></p>
<p><b>VSL#3® / Vivomixx® food supplement</b> DNP</p>		<p><b>in line with GMMMG</b></p>

## Section 2: Cardiovascular System

Supported by the  
formulary (click here)



### 2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

### 2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

### 2.3 Anti-arrhythmic drugs

- 2.3.2 Drugs for Arrhythmias

### 2.4 Beta-adrenoceptor blocking drugs

### 2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
  - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
  - 2.5.5.2 Angiotensin-II Receptor Antagonists
  - 2.5.5.3 Renin Inhibitors
  - 2.5.5.4 Heart Failure

### 2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

### 2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

### 2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

### 2.9 Antiplatelet drugs

### 2.10 Stable angina, acute coronary syndromes & fibrinolysis

- 2.10.2 Fibrinolytic Drugs

### 2.11 Antifibrinolytic drugs & haemostatics

### 2.12 Lipid-regulating drugs

### 2.13 Local sclerosants

### 2.14 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines

CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Prophylaxis against infective endocarditis (CG64)  
 Familial hypercholesterolaemia (CG71)  
 Chest pain of recent onset (CG95)  
 Stable angina (CG126)  
 Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)  
 Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)  
 Chronic heart failure in adults: diagnosis and management (NG106)  
 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)  
 Hypertension in pregnancy: diagnosis and management (NG133)  
 Hypertension in adults: diagnosis and management (NG136)  
 Acute coronary syndromes (NG185)  
 Atrial fibrillation: diagnosis and management (NG196)  
 Volanesorsen for treating familial chylomicronaemia syndrome (HST13)  
 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47)  
 Myocardial infarction - thrombolysis (TA52)  
 Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)  
 Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated by TA95 & TA126)  
 Hypercholesterolaemia - Ezetimibe (TA132)  
 Coronary artery disease - drug eluting stents (TA152)  
 Venous thromboembolism - dabigatran (TA157)  
 Rivaroxaban for the prevention of VTE (TA170)  
 Atrial Fibrillation - dronedarone (TA197)  
 Vascular disease - clopidogrel and dipyridamole (TA210)  
 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)  
 Acute coronary syndromes - ticagrelor (TA236)  
 Venous thromboembolism - apixaban (hip and knee surgery) (TA245)  
 Atrial fibrillation - dabigatran etexilate (TA249)  
 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)  
 Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)  
 Stroke (acute, ischaemic) - alteplase (TA264)  
 Chronic heart failure - ivabradine (TA267)  
 Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)  
 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)  
 Prasugrel with PCI for treating ACS (review of TA182) (TA317)  
 Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)  
 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)  
 Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)  
 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)  
 Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)  
 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)  
 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)  
 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)  
 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)  
 Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)  
 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)  
 Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)  
 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)  
 andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)  
 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)  
 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)  
 Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)  
 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)  
 Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)  
 Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)  
 Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)  
 Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)  
 Tenecteplase for treating acute ischaemic stroke (TA990)  
 Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

## GMMMG Formulary

Formulary Homepage  
 Chapter 2: Cardiovascular system (v8.5 - Dec-24)  
 GMMMG Adult [Red/Amber/Green](#); DNP and [Grey](#) Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

## 2.1 Positive inotropic drugs



### 2.1.1 Cardiac Glycosides

#### Digoxin

tablets; elixir; injection

1<sup>st</sup> line use

#### Digoxin-specific antibody



infusion



### 2.1.2 Phosphodiesterase Inhibitors

#### Enoximone

Perfan® 5mg/1mL injection



#### Milrinone

Primacor® 10mg/10mL injection

1<sup>st</sup> line use Paediatrics

#### Levosimendan

Simdax® 12.5mg/5mL Injection



**RESTRICTED** adults.  
Cardiology ITU Consultant only

## 2.2 Diuretics



### 2.2.1 Thiazides & Related Diuretics

#### Bendroflumethiazide

tablets

1<sup>st</sup> line use

#### Chlortalidone

tablets



#### Metolazone

Green

tablets

2<sup>nd</sup> line use with loop diuretic

MHRA Drug Safety Update (Jan-23): Xaqu (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations

### 2.2.2 Loop Diuretics

#### Furosemide

tablets; liquid; injection

1<sup>st</sup> line use

#### Bumetanide

tablets; oral solution

2<sup>nd</sup> line use

### 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists

#### Amiloride hydrochloride

tablets; oral solution

1<sup>st</sup> line use

#### Spirolactone

tablets

1<sup>st</sup> line use

MHRA Drug Safety Update (Feb-16): Spirolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

#### Eplerenone

Green

tablets



**RESTRICTED** adults.  
Cardiology Consultant only

#### Finerenone

Green

Kerendia® tablets



**RESTRICTED** adults.  
Diabetes / Renal Consultant only

### 2.2.4 Potassium-sparing Diuretics with other Diuretics

#### Co-amilofruse

tablets

1<sup>st</sup> line use

### 2.2.5 Osmotic Diuretics

#### Mannitol

infusion



## 2.3 Anti-arrhythmic drugs



### 2.3.2 Drugs for Arrhythmias

#### Adenosine

injection



#### Amiodarone hydrochloride

Amber

Red

tablets; injection



MHRA Drug Safety Update (Mar-22): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision

#### Disopyramide

capsules; tablets



#### Flecainide acetate

Red

Paeds - until stabilised then

Green

tablets; injection



#### Lidocaine (lignocaine) hydrochloride

injection (see also section 15.2)



#### Mexiletine

Red

NaMuscla® 167mg capsules



#### Mexiletine hydrochloride

U

Mexitil® 50mg; 100mg; 200mg capsules



#### Propafenone hydrochloride

tablets



#### Dronedarone

Green

tablets



**RESTRICTED**  
Neurology only

**RESTRICTED**  
Cardiology / Neurology only

**RESTRICTED** adults. Cardiology  
Consultant only, in line with TA197

MHRA Drug Safety Update (Oct-11): Dronedarone (Multaq ▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements

## 2.4 Beta-adrenoceptor blocking drugs



		NICE NG106
		NICE NG136
2.4 Beta-Adrenoceptor Blocking Drugs		NICE NG196
<b>Atenolol</b> tablets; liquid; injection	 	
<b>Bisoprolol fumarate</b> tablets	  	<b>RESTRICTED</b> adults. Cardiology Consultant only
<b>Carvedilol</b> tablets	  	<b>RESTRICTED</b> adults. Cardiology Consultant only <b>ALSO 2ND LINE FOR VARICEAL BLEED</b>
<b>Esmolol hydrochloride</b> injection	 	<b>RESTRICTED</b> .I.V. only
<b>Etilefrine hydrochloride</b>  tablets		<b>RESTRICTED</b> Haematology Consultants - SCD
<b>Labetalol hydrochloride</b> tablets; injection	 	<b>RESTRICTED</b> oral preps in pregnancy
<b>Metoprolol tartrate</b> tablets; injection	 	
<b>Nadolol</b> tablets	  	<b>RESTRICTED</b> paed. ventricular arrhythmias in long QT syndrome
<b>Nebivolol</b> tablets	 	
<b>Propranolol hydrochloride</b> tablets; capsules; oral solution; injection	  	<b>RESTRICTED</b> not in Cardiology
<b>Sotalol hydrochloride</b> tablets	 	

## 2.5 Hypertension & heart failure































		NICE NG106
		NICE NG136
		NICE NG196
2.5.1 Vasodilator Antihypertensive Drugs		NHSE PAH
<b>Hydralazine hydrochloride</b>		1 <sup>st</sup> line use
tablets; injection		
<b>Minoxidil</b>		
tablets		
<b>Ambrisentan</b>		<b>RESTRICTED</b> PAH in line with NHSE
tablets		
<b>Bosentan</b>		<b>RESTRICTED</b> PAH in line with NHSE
tablets		
<b>Sildenafil</b>		<b>RESTRICTED</b> PAH in line with NHSE
Revatio® tablets; injection (see also section 7.4.5)		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio and Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
<b>Macitentan</b>		<b>RESTRICTED</b> PAH in line with NHSE
Opsumit® tablets		
<b>Tadalafil</b>		<b>RESTRICTED</b> PAH in line with NHSE
Adcirca® tablets (see also section 7.4.5)		
2.5.2 Centrally Acting Antihypertensive Drugs		
<b>Clonidine hydrochloride</b>		
tablets; oral solution; injection; patches		
<b>Methyldopa</b>		
tablets		
<b>Moxonidine</b>		<b>RESTRICTED 3<sup>rd</sup> line use</b> after other treatments fail
tablets		
2.5.4 Alpha-Adrenoceptor Blocking Drugs		
<b>Doxazosin</b>		1 <sup>st</sup> line use
1mg; 2mg & 4mg tablets		
<b>Phenoxybenzamine hydrochloride</b>		<b>RESTRICTED adults.</b> Specialist initiation only
10mg capsules		
<b>Phentolamine mesilate</b>		<b>RESTRICTED adults.</b> Specialist use, theatres only
injection		
2.5.5 Drugs Affecting the Renin-Angiotensin System		
2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
<b>Ramipril</b>		
1.25mg; 2.5mg; 5mg & 10mg capsules		
<b>Captopril</b>		<b>RESTRICTED</b> Paediatrics only
12.5mg; 25mg & 50mg tablets		
<b>Lisinopril</b>		1 <sup>st</sup> line use
2.5mg; 5mg; 10mg & 20mg tablets		
<b>Perindopril erbumine</b>		
2mg; 4mg & 8mg tablets		



**2.5.5.2 Angiotensin-II Receptor Antagonists**

MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

<b>Candesartan cilexetil</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> 2mg; 4mg; 8mg; 16mg & 32mg tablets   	<b>1<sup>st</sup> line use</b> hypertension 
<b>Losartan potassium</b> 12.5mg; 25mg; 50mg & 100mg tablets   	<b>2<sup>nd</sup> line use</b> hypertension
<b>Irbesartan</b> 75mg; 150mg & 300mg tablets   	<b>2<sup>nd</sup> line use</b> hypertension
<b>Valsartan</b> 40mg; 80mg & 160mg capsules   	<b>2<sup>nd</sup> line use</b> hypertension
<b>Sacubitril / Valsartan</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> 24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets    	<b>RESTRICTED</b> use in line with NICE TA388
<b>2.5.5.3 Renin inhibitors</b>	
<b>Aliskiren</b> <span style="border: 1px solid black; padding: 2px;">DNP</span> 150mg; 300mg tablets   	<b>RESTRICTED adults.</b> Specialist initiation only
MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardiovascular and renal adverse reactions	
<b>2.5.5.4 Heart Failure</b>	
<b>Dapagliflozin</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> Forxiga ® tablets    	<b>RESTRICTED adults.</b> Specialist initiation in line with TA679
<b>Empagliflozin</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> Jardiance ® tablets    	<b>RESTRICTED adults.</b> Specialist initiation in line with TA773

## 2.6 Nitrates, calcium-channel blockers & other antianginals



### 2.6.1 Nitrates

#### Glyceryl trinitrate

S/L tablets; S/L spray; patches; Injection; ointment



#### Isosorbide mononitrate

tablets; capsules



### 2.6.2 Calcium-channel Blockers

#### Amlodipine

tablets; oral solution



**1<sup>st</sup> choice dihydropyridine**



#### Diltiazem hydrochloride

tablets; capsules; ointment



**1<sup>st</sup> choice non-dihydropyridine  
PRESCRIBE BY BRAND NAME**

#### Nifedipine

tablets; capsules; oral drops



**2<sup>nd</sup> choice dihydropyridine  
PRESCRIBE BY BRAND NAME**

#### Verapamil hydrochloride

tablets; injection; oral solution



**2<sup>nd</sup> choice non-dihydropyridine**

#### Nimodipine

tablets; infusion



**RESTRICTED subarachnoid haemorrhage / I.V. then oral**

### 2.6.3 Other Antianginal Drugs

#### Nicorandil

tablets



**1<sup>st</sup> line use**

MHRA Drug Safety Update (Jan-16): Nicorandil (Ikorel): now 2nd-line treatment for angina - risk of ulcer complications

#### Ivabradine

Green

tablets



**RESTRICTED adults 2<sup>nd</sup> line. Cardiology Consultant only**

MHRA Drug Safety Update (Dec-14): Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects

#### Ranolazine

Green

M/R tablets



**RESTRICTED adults 3<sup>rd</sup> line angina patients not suitable for surgery**

### 2.6.4 Peripheral Vasodilators & Related Drugs

#### Naftidrofuryl oxalate

capsules



#### Defibrotide

Red

££

infusion

PbR X



**RESTRICTED Specialist use only in line with NHSE**



## 2.7 Sympathomimetics



### 2.7.1 Inotropic Sympathomimetics

<b>Dobutamine</b> infusion	 	<b>RESTRICTED / V.</b> Specialist use only
<b>Dopamine hydrochloride</b> infusion	 	<b>RESTRICTED / V.</b> Specialist use only
<b>Dopexamine</b> infusion	 	<b>RESTRICTED / V.</b> Specialist use only
<b>Isoprenaline</b> injection	 	<b>RESTRICTED / V.</b> Specialist use only

### 2.7.2 Vasoconstrictor Sympathomimetics

<b>Adrenaline acid tartrate</b>  1 in 1000 (0.1%w/v) cutaneous solution	  	<b>Specialist use endoscopic sinus surgery</b>
<b>Ephedrine hydrochloride</b> injection	 	<b>RESTRICTED / V.</b> Specialist use only
<b>Metaraminol</b>  injection	 	
<b>Midodrine</b>  tablets	  	<b>Specialist use Cardiology / Healthcare of the elderly</b>
<b>Noradrenaline acid tartrate</b> infusion	 	<b>RESTRICTED / V.</b> Specialist use only
<b>Phenylephrine hydrochloride</b> injection	 	<b>RESTRICTED / V.</b> Specialist use only
<b>2.7.3 Cardiopulmonary Resuscitation</b>		
<b>Adrenaline / Epinephrine</b> injection	 	

## 2.8 Anticoagulants & protamine



2.8.1 Parenteral Anticoagulants		NICE NG89
<b>ACD-A Anticoagulant Citrate Dextrose</b>		<b>RESTRICTED</b> Specialist use only CRRT
solution	MMC BNF emc	
<b>Dalteparin sodium</b>		1 <sup>st</sup> line LMWH
injection	MMC BNF emc	
<b>Epoprostenol</b>		<b>RESTRICTED</b> / I.V. Specialist use only
infusion	PbR X BNF emc	
MHRA Drug Safety Update (Dec-14): Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices		
<b>Heparin</b>		
injection; infusion	BNF emc	
<b>Bivalirudin</b>		<b>RESTRICTED</b> adults. Cardiac Catheter Lab only.
infusion	NICE MMC BNF emc	
<b>Fondaparinux sodium</b>		<b>RESTRICTED</b> adults. Haematology Consultants only.
injection	MMC BNF emc	
<b>Tinzaparin sodium</b>		<b>RESTRICTED</b> Obs & Gynae; ACS & VTE in Renal impairment only. Paeds: haemodialysis
injection	MMC BNF emc	
<b>Enoxaparin sodium</b>		<b>RESTRICTED</b> ACS & VTE in Renal impairment only.
injection	MMC BNF emc	
<b>Argatroban monohydrate</b>		<b>RESTRICTED</b> adults. Treatment of HIT
infusion	MMC BNF emc	
2.8.2 Oral Anticoagulants		
<b>Acenocoumarol</b>		<b>RESTRICTED</b> warfarin intolerant patients only.
tablets	BNF emc	
<b>Phenindione</b>		
tablets	BNF emc	
<b>Warfarin sodium</b>		
tablets	PbR X BNF emc	
MHRA Drug Safety Update (Jun-24): Warfarin: be alert to the risk of drug interactions with tramadol		
MHRA Drug Safety Update (Oct-20): Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic		
MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR		
MHRA Drug Safety Update (Jul-16): Warfarin: reports of calciphylaxis		
<b>Apixaban</b>		<b>RESTRICTED</b> in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
<b>Dabigatran etexilate</b>		<b>RESTRICTED</b> in line with NICE
capsules	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
MHRA Drug Safety Update (Jul-12): Dabigatran (Pradaxa ▼): risk of serious haemorrhage		
<b>Edoxaban</b>		<b>RESTRICTED</b> in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
<b>Rivaroxaban</b>		<b>RESTRICTED</b> in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
MHRA Drug Safety Update (Jul-19): Rivaroxaban (Xarelto ▼): reminder that 15 mg and 20 mg tablets should be taken with food		
MHRA Drug Safety Update (Oct-18): Rivaroxaban (Xarelto ▼) after TAVR: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial		

**Antidotes****Andexanet alfa**

Ondexxya® infusion

**RESTRICTED** in line with NICE**Idarucizumab**

Praxbind® infusion





























**RESTRICTED** reversal of dabigatran  
in emergency surgery**2.8.3 Protamine Sulfate****Protamine sulfate**

injection



## 2.9 Antiplatelet drugs



		NICE NG185
<b>Aspirin</b> tablets (dispersible & E/C); suppositories  		
<b>Clopidogrel</b> tablets MHRA Drug Safety Update (Dec-13): Clopidogrel: risk of acquired haemophilia MHRA Drug Safety Update (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice     		For ACS patients; stroke patients intolerant of aspirin; high-risk patients stroked on aspirin
<b>Ticagrelor</b> Green tablets; orodispersible tablets    		In combination with aspirin for primary PCI in ACS patients & in line with NICE TA420
<b>Prasugrel</b> Green tablets MHRA Drug Safety Update (Jan-14): Prasugrel (Efient): increased risk of bleeding MHRA Drug Safety Update (May-11): Prasugrel (Efient ▼): rare but serious hypersensitivity reactions     		<b>RESTRICTED</b> adults. Cardiac Catheter Lab as per NICE
<b>Dipyridamole</b> M/R capsules; oral suspension; tablets; injection    		2 <sup>RY</sup> prevention of stroke in patients already on aspirin
<b>Tirofiban</b> infusion    		<b>RESTRICTED</b> adults. Cardiac Catheter Lab only (1 <sup>st</sup> line)
<b>Eptifibatide</b> injection; infusion    		<b>RESTRICTED</b> adult patients admitted on this or tirofiban

## 2.10 Stable angina, ACS & fibrinolysis



- Stable angina (BNF treatment summary)
- Acute coronary syndromes (BNF treatment summary)
- Fibrinolytic Drugs (BNF treatment summary)

### 2.10.2 Fibrinolytic Drugs

NICE CG126

NICE NG128

#### Tenecteplase

Red

injection

NICE MMC BNF emc

#### Streptokinase

Red

infusion

NICE BNF emc

#### Urokinase

Red

injection

BNF emc

#### Alteplase

Red

injection; infusion

NICE MMC BNF emc

**RESTRICTED**

## 2.11 Antifibrinolytic drugs & haemostatics



### Antifibrinolytic Drugs & Haemostatics

<b>Etamsylate</b>		
tablets		
<b>Tranexamic acid</b>		
injection; tablets		
<b>Aprotinin</b>		<b>RESTRICTED</b>
infusion		
<b>Aminocaproic acid</b>		<b>RESTRICTED</b>
sachets		
<b>Emicizumab</b>		<b>RESTRICTED</b> Haematology as per NHSE
Hemlibra® injection		
<b>Vonicog alfa</b>		<b>RESTRICTED</b> Haematology as per NHSE
Veyvondi® injection		



## 2.12 Lipid-regulating drugs



Statins		
<b>Simvastatin</b>		
tablets		
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
<b>Atorvastatin</b>		<b>1<sup>st</sup> line use</b>
tablets		
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
<b>Rosuvastatin</b>		<b>RESTRICTED</b> <b>Not stocked</b>
tablets		
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
<b>Pravastatin sodium</b>		<b>RESTRICTED MCSH</b> for cases with potential drug interactions
tablets		
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Bile Acid Sequestrants		
<b>Colestyramine</b>		
sachets (see also section 1.9.2)		
<b>Colesevelam hydrochloride</b>		<b>RESTRICTED</b> adults. Gastro & Lipid Clinic Consultants only
tablets (see also section 1.9.2)		
Fibrates		
<b>Bezafibrate</b>		<b>1<sup>st</sup> line use</b>
M/R tablets; tablets		
<b>Fenofibrate</b>		<b>2<sup>nd</sup> line use</b>
67mg / 200mg / 267mg capsules; 160mg tablets		
Omega-3 fatty acid compounds		
<b>Omega-3-acid ethyl esters</b>		<b>2<sup>RY</sup> prevention post MI / Prevention of preterm birth</b>
capsules		
MHRA Drug Safety Update (Jan-24): Omega-3-acid ethyl ester (1000mg caps): dose-dependent increased risk of AF in patients with established CV diseases or CV risk factors		
<b>Ezetimibe</b>		<b>RESTRICTED</b> adults. Lipid Clinic Consultants only
10mg tablets		
Lipid-regulating drugs		
<b>Alirocumab</b>		<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with TA393
Praluent® injection		
<b>Bempedoic acid (see also Nustendi®)</b>		<b>RESTRICTED</b> adults. Consultants in line with TA694
Nilemdo® tablets		
<b>Bempedoic acid with ezetimibe (see also Nilemdo®)</b>		<b>RESTRICTED</b> adults. Consultants in line with TA694
Nustendi® tablets		
<b>Evinacumab</b>		<b>RESTRICTED</b> adults. Consultants in line with TA1002
Repatha® injection		
<b>Evolocumab</b>		<b>RESTRICTED.</b> Lipid Clinic Consultants only for HoFH / & NICE TA394
Repatha® injection		
<b>Icosapent ethyl</b>		<b>RESTRICTED</b> adults in line with NICE TA805
Vazkepa® capsules		
<b>Inclisiran</b>		<b>RESTRICTED</b> adults. Consultants in line with TA733 for Primary Care Referral
Leqvio® injection		
<b>Lomitapide</b>		<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with NHSE
Lojuxta® capsules		



**Volanesorsen**

Red   
Waylivra® injection



**RESTRICTED** adults. Lipid Clinic  
Consultants in line with HST13

## 2.13 Local sclerosants



### Local Sclerosants

**Ethanolamine oleate**

injection




























**Sodium tetradecyl sulfate**

injection



## 2.14 Miscellaneous preparations



<p><b>Ajmaline</b>    <i>Gilurytmal</i>® 50mg/10mL injection  </p>	<p><b>RESTRICTED</b> adults.                  Cardiology Consultant only</p>
<p><b>Dapagliflozin</b>                    tablets      </p>	<p><b>RESTRICTED</b>                  in line with NICE TA679 / TA902</p>
<p>MHRA Drug Safety Update (Dec-21): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus</p>	
<p><b>Empagliflozin</b>                    tablets      </p>	<p><b>RESTRICTED</b>                  in line with NICE TA929</p>
<p><b>Mavacamten</b>     <i>Camzyos</i>® capsules       </p>	<p><b>RESTRICTED specialist use</b>                  in line with NICE TA913</p>
<p><b>Regadenoson</b>    <i>Rapiscan</i>® 400micrograms/5mL injection   </p>	<p><b>RESTRICTED</b> adults.                  Myocardial perfusion scans</p>

Non-Formulary Items		GMMMG
<b>Cilostazol</b> DNP <i>Pletal® 50mg; 100mg tablets</i>	   	<b>REJECTED in line with NICE TA223</b>
<b>Doxazosin</b> DNP <i>MR tablets / 8mg immediate release tablets</i>	   	
<b>Inositol nicotinate</b> DNP <i>Hexopal® tablets</i>	   	<b>REJECTED in line with NICE TA223</b>
<b>Pentoxifylline</b> DNP <i>Trental® tablets</i>	   	<b>REJECTED in line with NICE TA223</b>
<b>Perindopril arginine</b> DNP <i>2.5mg; 5mg &amp; 10mg tablets</i>	 	
<b>Simvastatin with ezetimibe</b> DNP <i>Inegy® 10mg/20mg; 10mg/40mg &amp; 10mg/80mg tablets</i>	   	

## Section 3: Respiratory System

Supported by the  
formulary (click here)



### 3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers
  - Inhaler Devices
  - Nebuliser Diluent

### 3.2 Corticosteroids

- Compound preparations

### 3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

### 3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

### 3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants

### 3.6 Oxygen (refer to oxygen guidelines)

### 3.7 Mucolytics

### 3.8 Aromatic inhalations

### 3.9 Cough preparations

- 3.9.1 Cough Suppressants
  - Cough Suppressants (Palliative Care ONLY)
- 3.9.2 Demulcent & expectorant cough preparations

### 3.10 Systemic Nasal Decongestants

### 3.11 Antifibrotics

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Idiopathic pulmonary fibrosis (CG163)  
 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)  
 Inhaler devices for children under 5 (TA10)  
 Asthma (older children) - inhaler devices (TA38)  
 Asthma (in children) - corticosteroids (TA131)  
 Asthma (in adults) - corticosteroids (TA138)  
 Venom anaphylaxis - immunotherapy pharmlagen (TA246)  
 Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)  
 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)  
 Omalizumab for previously treated chronic spontaneous urticaria (TA339)  
 Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)  
 Reslizumab for treating severe eosinophilic asthma (TA479)  
 Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)  
 Benralizumab for treating severe eosinophilic asthma (TA565)  
 Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)  
 Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)  
 Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)  
 Dupilumab for treating severe asthma with type 2 inflammation (TA751)  
 Palforzia for treating peanut allergy in children and young people (TA769)  
 Tezepelumab for treating severe asthma (TA880)  
 Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

## GMMMG Formulary

Formulary Homepage  
 Chapter 3: Respiratory system (v9.4 - Dec-24)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

# 3.1 Bronchodilators



*Asthma (chronic)*      *Asthma (acute)*

**Methacholine chloride**



Provocholine® nebuliser solution

MMC      emc

**RESTRICTED detection test for bronchial airway hyperreactivity**

## 3.1.1 Adrenoceptor agonists



### 3.1.1.1 Selective beta<sub>2</sub> agonists

**Salbutamol**

Red injection

MMC      BNF      emc

**Terbutaline sulfate**

Red injection

BNF      emc

**Salmeterol**

BNF      emc

**Formoterol fumarate**

MMC      BNF      emc

**Asthma BTS step 3 add-on therapy**

### 3.1.1.2 Other Adrenoceptor Agonists

**Ephedrine hydrochloride**

BNF      emc

### 3.1.2 Antimuscarinic Bronchodilators



**Ipratropium bromide**

BNF      emc

**1<sup>st</sup> line use**

**Tiotropium**

MMC      BNF      emc

**2<sup>nd</sup> line use  
COPD maintenance**

MHRA Drug Safety Update (Feb-15): Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

**Aclidinium bromide**

MMC      BNF      emc

**2<sup>nd</sup> line use  
COPD maintenance**

Eklira Genuair®

**Glycopyrronium bromide**

MMC      BNF      emc

**2<sup>nd</sup> line use  
COPD maintenance**

Seebri Breezhaler®

**Umeclidinium bromide**

MMC      BNF      emc

**2<sup>nd</sup> line use  
COPD maintenance**

Incruse Ellipta®

### Compound Preparations

**Aclidinium bromide with formoterol fumarate dihydrate**

MMC      BNF      emc

**3<sup>rd</sup> line use  
COPD maintenance**

Duaklir Genuair®

### 3.1.3 Theophylline

**Theophylline**

M/R tablets; M/R capsules

BNF      emc

**1<sup>st</sup> line use  
PRESCRIBE BY BRAND NAME**

**Aminophylline**
























Red injection

M/R tablets; injection

BNF      emc

**PRESCRIBE BY BRAND NAME**



3.1.4 Compound Bronchodilator Preparations		GMMMG
<b>Ipratropium bromide with salbutamol</b>		
<i>Combivent®</i>	 	
<b>Glycopyrronium bromide with formoterol fumarate</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance
<i>Bevespi Aerosphere®</i>	  	
<b>Glycopyrronium bromide with indacaterol maleate</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance
<i>Ultibro®</i>	  	
<b>Tiotropium bromide monohydrate with olodaterol hydrochloride</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance
<i>Spolto Respimat®</i>	  	
<b>Umeclidinium bromide with vilanterol trifenate</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance
<i>Anoro Ellipta®</i>	  	
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers		GMMMG GMMMG GMMMG
Inhaler Devices		
<b>Volumatic® (spacer inhaler)</b>		
	 	
<b>Aerochamber® Plus (spacer device)</b>		
	 	
<b>Able Spacer® (spacer device)</b>		
	  	
Nebuliser Diluent		
<b>Sodium chloride</b>		
0.9% nebuliser diluent	 	

## 3.2 Corticosteroids



Corticosteroids		GMMMG	GMMMG	GMMMG
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects				
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration				
<b>Beclometasone dipropionate</b>				
MDI (Clenil Modulite® 50, 100, 200, 250)	NICE	MMC	BNF	emc
<b>Beclometasone dipropionate (CFC-free)</b>				
MDI (Qvar Easi-Breathe® or Qvar Autohaler® 50, 100)	NICE	MMC	BNF	emc
<b>Budesonide</b>				
DPI (Easyhaler®; Pulmicort® Turbohaler® 100, 200, 400) 500micrograms/2mL & 1mg/2mL nebuliser liquid	NICE	MMC	BNF	emc
<b>Fluticasone propionate</b>				
MDI (FlixotideEvohaler®) 50, 125, 250; DPI (FlixotideAccuhaler® 50, 100, 250, 500)			BNF	emc
<b>Compound preparations</b>				
<b>Budesonide with formoterol fumarate</b>				
DPI (Fobumix Easyhaler® 80/4.5, 160/4.5, 320/9); DPI (Symbicort Turbohaler® 100/6, 200/6, 400/12); DPI (Duoresp Spiromax® 160/4.5, 320/9); DPI (WockAir® 160/4.5, 320/9)	NICE	MMC	BNF	emc
			GMMMG	GMMMG
<b>Beclometasone dipropionate with formoterol fumarate</b>				
MDI (Luforbec®; Fostair®; 100/6, 200/6); DPI (Fostair NEXThaler® 100/6, 200/6)		MMC	BNF	emc
<b>Fluticasone furoate with vilanterol trifenate</b>				
DPI (Relvar Ellipta® 92/22 asthma or COPD; 184/22 asthma)		MMC	BNF	emc
<b>Fluticasone propionate with salmeterol</b>				
MDI (Sirdupla® 125, 250)		MMC	BNF	emc
<b>Fluticasone propionate with salmeterol</b>				
MDI (SeretideEvohaler® 50, 125, 250)	NICE	MMC	BNF	emc
<b>Fluticasone propionate with formoterol fumarate</b>				
MDI (Flutiform® 50/5, 125/5, 250/10)		MMC	BNF	emc
<b>Beclometasone dipropionate with formoterol fumarate &amp; glycopyrronium bromide</b>				
MDI (Trimbow 87/5/9® & 172/5/9®) DPI (Trimbow NEXThaler 88/5/9®)		MMC	BNF	emc
<b>Fluticasone furoate with umeclidinium bromide &amp; vilanterol trifenate</b>				
DPI (Trelegy Ellipta® 92/55/22 micrograms)		MMC	BNF	emc
<b>Formoterol fumarate with glycopyrronium bromide &amp; budesonide</b>				
DPI (Trixeo Aerosphere® 5/7.2/160 micrograms)		MMC	BNF	emc
<b>Indacaterol with mometasone furoate</b>				
DPI (Ateectura® Breezhaler®)		MMC	BNF	emc
<b>Mometasone furoate with glycopyrronium bromide &amp; indacaterol</b>				
DPI (Enerzair® Breezhaler®)		MMC	BNF	emc
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects				
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration				

## 3.3 Cromoglicate & related therapy & leukotriene receptor antagonists



### 3.3.1 Cromoglicate & Related Therapy

#### Sodium cromoglicate



### 3.3.2 Leukotriene Receptor Antagonists

#### Montelukast

tablets; chewable tablets; sachets



BTS step 2 or 3 in paediatrics

MHRA Drug Safety Update (Apr-24): Montelukast: reminder of the risk of neuropsychiatric reactions

MHRA Drug Safety Update (Sep-19): Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions

### 3.3.3 Phosphodiesterase type-4 inhibitors

#### Roflumilast

Green

tablets



**RESTRICTED**  
as per NICE TA461

### 3.4 Antihistamines, hyposensitisation & allergic emergencies



#### 3.4.1 Antihistamines

##### Non-sedating antihistamines

###### Cetirizine hydrochloride

tablets; oral solution



###### Loratadine

tablets; oral solution



###### Desloratadine

tablets; oral solution



**RESTRICTED**  
children 1-2 years old

###### Fexofenadine hydrochloride

tablets



##### Sedating antihistamines

###### Chlorphenamine maleate

tablets; oral solution; injection



###### Cyprohepatadine hydrochloride

4mg tablets



###### Cyprohepatadine hydrochloride

2mg/5mL liquid



**Approved for use between Sep-24 & Dec-24 during tablet shortage**

###### Hydroxyzine hydrochloride

tablets; oral solution



MHRA Drug Safety Update (Apr-15): Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes

###### Promethazine hydrochloride

tablets; oral solution



###### Alimemazine tartrate

DNP

tablets; oral solution



#### 3.4.2 Allergen Immunotherapy

##### Allergoid immunotherapy tablets



Lofarma Lais®



**RESTRICTED**  
Immunology Consultants only

##### Bee venom extract

Red

injection



**RESTRICTED**  
Immunology Consultants only

##### Grass & Rye or tree pollen extract

Red

Pollinex®



**RESTRICTED**  
Immunology Consultants only

##### Grass pollen extract

DNP

Grazax® oral lyophilisates



**RESTRICTED**  
Immunology Consultants only

##### House dust mite extract

Red

Acarizax 12-SQ HDM oral lyophilisates®



**RESTRICTED**  
Immunology Consultants only

##### Peanut protein powder

Red



Palforza® oral powder in capsules; sachet



**RESTRICTED**  
Immunology Consultants only

##### Wasp venom extract

Red

injection



**RESTRICTED**  
Immunology Consultants only

##### White birch (*Betula verrucosa*) pollen extract

Red

Itulazax 12-SQ Bet oral lyophilisates®



**RESTRICTED**  
Immunology Consultants only

##### Omalizumab

###### Omalizumab

Red

























































































DNP



injection



**RESTRICTED**  
as per NICE

<b>Anti-interleukin-5 (IL-5) antibody</b>		
<b>Benralizumab</b>   <i>Fasenra</i> ® injection      		<b>RESTRICTED</b> as per NICE TA565
<b>Dupilumab</b>    <i>Dupilumab</i> ® injection (see also section 13.5.3)      		<b>RESTRICTED</b> as per NICE TA751
MHRA Drug Safety Update (Nov-22): Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management		
<b>Mepolizumab</b>   <i>Nucala</i> ® injection      		<b>RESTRICTED</b> as per NICE
<b>Reslizumab</b>   <i>Cinqaero</i> ® infusion      		<b>RESTRICTED</b> as per NICE TA479 <b>NOT STOCKED</b>
<b>Tezepelumab</b>   <i>Tezspire</i> ® injection      		<b>RESTRICTED</b> as per NICE TA880
<b>3.4.3 Allergic Emergencies</b>		
<b>Adrenaline / epinephrine</b> injection  		<b>PRESCRIBE BY BRAND NAME</b>
MHRA Drug Safety Update (Jun-23): Adrenaline auto-injectors (AAIs): new guidance and resources for safe use		
MHRA Drug Safety Update (Nov-21): Adrenaline auto-injectors: reminder for prescribers to support safe and effective use		
MHRA Drug Safety Update (Aug-17): Adrenaline auto-injectors: updated advice after European review		
<b>Berotrastat</b>   <i>Orladeyo</i> ® capsules      		<b>RESTRICTED</b> <b>specialist use only</b> as per NICE TA738
<b>C1 esterase inhibitor</b>   <i>Beriner</i> ®; <i>Cinryze</i> ® injection      		<b>RESTRICTED</b> acute attacks of HAE 
<b>Conestat alfa</b>   <i>Ruconest</i> ® injection      		<b>RESTRICTED</b> adults acute attacks of HAE
<b>Icatibant</b>   <i>Firazyr</i> ® injection      		<b>RESTRICTED</b> adults acute attacks of HAE
<b>Lanadelumab</b>   <i>Takhzyro</i> ® injection      		<b>RESTRICTED</b> in line with NICE TA606
<b>Oxandrolone</b>  tablets   		<b>RESTRICTED</b> adults acute attacks of HAE

### 3.5 Respiratory stimulants & pulmonary surfactants



#### 3.5.1 Respiratory Stimulants

**Doxapram hydrochloride**

injection (see also section 15.1.7)



**Caffeine citrate**

injection



**RESTRICTED**  
apnoea in premature babies

#### 3.5.2 Pulmonary Surfactants

**Poractant alfa**



Curosurf® liquid



## 3.6 Oxygen (refer to oxygen guidelines)



# 3.7 Mucolytics



## Mucolytics

### Sodium chloride (hypertonic)

*Nebusal*® 7% nebulules



### Mannitol inhalation powder

Red

**RESTRICTED**  
Respiratory only in line with NICE

*Bronchitol*® capsules



### Mannitol diagnostic kit

Red

**RESTRICTED**  
Respiratory only

*Osmohale*® capsules



### Acetylcysteine

Green

effervescent tablets; injection; sachets



### Carbocisteine

Green

capsules; oral solution; sachets



**RESTRICTED**  
COPD Consultant / referral only

### Dornase alfa

Red ££

*Pulmozyme*® nebulules



**RESTRICTED**  
Respiratory only

### Ivacaftor with tezacaftor and elexacaftor

Red ££

*Kafrio*® tablets



**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (*Kafrio*▼) in combination with ivacaftor (*Kalydeco*): risk of serious liver injury; updated advice on LFT

### Ivacaftor

Red ££

*Kalydeco*® tablets; granules



**RESTRICTED**  
Paediatric Consultants only

MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (*Kafrio*▼) in combination with ivacaftor (*Kalydeco*): risk of serious liver injury; updated advice on LFT

### Lumacaftor with ivacaftor

Red ££

*Orkambi*® tablets; granules



**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (*Kafrio*▼) in combination with ivacaftor (*Kalydeco*): risk of serious liver injury; updated advice on LFT

### Tezacaftor with ivacaftor

Red ££

*Symkevi*® tablets



**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (*Kafrio*▼) in combination with ivacaftor (*Kalydeco*): risk of serious liver injury; updated advice on LFT



### 3.8 Aromatic inhalations



#### Aromatic Inhalations

**Benzoin Tincture, Compound, BP**

*Friars' Balsam liquid*



**Menthol and Eucalyptus Inhalation, BP 1980**

inhalation vapour



## 3.9 Cough preparations



### 3.9.1 Cough Suppressants

#### Codeine phosphate

oral solution



MHRA Drug Safety Update (Feb-24): Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine

MHRA Drug Safety Update (Jul-23): Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine

#### Dextromethorphan hydrobromide

oral solution



**RESTRICTED**  
non-ketotic hyperglycaemia

### Cough Suppressants (*Palliative Care ONLY*)

#### Methadone hydrochloride

liquid



#### Morphine hydrochloride

oral solution



### 3.9.2 Demulcent & expectorant cough preparations

#### Simple Linctus

liquid



### 3.10 Systemic nasal decongestants



#### Systemic Nasal Decongestants

**NO DRUGS ARE RECOMMENDED FROM THIS GROUP**



**NHSE: OTC prescribing reduction**

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)

### 3.11 Antifibrotics



#### Antifibrotics

##### Pirfenidone



capsules; tablets



**RESTRICTED**  
Respiratory Consultants only  
**NOT STOCKED**

MHRA Drug Safety Update (Nov-20): Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing

# Non-Formulary Items



## Levocetirizine hydrochloride

DNP

Xyzal® tablets



**in line with GMMMG**

## Pholcodine

oral solution



**Withdrawn from UK market as per  
MHRA alert March 2023**

MHRA Drug Safety Update (Mar-23): Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure

# Chapter 4: Central Nervous System

Supported by the  
formulary ([click here](#))



## 4.1 Hypnotics & anxiolytics

- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates
- 4.1.4 Other hypnotics and anxiolytics

## 4.2 Drugs used in psychoses & related disorders

- 4.2.1 Antipsychotic Drugs
- 4.2.2 Antipsychotic Depot Injections
- 4.2.3 Drugs used for mania and hypomania

## 4.3 Antidepressant drugs

- 4.3.1 Tricyclic & Related Antidepressant Drugs
- 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
- 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
- 4.3.4 Other Antidepressant Drugs

## 4.4 CNS stimulants & drugs used for ADHD

## 4.5 Drugs used in the treatment of obesity

## 4.6 Drugs used in nausea & vertigo

## 4.7 Analgesics

- 4.7.1 Non-Opioid Analgesics
- 4.7.2 Opioid Analgesics
- 4.7.3 Neuropathic Pain
- 4.7.4 Antimigraine Drugs

## 4.8 Antiepileptic drugs

- 4.8.1 Control of the Epilepsies
- 4.8.2 Drugs Used in Status Epilepticus

## 4.9 Drugs used in Parkinsonism & related disorders

- 4.9.1 Dopaminergic Drugs Used in Parkinsonism
- 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
- 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders

## 4.10 Drugs used in substance dependence

## 4.11 Drugs for dementia

## Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Obsessive compulsive disorder (OCD) & body dysmorphic disorder (BDD) (CG31)  
 Management of Obesity (CG43) (replaces TA22, TA31 & TA46)  
 Drug misuse: opioid detoxification (CG52)  
 Depression with a chronic physical health problem (CG91)  
 Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)  
 Anxiety (CG113) (replaces CG22)  
 Neuropathic pain - pharmacological management (CG173)  
 Psychosis and schizophrenia in adults (CG178)  
 Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)  
 Eating Disorders: recognition and treatment (NG69)  
 Parkinson's disease in adults (NG71)  
 Attention deficit hyperactivity disorder: diagnosis and management (NG87)  
 Stop smoking interventions and services (NG92)  
 Dementia: supporting people with dementia and their carers in health and social care (NG97)  
 Post-traumatic stress disorder (NG116)  
 Depression in children and young people: identification and management (NG134)  
 Epilepsies in children, young people and adults (NG217)  
 Depression in adults: treatment and management (NG222)  
 Motor Neurone Disease: Riluzole (TA20)  
 Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)  
 Drug Misuse: Methadone & Buprenorphine (TA114)  
 Drug Misuse: Naltrexone (TA115)  
 Smoking Cessation: Varenicline (TA123)  
 Schizophrenia - aripiprazole (TA213)  
 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)  
 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)  
 Bipolar disorder (children) - aripiprazole (TA292)  
 Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)  
 Vortioxetine for treating major depressive episodes (TA367)  
 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)  
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)  
 Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome (TA615)  
 Galcanezumab for preventing migraine (TA659)  
 Cenobamate for treating focal onset seizures in epilepsy (TA753)  
 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)  
 Fremanezumab for preventing migraine (replacing TA631) (TA764)  
 Fenfluramine for treating seizures associated with Dravet syndrome (TA808)  
 Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)  
 Eptinezumab for preventing migraine (TA871)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Rimegepant for preventing migraine (TA906)  
 Rimegepant for treating migraine (TA919)  
 Daridorexant for treating long-term insomnia (TA922)  
 Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)  
 Atogepant for preventing migraine (TA973)  
 Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)  
 Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)

## GMMMG Formulary

Formulary Homepage  
 Chapter 4: Central Nervous system (v10.12 - Dec-24)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

# 4.1 Hypnotics & anxiolytics



4.1.1 Hypnotics		NICE CG112
<b>Benzodiazepines</b>		
<b>Temazepam</b> 	tablets; oral solution (see also section 15.1.4.1) BNF emc	
<b>Nitrazepam</b>	tablets; oral suspension BNF emc	
<b>Zaleplon, Zolpidem &amp; Zopiclone</b>		
<b>Zopiclone</b>	tablets NICE BNF emc	
<b>Chloral &amp; Derivatives</b>		
<b>Chloral hydrate</b>	oral solution; suppositories MMC BNF emc	
MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication		
<b>Chloral hydrate</b>	500mg/5mL oral solution MMC BNF emc	<b>RESTRICTED</b> paediatric patients on ketogenic diets
MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication		
<b>Clomethiazole</b>	192mg capsules BNF emc	
<b>Sodium oxybate</b>		
<b>Sodium oxybate</b> 	oral solution PbR X MMC BNF blue-teq emc	<b>RESTRICTED</b> 2 <sup>nd</sup> line narcolepsy with cataplexy
<b>Melatonin</b>		
<b>Melatonin</b>	capsules; tablets; oral solution MMC BNF emc	<b>RESTRICTED</b> GMMMG
Melatonin (licensed product 1 <sup>st</sup> line) - Paediatric patients, e.g. sleep disorders, ADHD		Amber
Melatonin (licensed product only) - Adult patients over 55yrs of age		Green
Melatonin - management of jet lag		DNP
<b>4.1.2 Anxiolytics</b>		NICE CG113
<b>Benzodiazepines</b>		
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression		
<b>Chlordiazepoxide hydrochloride</b> 	capsules BNF emc	<b>Symptomatic relief of acute alcohol withdrawal</b>
<b>Diazepam</b>	tablets; liquid; injection; rectal tube (see also sections 4.8.2; 10.2.2 & 15.1.4.1) BNF emc	
<b>Lorazepam</b>	tablets; injection (see also section 4.8.2 & 15.1.4.1) BNF emc	
<b>Oxazepam</b>	tablets BNF emc	
<b>Buspirone</b>		
<b>Buspirone hydrochloride</b>	tablets BNF emc	
<b>Others</b>		
<b>Pregabalin</b> 	capsules; oral solution MMC BNF emc	<b>RESTRICTED</b> generalised anxiety disorder after standard treatment following NICE has failed.



**4.1.3 Barbiturates****NO DRUGS ARE RECOMMENDED FROM THIS GROUP****4.1.4 Other hypnotics and anxiolytics****Daridorexant hydrochloride**

Green

Quviviq® tablets

   **RESTRICTED**  
in line with NICE TA922  
**NOT for initiation in 2<sup>ry</sup> care**

## 4.2 Drugs used in psychoses & related disorders



### 4.2.1 Antipsychotic Drugs

NICE CG178

MHRA Drug Safety Update (May-12): Antipsychotics: initiative to reduce prescribing to older people with dementia

#### Chlorpromazine hydrochloride

Green

tablets; oral solution; injection

MMC BNF emc

#### Haloperidol

Green

tablets; capsules; oral solution (500microgram tablets see DNP)

BNF emc

MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium

#### Levomepromazine

Green

6.25mg, 25mg tablets; oral solution; injection

MMC BNF emc

#### Promazine hydrochloride

tablets; oral solution

BNF emc

#### Sulpiride

tablets; oral solution

BNF emc

#### Trifluoperazine

tablets; oral solution

BNF emc

#### Zuclophenthixol

tablets

BNF emc

### Atypical Antipsychotic Drugs

#### Amisulpride

Amber Red

tablets; oral solution

MMC BNF emc

**RESTRICTED** adults.  
Consultant Psychiatrist only

#### Aripiprazole

Amber Red

tablets; oral solution

NICE MMC BNF emc

**RESTRICTED** paediatrics.  
Consultant Psychiatrist only

MHRA Drug Safety Update (Dec-23): Aripiprazole (Ablify and generic brands): risk of pathological gambling

#### Clozapine

Red

tablets

BNF emc

MHRA Drug Safety Update (Aug-20): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity

MHRA Drug Safety Update (Oct-17): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus

#### Olanzapine

Amber Red

tablets; orodispersible tablets; oral solution

BNF emc

#### Quetiapine

Amber Red

tablets; M/R tablets

MMC BNF emc

**RESTRICTED** - Consultant initiation -  
schizophrenia patients

#### Risperidone

Amber Red

tablets; orodispersible tablets; oral solution

BNF emc

### 4.2.2 Antipsychotic Depot Injections

#### Flupentixol decanoate

Amber

injection

BNF emc

**RESTRICTED**  
Consultant Psychiatrist only

#### Fluphenazine decanoate

Amber

injection

BNF emc

**RESTRICTED**  
Consultant Psychiatrist only

#### Haloperidol decanoate

Amber

injection

BNF emc

**RESTRICTED**  
Consultant Psychiatrist only

MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium

#### Risperidone

Amber

injection

BNF emc

**RESTRICTED**  
Consultant Psychiatrist only

#### Zuclophenthixol decanoate

Amber

injection

BNF emc
























**RESTRICTED**  
Consultant Psychiatrist only

4.2.3 Drugs used for mania and hypomania		
<p><b>Lithium carbonate</b></p> <p><span style="background-color: #f4a460; padding: 2px;">Amber</span></p> <p>tablets; M/R tablets</p>		<p><b>PRESCRIBE BY BRAND NAME</b></p>
<p><b>Lithium citrate</b></p> <p><span style="background-color: #f4a460; padding: 2px;">Amber</span></p> <p>oral solution</p>		<p><b>PRESCRIBE BY BRAND NAME</b></p>
<p><b>Valproic acid</b></p> <p><span style="background-color: #4CAF50; padding: 2px;">Green</span></p> <p>Gastro-resistant tablets</p>		
<p>MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance</p> <p>MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended</p>		

## 4.3 Antidepressant drugs



		NICE CG31
		NICE CG91
4.3.1 Tricyclic & Related Antidepressant Drugs		NICE NG134
Tricyclic antidepressants		NICE NG222
<b>Amitriptyline hydrochloride</b> (standard release preparations only)		
tablets; oral solution (see also section 7.4.2)		
<b>Clomipramine hydrochloride</b> (standard release preparations only)		
capsules		
<b>Doxepin hydrochloride</b>		
capsules		
<b>Imipramine hydrochloride</b>		
tablets		
<b>Lofepramine</b>		1 <sup>st</sup> line use
tablets; oral suspension		
<b>Nortriptyline</b>		
tablets		
<b>Trimipramine</b>		
DNP tablets; capsules		
<b>Tricyclic-related antidepressants</b>		
<b>Mianserin hydrochloride</b>		<b>RESTRICTED</b> initiation by Psychiatrist
tablets		
<b>Trazodone hydrochloride</b>		<b>RESTRICTED</b> initiation by Psychiatrist
capsules; tablets; oral solution		
<b>4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)</b>		
<b>Isocarboxazid</b>		<b>RESTRICTED</b> initiation by Psychiatrist
Red tablets		
<b>Phenelzine</b>		<b>RESTRICTED</b> initiation by Psychiatrist
Red 15mg tablets		
<b>Tranlycypromine</b>		<b>RESTRICTED</b> initiation by Psychiatrist
Red 10mg tablets		
<b>Reversible Monoamine-Oxidase Inhibitors (MAOIs)</b>		
<b>Moclobemide</b>		<b>RESTRICTED</b> 2 <sup>nd</sup> line initiation by Psychiatrist
Green 150mg; 300mg tablets		
<b>4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)</b>		
MHRA Drug Safety Update (Jan-21): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery		
<b>Fluoxetine</b>		
capsules; tablets; dispersible tablets; oral solution		
<b>Citalopram</b>		
tablets; oral drops		
MHRA Drug Safety Update (Jul-16): Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
<b>Sertraline</b>		
tablets; oral suspension		
<b>Fluvoxamine maleate</b>		
tablets		
<b>Paroxetine</b>		
tablets; oral suspension		

<b>Escitalopram</b> tablets  	<b>RESTRICTED</b> Mental Health Trust initiation only
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation	
<b>4.3.4 Other Antidepressant Drugs</b>	
<b>Venlafaxine</b>  M/R capsules; tablets; M/R tablets  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Mirtazapine</b> tablets; orodispersible tablets; oral solution   	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Duloxetine</b>  gastro-resistant tablets  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Flupentixol</b> tablets  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Reboxetine</b> tablets   	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Tryptophan</b> capsules  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Vortioxetine</b>  tablets    	<b>RESTRICTED</b> initiation by Psychiatrist

## 4.4 CNS stimulants & drugs used for ADHD



4.4 CNS stimulants & drugs used for ADHD		NICE NG87
<b>Atomoxetine</b> Amber capsules NICE MMC BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Jan-12): Atomoxetine (Strattera ▼): increases in blood pressure and heart rate MHRA Drug Safety Update (Mar-09): Atomoxetine: risk of psychotic or manic symptoms in children and adolescents		
<b>Dexamfetamine</b> Amber  Red tablets NICE MMC BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
<b>Guanfacine</b> Amber Prolonged release tablets NICE MMC BNF emc		<b>RESTRICTED</b> 2 <sup>nd</sup> line use for ADHD
<b>Lisdexamfetamine</b> Amber capsules NICE MMC BNF emc		<b>RESTRICTED</b> 2 <sup>nd</sup> line use for ADHD
<b>Methylphenidate</b> Amber tablets; M/R tablets; capsules; M/R capsules NICE MMC BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice <b>PRESCRIBE BY BRAND NAME</b>
MHRA Drug Safety Update (Sep-22): Methylphenidate long-acting (MR) preparations: caution if switching between products due to differences in formulations MHRA Drug Safety Update (Mar-09): Methylphenidate: safe and effective use to treat ADHD		
<b>Modafinil</b> Green DNP Red tablets BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Nov-20): Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy MHRA Drug Safety Update (Mar-11): Modafinil (Provigil): now restricted to narcolepsy		
<b>Solriamfetol hydrochloride</b> Red Sunosi® tablets NICE MMC BNF emc		<b>RESTRICTED</b> Sleep Centre only in line with NICE

## 4.5 Drugs used in the treatment of obesity



### 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract

**NICE CG43**

**Orlistat**

**RESTRICTED**

**Consultant initiation - Paeds. only**

capsules



MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines

## 4.6 Drugs used in nausea &amp; vertigo

**Antihistamines****Cyclizine**

tablets; injection

**1<sup>st</sup> line use****Promethazine hydrochloride**

tablets; oral solution (see also section 3.4.1)

**Promethazine teoclate**

tablets

**Phenothiazines & Related Drugs****Prochlorperazine**

tablets; buccal tablet; injection

**Droperidol**

injection

**RESTRICTED**  
Consultant initiation only for PONV**Domperidone & Metoclopramide****Domperidone**

tablets; oral suspension (see also section 1.2)



MHRA Drug Safety Update (Dec-19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects

MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects

**Metoclopramide hydrochloride**

tablets; oral suspension; injection (see also section 1.2)



MHRA Drug Safety Update (Aug-13): Metoclopramide: risk of neurological adverse effects

**5HT<sub>3</sub>-receptor antagonists****Ondansetron**

Red Green

tablets; orodispersible tablets; injection; oral solution; orodispersible film

**RESTRICTED - Chemotherapy induced & post-op vomiting**

MHRA Drug Safety Update (Jul-13): Ondansetron for intravenous use: dose-dependent QT interval prolongation

MHRA Drug Safety Update (Aug-12): Ondansetron (Zofran): important new intravenous dose restriction

**Neurokinin 1-receptor antagonist****Aprepitant**

80mg; 125mg capsules; 25mg/mL oral suspension

**RESTRICTED**  
highly / moderately emetogenic CINV**Cannabinoids****Nabilone**

Red

0.25mg; 1mg capsules

**RESTRICTED**  
highly emetogenic CINV**Hyoscine****Hyoscine hydrobromide**

patches; tablets (for Hyoscine butylbromide see section 1.2)



MHRA Drug Safety Update (Jul-23): Hyoscine hydrobromide patches: risk of anticholinergic side effects, including hyperthermia

**Other Drugs for Ménière's Disease****Betahistine dihydrochloride**

tablets





## 4.7 Analgesics



## 4.7.1 Non-Opioid Analgesics

(see also Chapter 10 for NSAIDs)

## Paracetamol

tablets; soluble tablets; infusion; injection; oral suspension; suppositories

1<sup>st</sup> line use

## Sucrose 24% solution

Sweet-Ease® oral solution


**RESTRICTED**  
 Pain relief in neonates

## Compound Analgesic Preparations

## Paracetamol and codeine (Co-codamol)

Co-codamol® tablets; effervescent tablets



## Paracetamol and dihydrocodeine (Co-dydramol)

tablets



## 4.7.2 Opioid Analgesics

MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction

## Buprenorphine



NOT patch


**RESTRICTED**

## Codeine phosphate

tablets; syrup; injection



MHRA Drug Safety Update (Jul-13): Codeine for analgesia: restricted use in children because of reports of morphine toxicity

MHRA Drug Safety Update (Jun-13): Codeine: restricted use as analgesic in children and adolescents after European safety review

## Diamorphine hydrochloride



injection



## Difelikefalin

Red

Kapruvia® injection


**RESTRICTED**  
 Renal Consultants in line with NICE  
 NHSE M4C
Dihydrocodeine tartrate **standard release preparations only**

tablets



## Fentanyl

Green

NOT lozenge (see also section 15.1.4.3)


**RESTRICTED** Spray palliative care &  
 haematology initiation (Wd44)

MHRA Drug Safety Update (Oct-18): Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children

MHRA Drug Safety Update (Sep-08): Serious and fatal overdose of fentanyl patches

## Methadone hydrochloride



oral solution


**RESTRICTED**  
 palliative care & substance misuse

## Morphine sulfate



tablets; M/R tablets; capsules; M/R capsules; oral solution; injection



## Morphine sulfate

Green

Actimorph® orodispersible tablets


**RESTRICTED**  
 palliative care / GMMMG

## Oxycodone hydrochloride



capsules; liquid; tablets; M/R tablets; injection


**RESTRICTED**  
 2<sup>nd</sup> line for morphine intolerance

## Pethidine hydrochloride



injection; tablets



## Tapentadol hydrochloride MR



tablets


**RESTRICTED**  
 3<sup>rd</sup> line - Pain Team Consultants only

MHRA Drug Safety Update (Jan-19): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines

## Tramadol hydrochloride



capsules; M/R capsules; tablets; M/R tablets; soluble tablets; injection



**4.7.3 Neuropathic Pain**

**Amitriptyline**

tablets; oral solution



**Carbamazepine**

Green

tablets; M/R tablets; oral solution; suppositories



MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

**Gabapentin**

Green



capsules; oral suspension



MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression

Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin

**Pregabalin**

Green



capsules; oral solution



**3<sup>rd</sup> / 4<sup>th</sup> line use if gabapentin contraindicated or not tolerated**

MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression

MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin

**4.7.4 Antimigraine Drugs**

**4.7.4.1 Treatment Of Acute Migraine**

**Analgesics**

**Aspirin**

tablets; dispersible tablets; E/C tablets; suppositories



**Paracetamol**

tablets; soluble tablets; oral suspension; infusion; suppositories



**Ibuprofen**

tablets; M/R tablets; oral suspension; sachets



**5HT<sub>1</sub> receptor agonists**

**Sumatriptan**

tablets; nasal spray; injection



**4.7.4.2 Prophylaxis of Migraine**

**Botulinum toxin type A**

Red

Botox® injection



**RESTRICTED  
Specialist use only  
in line with NICE**

**Clonidine hydrochloride**

tablets




**Erenumab**

Red



injection



**RESTRICTED  
Specialist use only  
NOT STOCKED**

**Eptinezumab**

Red



injection



**RESTRICTED  
Specialist use only  
NOT STOCKED**

**Fremanezumab**

Red



injection




**RESTRICTED  
Specialist use only  
NOT STOCKED**

**Galcanezumab**

Red



injection



**RESTRICTED  
Specialist use only  
NOT STOCKED**

**Pizotifen**

tablets



**Rimegepant**

Green

oral lyophilisate



**RESTRICTED  
Specialist use only  
in line with NICE**

# 4.8 Antiepileptic drugs

Green



## 4.8.1 Control of the Epilepsies

NICE NG217

### Carbamazepine

Green

tablets; M/R tablets; oral solution; suppositories

NICE BNF emc

MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

### Phenobarbital

Green



tablets; oral solution; injection

NICE BNF emc

### Phenytoin sodium

Green

capsules; oral suspension; injection

NICE BNF emc

### Sodium valproate

Green

tablets; M/R tablets; oral solution; M/R granules; injection

NICE BNF emc

MHRA Drug Safety Update (Sep-24): Valproate use in men: as a precaution, men and their partners should use effective contraception

MHRA Drug Safety Update (Jan-24): Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age

MHRA Drug Safety Update (Oct-23): Valproate: dispense full packs of valproate-containing medicines

MHRA Drug Safety Update (Aug-23): Valproate: re-analysis of study on risks in children of men taking valproate

MHRA Drug Safety Update (Dec-22): Valproate: reminder of current Pregnancy Prevention Programme requirements...

MHRA Drug Safety Update (Jan-20): Valproate (Epilem ▼, Depakote ▼) pregnancy prevention programme: updated educational materials

MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance...

MHRA Drug Safety Update (Apr-18): Valproate medicines (Epilem ▼, Depakote ▼): contraindicated in women & girls of childbearing potential unless conditions of PPP met

MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended

### Cenobamate

Green

Ontozry® tablets

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only in line with NICE

### Clobazam

Green

tablets; oral suspension

NICE BNF emc

**RESTRICTED**  
Specialist use only

### Clonazepam

Green

tablets; oral solution; injection

NICE BNF emc

**RESTRICTED**  
Specialist use only

### Eslicarbazepine acetate

Green

tablets; oral suspension

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only in line with NICE

### Ethosuximide

Green

capsules; oral solution

NICE BNF emc

**RESTRICTED**  
Paediatrics only

### Fenfluramine hydrochloride

Red

Fintepla® oral solution

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only in line with NICE

### Gabapentin

Green



capsules; oral suspension

NICE BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression

Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin

### Lacosamide

Green

tablets; oral solution; infusion

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only

### Lamotrigine

Green

tablets; dispersible tablets

NICE BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review

### Levetiracetam

Green

tablets; oral solution; infusion; granules

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review

### Brivaracetam

Green

tablets; oral solution; injection

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only

### Oxcarbazepine



































































Green

tablets; oral suspension

NICE BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions








<b>Perampanel</b>  tablets; oral suspension   	<b>RESTRICTED</b> Specialist use only
<b>Pregabalin</b>   capsules; oral solution    	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin	
<b>Primidone</b>  tablets  	<b>RESTRICTED</b> Specialist use only
<b>Rufinamide</b>  tablets    	<b>RESTRICTED</b> Specialist use only Lennox-Gastaut Syndrome
<b>Stiripentol</b>  capsules; sachets    	<b>RESTRICTED</b> Specialist use only
<b>Tiagabine</b>  tablets    	<b>RESTRICTED</b> Specialist use only
<b>Topiramate</b>  tablets; capsules    	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Jun-24): Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme	
<b>Vigabatrin</b>  tablets; sachets   	<b>RESTRICTED</b> Specialist use only
<b>Zonisamide</b>  capsules    	<b>RESTRICTED</b> Specialist use only
<b>Cannabidiol (CBD)</b>   Epidyolex®    	<b>RESTRICTED</b> Specialist use only in line with NICE TA614 / TA615
<b>4.8.2 Drugs Used in Status Epilepticus</b>	
<b>Lorazepam</b> tablets; injection (see also section 4.1.2 & 15.1.4.1)  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Diazepam</b> tablets; liquid; injection; rectal tube (see also sections 4.1.2; 10.2.2 & 15.1.4.1)  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Clonazepam</b>  tablets; oral solution; injection  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Midazolam</b>   oromucosal solution; injection; infusion (see also section 15.1.4.1)  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Paraldehyde</b> injection; rectal solution 	
<b>Phenytoin sodium</b>  capsules; oral suspension; injection  	
<b>Sulthiame</b>  Ospolot® 50mg tablets  	<b>RESTRICTED</b> Consultant Neurologist use only

## 4.9 Drugs used in Parkinsonism &amp; related disorders



4.9.1 Dopaminergic Drugs Used in Parkinsonism		NICE NG71
<b>Amantadine hydrochloride</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> capsules; oral solution	NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Apomorphine hydrochloride</b> <span style="background-color: orange; color: white; padding: 2px;">Amber</span> injection; infusion MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects	NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Cabergoline</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets	NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Co-beneldopa</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> capsules; M/R capsules; dispersible tablets	NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Co-careldopa</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets; M/R tablets	PbR X NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Entacapone</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets	MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Opicapone</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> capsules	MMC BNF emc	<b>RESTRICTED 2<sup>nd</sup> line</b> Specialist use only
<b>Pramipexole</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets; M/R tablets	MMC BNF emc	<b>RESTRICTED 3<sup>rd</sup> line add-on use</b> Specialist use only
<b>Rasagiline</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets	MMC BNF emc	<b>RESTRICTED</b> patients with end of dose fluctuations
<b>Ropinirole</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets; M/R tablets	BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Rotigotine</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> transdermal patches	NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only. NBM patients
<b>Safinamide</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets	MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Selegiline</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets	BNF emc	<b>RESTRICTED</b> Specialist use only
<b>4.9.2 Antimuscarinic Drugs Used in Parkinsonism</b>		
<b>Orphenadrine hydrochloride</b> oral solution	BNF emc	
<b>Procyclidine (Oral &amp; IM)</b> tablets; oral solution; injection	BNF emc	
<b>Trihexyphenidyl hydrochloride</b> tablet; syrup	MMC BNF emc	

**4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders**

<p><b>Propranolol hydrochloride</b></p> <p>tablets; M/R capsules; oral solution; injection</p>		
<p><b>Haloperidol</b></p> <p>Green</p> <p>tablets; capsules; oral solution (500microgram tablets see DNP)</p>		<p><b>RESTRICTED</b> Specialist use only</p>
<p>MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium</p>		
<p><b>Piracetam</b></p> <p>tablets; oral solution</p>		<p><b>RESTRICTED</b> Specialist use only</p>
<p><b>Tetrabenazine</b></p> <p>tablets</p>		<p><b>RESTRICTED</b> Specialist use only</p>
<p><b>Torsion Dystonias &amp; Other Involuntary Movements</b></p>		
<p>The dose of botulinum toxin is specific to each individual preparation and is <b>NOT</b> interchangeable. The doses for different indications vary - consult product literature &amp; specialist guidance</p>		
<p><b>Botulinum toxin type A</b></p> <p>Red</p> <p>Botox® injection</p>		<p><b>RESTRICTED</b> Specialist use only see decision tables</p>
<p><b>Botulinum toxin type A</b></p> <p>Red</p> <p>Dysport® injection</p>		<p><b>RESTRICTED</b> Specialist use only</p>
<p><b>Botulinum toxin type A</b></p> <p>Red</p> <p>Xeomin® injection</p>		<p><b>RESTRICTED</b> Specialist use only see decision tables</p>

## 4.10 Drugs used in substance dependence



### 4.10.1 Alcohol dependence

**Nalmefene**

Green

NICE MMC BNF emc

**RESTRICTED** - Specialist use only in line with NICE TA325

**NOT STOCKED**

**NICE NG92**

### 4.10.2 Nicotine dependence

**Nicotine Replacement Therapy**

patches, lozenges, inhalator, microtabs

BNF emc

**1<sup>st</sup> line use**

**Cytisinicline**

Green

Cytisine 1.5mg tablets

MMC BNF emc

**1<sup>st</sup> line use**

**Bupropion hydrochloride**

tablets

NICE BNF emc

MHRA Drug Safety Update (Nov-20): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs

**Varenicline**

tablets

NICE MMC BNF emc

**NICE CG52**

### 4.10.3 Opioid Dependence

MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction

**Buprenorphine**

Green



sublingual tablets

NICE BNF emc

**RESTRICTED** Initiation by substance misuse specialist

**Methadone hydrochloride**



oral solution

NICE BNF emc

**RESTRICTED** Initiation by substance misuse specialist

**Naltrexone hydrochloride**

Red

Amber

tablets

NICE MMC BNF emc

















**RESTRICTED**  
Gastro Consultant - cholestatic itch

## 4.11 Drugs for dementia



4.11 Drugs for Dementia		NICE NG97
<b>Donepezil hydrochloride</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets; orodispersible tablets NICE MMC BNF emc		<b>RESTRICTED</b> Specialist use only
<b>Galantamine</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> M/R capsules; tablets NICE BNF emc		<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals		
<b>Memantine hydrochloride</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets; oral solution NICE MMC BNF emc		<b>RESTRICTED</b> Specialist use only
<b>Rivastigmine</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> capsules; oral solution; transdermal patches NICE MMC BNF emc		<b>RESTRICTED</b> Specialist use only
<b>Dementia - as per NICE TA217 &amp; NG97 Green (following specialist initiation)</b>		<span style="background-color: green; color: white; padding: 2px;">Green</span>



Non-Formulary Items		
<b>Haloperidol</b> DNP 500microgram tablets    	<b>in line with GMMMG</b>	
<b>Foslevodopa with foscavidopa</b> Red Produodopa® 240mg/mL / 12mg/mL infusion    	<b>Not stocked patients referred to NCA</b>	
<b>Eplontersen sodium</b> Red Wainzua® 45mg/0.8mL injection    	<b>MFT not a commissioned centre patients referred to NAC - Royal Free</b>	
<b>Tafamidis</b> Red Vyndaqel® capsules    	<b>MFT not a commissioned centre patients referred to NAC - Royal Free</b>	
<b>Vutrisiran</b> Red Amvuttra® injection    	<b>MFT not a commissioned centre patients referred to NAC - Royal Free</b>	

## Section 5: Infections

Supported by the  
formulary ([click here](#))



### 5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulfonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antileprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

### 5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

### 5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

### 5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

### 5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, Enterobius vermicularis)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

### Non-Formulary Items

## Trust Guidelines

MFT Adult Antimicrobial guidelines  
 MFT Paediatric Antimicrobial guidelines  
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Prophylaxis against infective endocarditis (CG64)  
 Bacterial meningitis and meningococcal septicaemia (CG102)  
 Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)  
 Hepatitis B (Chronic) (CG165)  
 Tuberculosis (NG33)  
 Sinusitis (acute): antimicrobial prescribing (NG79)  
 Sore throat (acute): antimicrobial prescribing (NG84)  
 Otitis media (acute): antimicrobial prescribing (NG91)  
 Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)  
 Cough (acute): antimicrobial prescribing (NG120)  
 Surgical site infections: prevention and treatment (NG125)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Hepatitis B: Entecavir (TA153)  
 Hepatitis B: Telbivudine (TA154)  
 Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)  
 Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)  
 Hepatitis B: Tenofovir disoproxil (TA173)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Sofosbuvir for treating chronic hepatitis C (TA330)  
 Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)  
 Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)  
 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)  
 Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)  
 Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)  
 Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)  
 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)  
 Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)  
 Cabotegravir with rilpivirine for treating HIV-1 (TA757)  
 Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)  
 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)  
 Bulevirtide for treating chronic hepatitis D (TA896)  
 Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

## GMMM Formulary

Formulary Homepage  
 Chapter 5: Infections (v8.2 - Sep-24)  
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red/Amber/Green](#) Drug List

**RESTRICTED USE ANTIBIOTICS**

1. Must be recommended / approved for use by consultant medical microbiologist
2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
3. Only available from Pharmacy

**RESERVED USE ANTIBIOTICS**

1. Can be used only in accordance with the restrictions outlined below.
2. Indication must be clearly documented on the prescription chart.
3. If being used outside of guidelines Microbiology approval must be sought as above.

**UNRESTRICTED USE ANTIBIOTICS**

1. Can be used according to CMFT Trust guidelines, (those drugs not marked Restricted or Reserved)

**5.1 Antibacterial drugs**



**5.1.1 Penicillins**

**5.1.1.1 Benzylpenicillin & Phenoxyethylpenicillin**

**Benzylpenicillin sodium (Penicillin G)**

600mg injection



**Phenoxyethylpenicillin (Penicillin V)**

tablets



**Benzathine benzylpenicillin**



injection



**RESTRICTED**  
unlicensed treatment for syphilis

**5.1.1.2 Penicillinase-Resistant Penicillins**

**Flucloxacillin**

capsules; injection; oral solution



**Temocillin**

1g injection



**RESTRICTED** infection caused by  
multi-resistant coliforms.  
**Micro only**

**5.1.1.3 Broad Spectrum Penicillins**

**Amoxicillin**

capsules; oral suspension; injection



**Co-amoxiclav**

tablets; oral suspension; injection



**5.1.1.4 Antipseudomonal Penicillins**

**Piperacillin with tazobactam**

injection



**RESERVED**  
serious / resistant infections

**Ticarcillin with clavulanic acid**

Timentin® 3.2g injection



**RESERVED**  
serious / resistant infections

**5.1.1.5 Mecillinams**

**Pivmecillinam hydrochloride**

200mg tablets



**RESTRICTED** UTIs caused by  
resistant coliforms

**5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams**



**5.1.2.1 Cephalosporins**

**Cefalexin**

capsules; tablets; oral suspension



**Cefazolin**

injection



**RESTRICTED**  
on Micro. advice only

**Cefotaxime**

injection



**RESERVED**  
as per guidelines for children

**Ceftriaxone**

injection



































































**RESERVED**  
as per guidelines for children

**Cefuroxime**

injection
































































































































**RESERVED**  
as per guidelines for children

<b>Cefixime</b>		<b>RESERVED</b> GU infections only
tablets	  	
<b>Ceftazidime</b>		<b>RESERVED</b> pseudomonas infection in CF
injection	  	
<b>Cetazidime / Avibactam</b>		<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
Zavicefta® infusion	  	
<b>Ceftolozane sulfate / Tazobactam sodium</b>		<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
Zerbaxa® infusion	  	
<b>Ceftaroline fosamil</b>		<b>RESERVED</b> CAP & cSSTI treatment. <b>Micro. Consultant only</b>
Zinforo® infusion	  	
<b>Cefoxitin</b>		<b>RESERVED for treatment of</b> mycobacterium abscessus in CF. <b>Micro. Consultant only</b>
injection	  	
<b>Cefiderocol</b>		<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
Fetroja® infusion	  	
<b>5.1.2.2 Carbapenems</b>		
<b>Ertapenem</b>		<b>RESTRICTED</b> Outpatient therapy only
infusion	  	
<b>Imipenem with cilastatin</b>		<b>RESTRICTED</b> Non-Tuberculous Mycobacteria in CF
infusion	  	
<b>Imipenem with cilastatin &amp; relebactam</b>		<b>RESTRICTED</b> <b>Micro. Consultant only</b>
 Recarbrio® infusion	  	
<b>Meropenem</b>		<b>RESERVED</b> as per guidelines
injection	  	
<b>Meropenem with vaboractam</b>		<b>RESTRICTED</b> <b>Micro. Consultant only</b>
Vaborem® infusion	  	
<b>5.1.2.3 Other Beta-Lactam antibiotics</b>		
<b>Aztreonam</b>		<b>RESTRICTED</b> gram negative organisms
injection	 	
<b>Aztreonam lysine</b>		<b>RESTRICTED</b> 3 <sup>rd</sup> line CF patients with chronic pulmonary infection
  Cayston® nebuliser solution	  	
<b>Aztreonam with avibactam sodium</b>		
Emblaveo® infusion	  	
<b>5.1.3 Tetracyclines</b>		
<b>Doxycycline</b>		
capsules; tablets; dispersible tablets	  	
<b>Oxytetracycline</b>		
tablets	 	
<b>Demeclocycline hydrochloride</b>		<b>RESTRICTED</b> SIADH only
capsules (see also section 6.5.2)	  	
<b>Lymecycline</b>		<b>RESTRICTED</b> Non-Formulary <b>MMC approved for GP referral</b>
408mg capsules (see also section 13.6.2)	  	
<b>Minocycline</b>		
capsules; tablets	  	
<b>Tigecycline</b>		<b>RESERVED</b> as per guidelines
infusion	  	

**5.1.4 Aminoglycosides**

MHRA Drug Safety Update (Jan-21): Aminoglycosides (gentamicin, amikacin, tobramycin &amp; neomycin): increased risk of deafness in patients with mitochondrial mutations

<b>Amikacin</b>		<b>RESERVED</b> as per guidelines
injection	 <b>MMC</b>  	
<b>Gentamicin</b>		
injection	 	
<b>Tobramycin</b>		<b>RESERVED</b> as per guidelines
  		
injection; inhalation powder; nebuliser liquid	 <b>MMC</b>  	
<b>Neomycin sulfate</b>		<b>RESTRICTED</b> Gastro team only - op prep
oral solution	 	
<b>5.1.5 Macrolides</b>		
<b>Clarithromycin</b>		
tablets; oral suspension; infusion	 	
<b>Azithromycin</b>		<b>RESERVED</b> GU only or specialist use
tablets; oral suspension	 	
<b>Erythromycin</b>		<b>RESERVED</b> in pregnancy or neonates
tablets; oral suspension; injection	 	
MHRA Drug Safety Update (Dec-20): Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban		
MHRA Drug Safety Update (Dec-20): Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis		
<b>5.1.6 Clindamycin</b>		
<b>Clindamycin</b>		<b>RESERVED</b> as per guidelines
capsules; oral suspension; injection; 2% vaginal cream	 	
<b>5.1.7 Some other Antibacterials</b>		
<b>Chloramphenicol</b>		<b>RESERVED</b> as per guidelines
capsules; injection	 	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
<b>Dalbavancin</b>		
<b>Dalbavancin</b>		<b>RESTRICTED Consultant only</b>  <b>Micro. approval required</b>
500mg infusion	<b>MMC</b>  	
<b>Fidaxomicin</b>		<b>RESTRICTED</b> <i>clostridium difficile</i> associated diarrhoea <b>Micro. only</b>
 		
200mg tablets; 40mg/mL granules for oral suspension	<b>MMC</b>  	
<b>Fusidic Acid</b>		
<b>Fusidic acid (sodium fusidate)</b>		<b>RESERVED</b> as per guidelines
		
tablets; oral suspension; 2% cream	 	
MHRA Drug Safety Update (Sep-11): Systemic fusidic acid and interaction with statins		
<b>Glycopeptides</b>		
<b>Vancomycin</b>		
		
injection; capsules; oral suspension	<b>MMC</b>  	
<b>Teicoplanin</b>		<b>RESERVED</b> as per guidelines
injection	 	
<b>Daptomycin</b>		
<b>Daptomycin</b>		<b>RESTRICTED</b> as per guidelines
		
infusion	<b>MMC</b>  	
<b>Linezolid</b>		
<b>Linezolid</b>		<b>RESTRICTED</b> as per guidelines
		
tablets; infusion	<b>MMC</b>  	

<b>Polymyxins</b>		
<b>Colistimethate sodium</b>   injection  		<b>RESTRICTED</b> as per guidelines
<b>Colistimethate sodium (nebulised)</b>   Colomycin® injection     		<b>RESTRICTED specialist</b> for CF and non-CF bronchiectasis
<b>Colistimethate sodium (DPI)</b>   Colobreathe® inhalation powder    		<b>RESTRICTED</b> as per guidelines
MHRA Drug Safety Update (Nov-14): Colobreathe (colistimethate sodium dry powder for inhalation): risk of capsule breakage - new instructions for use		
<b>Pristinamycin</b>		
<b>Pristinamycin</b>   500mg tablets  		<b>RESTRICTED</b> as per BASHH guidelines for <i>Mycoplasma genitalium</i>
<b>Rifaximin</b>		
<b>Rifaximin</b>  550mg tablets (see also Ch1: Non-formulary items)    		<b>RESTRICTED</b> as per guidelines / NICE
<b>Spectinomycin</b>		
<b>Spectinomycin</b>  Kirin® injection   		<b>RESTRICTED</b> cephalosporin resistant gonorrhoea
<b>Taurolidine</b>		
<b>Taurolidine citrate 4%</b> TauroLock® 4% ampoules  		<b>RESTRICTED</b> as per CVC guidelines
<b>5.1.8 Sulfonamides &amp; Trimethoprim</b>		
<b>Trimethoprim</b> tablets; oral suspension  		
<b>Co-trimoxazole</b>  tablets; oral suspension; infusion  		<b>RESERVED</b> as per guidelines
<b>Sulfadiazine</b> tablets  		<b>RESTRICTED</b>
<b>5.1.9 Antituberculosis Drugs</b>  until patient stabilised then  		
<b>Bedaquiline</b>  tablets     		<b>RESTRICTED</b> MDR TB only 
<b>Ethambutol hydrochloride</b>  tablets    		
<b>Isoniazid</b>  tablets; oral solution; injection    		
<b>Pretomanid</b>  Dovprela® 200mg tablets   		<b>Restricted RR TB, MDR TB</b> and pre-XDR TB 
<b>Prothionamide</b>  tablets  		<b>RESTRICTED</b> MDR TB only
<b>Pyrazinamide</b>  tablets   		
<b>Rifampicin</b>  capsules; oral solution; infusion   		
<b>Rifabutin</b>  caspules  		<b>2<sup>nd</sup> line</b> where rifampicin not suitable
<b>Rifater®</b>  (Rifampicin with isoniazid & pyrazinamide) tablets   		

<b>Rifinah®</b> Green (Rifampicin with isoniazid) tablets	NICE BNF emc	
<b>Voractiv®</b> Green (Rifampicin with ethambutol hydrochloride, isoniazid and pyrazinamide) tablets	MMC BNF emc	
<b>Capreomycin sulfate</b> injection	NICE emc	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Cycloserine</b> capsules	BNF emc	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Delamanid</b> ££ tablets	MMC BNF emc	<b>RESTRICTED</b> MDR TB only
<b>Streptomycin</b> Red injection	NICE BNF emc	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Moxifloxacin</b> tablets; injection	NICE MMC BNF emc	<b>RESTRICTED</b>
<b>Para aminosalicylic acid (PAS)</b> granules	PbR X MMC BNF emc	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>5.1.10 Antileprotic Drugs</b>		
<b>Clofazimine</b> capsules	MMC BNF emc	<b>RESTRICTED</b> MDR TB only
<b>Dapsone</b> Green tablets	MMC BNF emc	<b>RESERVED</b>
<b>5.1.11 Metronidazole &amp; Tinidazole</b>		
<b>Metronidazole</b> tablets; oral suspension; infusion; suppositories; vaginal gel	MMC BNF emc	
<b>Tinidazole</b> tablets	BNF emc	<b>RESTRICTED</b>
<b>5.1.12 Quinolones</b>		
<b>Ciprofloxacin</b> tablets; oral suspension; infusion (see also sections 11.3.1 & 12.1.1)	BNF emc	<b>RESERVED</b> as per guidelines
<b>Delafloxacin</b> Red Quofenix® tablets; infusion	MMC BNF emc	<b>RESTRICTED Micro / Infectious diseases recommendation only</b>
<b>Levofloxacin</b> tablets; infusion (see also section 11.3.1)	MMC BNF emc	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Moxifloxacin</b> tablets; infusion	MMC BNF emc	<b>RESTRICTED</b> MDR TB only
<b>Nalidixic acid</b> tablets	BNF emc	<b>RESTRICTED</b> Urology use in children only
<b>Ofloxacin</b> tablets (see also section 11.3.1)	BNF emc	<b>RESTRICTED</b> GU infections only
<p>MHRA Drug Safety Update (Jan-24): Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate</p> <p>MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour</p> <p>MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk</p> <p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p> <p>MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling &amp; potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Nov-18): Systemic &amp; inhaled fluoroquinolones: small increased risk of aortic aneurysm &amp; dissection; advice for prescribing in high-risk patients</p>		



**5.1.13 Urinary-tract Infections****Nitrofurantoin**

M/R capsules; capsules; tablets



MHRA Drug Safety Update (Apr-23): Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions

MHRA Drug Safety Update (Sep-14): Nitrofurantoin now contraindicated in most patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m<sup>2</sup>**Fosfomycin**

sachets; infusion

**RESTRICTED**  
Micro recommendation only**Methenamine hippurate**

Hiprex® tablets

**RESTRICTED** Urology Consultants**Non-drug treatment****D-Mannose**

Waterfall D-Mannose® tablets / powder (food supplement)

**RESTRICTED** 5<sup>th</sup> line recurrent UTI  
after antibiotic options**Urease inhibitor****Acetohydroxamic acid**

Lithostat® tablets

**RESTRICTED** Urology Consultants



## 5.2 Antifungal drugs

### 5.2.1 Triazole Antifungals

#### Fluconazole

capsules; infusion; oral suspension.



#### Isavuconazole

capsules; infusion



**RESTRICTED**  
micro / specialist use only

#### Itraconazole

capsules; oral solution; infusion



#### Posaconazole

Red ££

G/R tablets; oral suspension; infusion



**RESTRICTED**  
micro / specialist use only

MHRA Drug Safety Update (Sep-16): Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable

#### Voriconazole

Red ££

tablets; oral suspension; infusion



**RESTRICTED**  
micro / specialist use only

### 5.2.3 Polyene Antifungals

#### Nystatin

100,000 units/mL oral suspension



#### Amphotericin (liposomal)

££

AmBisome® infusion (systemic use)



**RESTRICTED**  
micro / specialist use only

#### Amphotericin

££

Fungizone®



**RESTRICTED**  
micro / specialist use only

### 5.2.4 Echinocandin Antifungals

#### Anidulafungin

Red ££

Ecalta® infusion



**1<sup>st</sup> line RESTRICTED**  
micro / specialist use only

#### Micafungin

Red ££

Mycamine® infusion



**RESTRICTED**  
micro / specialist use only

#### Rezafungin

Red ££

Rezzayo® infusion



**RESTRICTED**  
micro / specialist use only

### 5.2.5 Other Antifungals

#### Griseofulvin

tablets



**2<sup>nd</sup> line**  
following topical therapy

#### Terbinafine

tablets



**2<sup>nd</sup> line**  
following topical therapy

#### Flucytosine

infusion


























































































































**RESTRICTED**  
micro / Neonates only




















































MHRA Drug Safety Update (Oct-20): Flucytosine (Ancotil): new contraindication in patients with DPD deficiency














## 5.3 Antiviral drugs



<p><b>Molnupiravir</b>  </p> <p>Lagevrio® 200mg capsules</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	<p><b>RESTRICTED CMDU</b>                  see COVID-19 guidance</p> <p></p>
<p><b>Nirmatrelvir with ritonavir</b>  </p> <p>Paxlovid® 150mg/100mg tablets</p> <p>PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> </p>	<p><b>RESTRICTED</b>                  see COVID-19 guidance</p> <p></p>
<p>MHRA Drug Safety Update (Nov-23): Nirmatrelvir, ritonavir (Paxlovid ▼): be alert to the risk of drug interactions with ritonavir</p>	
<p><b>Remdesivir</b>  </p> <p>Veklury® infusion</p> <p>PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> </p>	<p><b>RESTRICTED</b>                  see COVID-19 guidance</p> <p></p>
<p><b>Sotrovimab</b>  </p> <p>Veklury® infusion</p> <p>PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> </p>	<p><b>RESTRICTED</b>                  see COVID-19 guidance</p> <p></p>
<p><b>Tecovirimat monohydrate</b>  </p> <p>Tecovirimat SIGA® 200mg capsules</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	<p><b>RESTRICTED patients hospitalised due to monkeypox</b></p> <p></p>
<p><b>5.3.1 HIV Infection</b> </p>	<p><b>BHIVA treatment guidelines</b></p>
<p><b>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</b></p>	
<p><b>Abacavir</b>  </p> <p>tablets; oral solution</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	
<p><b>Bictegravir with emtricitabine &amp; tenofovir alafenamide</b>  </p> <p>Biktarvy® tablets</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	<p></p>
<p><b>Emtricitabine</b>  </p> <p>capsules</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	
<p><b>Lamivudine</b>  </p> <p>tablets; oral solution</p> <p>PbR X <b>BNF</b> </p>	
<p><b>Tenofovir disoproxil</b>  </p> <p>tablets; granules</p> <p>PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> </p>	
<p><b>Tenofovir alafenamide</b>  </p> <p>Descovy® / Odefsey® / Genvoya® tablets</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	<p><b>RESTRICTED</b>                  patients requiring new formulation</p> <p></p>
<p><b>Tenofovir disoproxil with efavirenz &amp; emtricitabine</b>  </p> <p>Atripla® tablets</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	
<p><b>Tenofovir with emtricitabine</b>  </p> <p>Truvada® tablets</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	<p></p>
<p><b>Emtricitabine with rilpivirine &amp; tenofovir</b>  </p> <p>Eviplera® tablets</p> <p>PbR X <b>MMC</b> <b>BNF</b> </p>	
<p><b>Zidovudine with lamivudine</b>  </p> <p>Combivir® tablets</p> <p>PbR X <b>BNF</b> </p>	

Protease Inhibitors		BHIVA treatment guidelines
<b>Atazanavir</b>   capsules    		
<b>Atazanavir with cobicistat</b>   Evotaz® tablets    		
<b>Darunavir</b>   tablets; oral suspension    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Darunavir with cobicistat</b>   Rezolsta® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Darunavir with cobicistat, emtricitabine &amp; tenofovir alafenamide</b>   Symtuza® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Fosamprenavir</b>   Telzir® tablets    		
<b>Fostemsavir tromethamine</b>   Rukobia® tablets    		
<b>Lopinavir with ritonavir</b>   Kaletra® tablets; oral solution   		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
<b>Ritonavir</b>   tablets; powder for oral suspension   		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
<b>Saquinavir</b>   tablets   		
Non-Nucleoside Reverse Transcriptase Inhibitors (Non-NRTIs)		BHIVA treatment guidelines
<b>Doravirine</b>   Pifeltro® tablets    		
<b>Doravirine with lamivudine &amp; tenofovir disoproxil fumarate</b>   Delstrigo® tablets    		
<b>Efavirenz</b>   tablets; capsules   		
<b>Etravirine</b>   Intence® tablets    		
<b>Nevirapine</b>   tablets; oral suspension; M/R tablets    		
<b>Rilpivirine</b>   Edurant® tablets / Rekambys® injection     		
Other Antiretrovirals (Integrase inhibitors; Fusion inhibitors; CCR5 antagonists)		BHIVA treatment guidelines
<b>Cabotegravir</b>   Vocabria® injection     		
<b>Dolutegravir</b>   Tivicay® tablets    		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
MHRA Drug Safety Update (Jun-18): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): increased risk of neural tube defects; DNP to women seeking to become pregnant...		
<b>Dolutegravir with abacavir &amp; lamivudine</b>   Triumeq® tablets    		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		

<b>Dolutegravir with lamivudine</b>   Dovato® tablets PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> 		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
<b>Dolutegravir with rilpivirine</b>   Juluca® tablets PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> 		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
<b>Enfuvirtide</b>   Fuzeon® injection PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> 		
<b>Maraviroc</b>   Celsentri® tablets PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> 		
<b>Raltegravir</b>   Isentress® tablets; chewable tablets; granules <b>MMC</b> <b>BNF</b> <b>emc</b> 		
<b>Pharmacokinetic enhancers of antiretrovirals</b>		
<b>Cobicistat</b>   Tybost® tablets PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> 		
<b>5.3.2 Herpesvirus Infection</b>		
<b>5.3.2.1 Herpes Simplex &amp; Varicella-Zoster Infection</b>		
<b>Aciclovir</b> tablets; oral suspension; infusion (see also section 13.10.3) <b>BNF</b> <b>emc</b> 		
<b>Valaciclovir</b> tablets <b>BNF</b> <b>emc</b> 		<b>RESTRICTED</b> Specialist use only Haematology / Renal
<b>5.3.2.2 Cytomegalovirus (CMV) Infection</b>		
<b>Cidofovir</b>   infusion PbR X <b>BNF</b> <b>emc</b> 		<b>RESERVED</b> Specialist use only
<b>Foscarnet sodium</b>   infusion PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> 		<b>RESERVED</b> Specialist use only; also for aggressive CMV retinitis
<b>Ganciclovir</b>   infusion (see also eye gel section 11.3.3) PbR X <b>BNF</b> <b>emc</b> 		<b>RESERVED</b> Specialist use only
<b>Letermovir</b>   Prevmis® tablets PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> 		<b>RESERVED</b> Specialist use only
<b>Maribavir</b>   Livtency® tablets PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>blueiq</b> 		<b>RESERVED</b> Specialist use only in line with NICE
<b>Valganciclovir</b>   tablets; oral solution PbR X <b>BNF</b> <b>emc</b> 		<b>RESERVED</b> Specialist use only
<b>5.3.3 Viral Hepatitis</b>		
<b>5.3.3.1 Chronic hepatitis B</b>		
<b>Adefovir dipivoxil</b>   Hepsera® tablets PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> 		<b>NICE CG165</b>
<b>Entecavir</b>   Baraclude® tablets PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> 		
<b>5.3.3.2 Chronic hepatitis C</b>		
		<b>NHSE Hepatitis C</b> 
MHRA Drug Safety Update (Jan-17): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR		
<b>Dasabuvir</b>   Exviera® tablets PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> <b>blueiq</b> 		<b>RESTRICTED</b> Specialist use only in line with NHSE Commissioning
<b>Elbasvir with grazoprevir</b>   Zepatier® tablets PbR X <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>blueiq</b> 		<b>RESTRICTED</b> Specialist use only in line with NICE TA413

<p><b>Glecaprevir with pibrentasvir</b>                         Maviret® tablets       </p>	<p><b>RESTRICTED Specialist use only</b>                      in line with NHSE and NICE TA499</p>
<p><b>Ombitasvir with paritaprevir &amp; ritonavir</b>                         Viekirax® tablets      </p>	<p><b>RESTRICTED Specialist use only</b>                      in line NICE / NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels</p>	
<p><b>Sofosbuvir</b>                         Sovaldi® tablets       </p>	<p><b>RESTRICTED Specialist use only</b>                      in line with NICE TA330</p> 
<p>MHRA Drug Safety Update (Aug-15): Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone</p>	
<p><b>Sofosbuvir with ledipasvir</b>                         Harvoni® tablets       </p>	<p><b>RESTRICTED Specialist use only</b>                      in line NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (May-15): Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone</p>	
<p><b>Sofosbuvir with velpatasvir</b>                         Epclusa® tablets       </p>	<p><b>RESTRICTED Specialist use only</b>                      in line with NICE TA430</p>
<p><b>Sofosbuvir with velpatasvir &amp; voxilaprevir</b>                         Vosevi® tablets       </p>	<p><b>RESTRICTED Specialist use only</b>                      in line with NICE TA507</p>
<p><b>5.3.3.3 Hepatitis D</b></p>	
<p><b>Bulevirtide</b>                         Hepcludex® injection       </p>	<p><b>RESTRICTED Specialist use only</b>                      in line with NICE TA896</p>
<p><b>5.3.4 Influenza</b></p>	
<p><b>Oseltamivir</b>                      Tamiflu® capsules; oral suspension     </p>	
<p>MHRA Drug Safety Update (Sep-12): Oseltamivir (Tamiflu): changed concentration and dosing dispenser of oral suspension</p>	
<p><b>Zanamivir</b>                      Relenza® inhalation powder     </p>	
<p><b>Zanamivir</b>                        Dectova® 10mg/mL infusion     </p>	<p><b>RESTRICTED</b>                      Virology approval only</p>
<p><b>5.3.5 Respiratory Syncytial Virus (RSV)</b></p>	
<p><b>Palivizumab</b>                         Synagis® 100mg/mL injection      </p>	<p><b>RESTRICTED Specialist use only</b></p> 
<p><b>Ribavirin</b>                         capsules; tablets      </p>	<p><b>RESTRICTED Specialist use only</b></p>

## 5.4 Antiprotozoal drugs



<b>Nitazoxanide</b>  500mg tablets; 100mg/5mL oral suspension		<b>RESTRICTED</b> Specialist use only
<span>PbR X</span> <b>MMC</b>		
<b>5.4.1 Antimalarials</b>		
<i>treatment</i> <i>prophylaxis</i>		
<b>Artesunate</b>  injection		<b>RESTRICTED</b> Specialist use only
<b>Artemether with lumefantrine</b>  tablets		<b>RESTRICTED</b> Specialist use only
		<b>MMC</b>
<b>Chloroquine</b>  tablets		<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
<b>Mefloquine</b>  tablets		<b>RESTRICTED</b> Specialist use only
<b>Primaquine</b>  tablets		<b>RESTRICTED</b> Specialist use only
<b>Proguanil hydrochloride</b>  tablets		<b>RESTRICTED</b> Specialist use only
<b>Proguanil hydrochloride with atovaquone</b>  <i>Malarone</i> ® tablets		<b>RESTRICTED</b> Specialist use only
<b>Pyrimethamine</b>  tablets		<b>RESTRICTED</b> Specialist use only
		<b>MMC</b>
<b>Pyrimethamine with sulfadoxine</b>  tablets		<b>RESTRICTED</b> Specialist use only
<b>Quinine dihydrochloride</b>  injection		<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
<b>Quinine sulfate</b>  tablets (see also section 10.2.2)		<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
<b>5.4.2 Amoebicides</b>		
<b>Metronidazole</b> (see also section 5.1.11)		
<b>Tinidazole</b> <i>Fasigyn</i> ® tablets		<b>RESERVED</b> Specialist use only
<b>Diloxanide furoate</b> tablets		<b>RESTRICTED</b> Non-formulary micro. recommendation only
<b>5.4.3 Trichomonacides</b>		
<b>Metronidazole</b> (see also section 5.1.11)		
<b>5.4.4 Antigiardial drugs</b>		
<b>Metronidazole</b> (see also section 5.1.11)		

**5.4.5 Leishmaniocides****Meglumine antimoniate**

injection

**RESTRICTED**  
treatment of Leishmaniocides**Paromomycin**

tablets

**RESTRICTED**  
treatment of Cryptosporidiosis**Sodium stibogluconate**

injection

**RESTRICTED**  
treatment of Leishmaniocides**5.4.7 Drugs for toxoplasmosis****Sulfadiazine**

tablets

**RESTRICTED**  
treatment of toxoplasmosis  
**micro. recommendation only****5.4.8 Drugs for pneumocystis pneumonia****Atovaquone**

oral suspension

**RESTRICTED**  
Specialist use only**Pentamidine isethionate**

injection

**RESTRICTED**  
Specialist use only



## 5.5 Anthelmintic



### 5.5.1 Drugs for Threadworms (pinworms, *Enterobius vermicularis*)

#### Albendazole



tablets



**RESTRICTED**  
Specialist use only

#### Mebendazole

chewable tablets; oral suspension



### 5.5.2 Ascaricides

#### Levamisole



tablets



**RESTRICTED**  
Specialist use only

### 5.5.5 Schistosomicides (bilharziasis)

#### Praziquantel



tablets



**RESTRICTED**  
Schistosomicides / tapeworm

### 5.5.6 Filaricides

#### Diethylcarbamazine



tablets



**RESTRICTED**  
Specialist use only

## Section 6: Endocrine System

Supported by the  
formulary (click here)



### 6.1 Drugs used in diabetes

#### 6.1.1 Insulins

##### 6.1.1.1 Short-acting insulins

##### 6.1.1.2 Intermediate & long-acting insulins

##### Biphasic insulins

#### 6.1.2 Antidiabetic drugs

##### 6.1.2.1 Sulphonylureas

##### 6.1.2.2 Biguanides

##### 6.1.2.3 Other antidiabetic drugs

##### Alpha glucosidase inhibitors

##### Dipeptidyl peptidase-4 (DPP-4) inhibitors

##### Rapid acting insulin secretagogues (meglitinides)

##### Glucagon-like peptide-1 (GLP-1) receptor agonists

##### Sodium-glucose co-transporter 2 (SGLT2) inhibitors

##### Thiazolidinediones

#### 6.1.4 Treatment of hypoglycaemia

#### 6.1.5 Treatment of diabetic nephropathy and neuropathy

#### 6.1.6 Diagnostic and monitoring agents for diabetes mellitus

### 6.2 Thyroid & antithyroid drugs

#### 6.2.1 Thyroid hormones

#### 6.2.2 Antithyroid drugs

### 6.3 Corticosteroids

#### 6.3.1 Replacement therapy

#### 6.3.2 Glucocorticoid therapy

### 6.4 Sex hormones

#### 6.4.1 Female sex hormones and their modulators

##### 6.4.1.1 Oestrogens & HRT

##### 6.4.1.2 Progestogens and progesterone receptor modulators

#### 6.4.2 Male sex hormones & antagonists

### 6.5 Hypothalamic and pituitary hormones & anti-oestrogens

#### 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

#### 6.5.2 Posterior pituitary hormones & antagonists

### 6.6 Drugs affecting bone metabolism

#### 6.6.1 Calcitonin & parathyroid hormone

#### 6.6.2 Bisphosphonates & other drugs affecting bone metabolism

### 6.7 Other endocrine drugs

#### 6.7.1 Bromocriptine & other dopaminergic drugs

#### 6.7.2 Drugs affecting gonadotrophins

#### 6.7.3 Metyrapone

#### 6.7.4 Somatomedins

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Safer insulin prescribing (KTT20)  
 Diabetes in pregnancy: management from preconception to the postnatal period (NG3)  
 Type 1 diabetes in adults: diagnosis and management (NG17)  
 Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)  
 Diabetic foot problems: prevention and management (NG19)  
 Type 2 diabetes in adults: management (NG28)  
 Heavy menstrual bleeding: assessment and management (NG88)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Human growth hormone - adults (TA64)  
 Diabetes (type 1) - insulin pump therapy (TA151)  
 Osteoporosis - Primary Prevention (TA160)  
 Osteoporosis - Secondary Prevention (TA161)  
 Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)  
 Osteoporotic Fractures - denosumab (TA204)  
 Bone metastases from solid tumours - denosumab (TA265)  
 Type 2 diabetes - Dapagliflozin combination therapy (TA288)  
 Diabetes (type 2) - canagliflozin (TA315)  
 Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)  
 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)  
 Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)  
 Bisphosphonates for treating osteoporosis (TA464)  
 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)  
 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)  
 Dapagliflozin with insulin for treating type 1 diabetes (TA597)  
 Sotagliflozin with insulin for treating type 1 diabetes (TA622)  
 Liraglutide for managing overweight and obesity (TA664)  
 Dapagliflozin for treating chronic kidney disease (TA775)  
 Romosozumab for treating severe osteoporosis (TA791)  
 Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)  
 Somatrogen for treating growth disturbance in people 3 years and over (TA863)  
 Tirzepatide for treating type 2 diabetes (TA924)  
 Empagliflozin for treating chronic kidney disease (TA942)  
 Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)  
 Abaloparatide for treating osteoporosis after menopause (TA991)  
 Burosumab for treating X-linked hypophosphataemia in adults (TA993)  
 Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

## GMMMG Formulary

Formulary Homepage  
 Chapter 6: Endocrine system (v10.4 - Dec-24)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

# 6.1 Drugs used in diabetes



## 6.1.1 Insulins

Type 1 diabetes



Type 2 diabetes



**Insulins must ONLY be initiated by practitioners experienced in their use**  
**Insulins must be prescribed by BRAND NAME**
















MHRA Drug Safety Update (Apr-15): High strength, fixed combination & biosimilar insulin products: minimising the risk of medication error













- NICE NG3
- NICE NG17
- NICE NG18
- NICE NG19
- NICE NG28

### 6.1.1.1 Short-acting insulins

Human	
<b>Actrapid®</b>	
Human Insulin	
<b>Apidra®</b>	
Insulin glulisine	
<b>Fiasp®</b>	
Insulin aspart	
<b>Humalog®</b>	
Insulin lispro	
<b>Humulin R®</b>	
Human Insulin	
<b>Humulin S®</b>	
Human Insulin	
<b>Insulin Lispro Sanofi®</b>	
Insulin lispro	
<b>Lyumjev®</b>	
Insulin lispro	
<b>NovoRapid®</b>	
Insulin aspart	
<b>Trurapi®</b>	
Insulin aspart	
Animal	
<b>Hypurin® Porcine Neutral</b>	
Insulin porcine	
6.1.1.2 Intermediate & long-acting insulins	
Human	
<b>Humulin I® Insulin</b>	
Isophane insulin	
<b>Insulatard®</b>	
Isophane insulin	
Animal	
<b>Hypurin® Porcine Isophane</b>	
Isophane insulin	

**Long-acting insulins**

<b>Human</b>		
<b>Levemir®</b>		
Insulin detemir	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Lantus®</b>		<b>2<sup>nd</sup> line use</b> in patients where normal basal insulins cause nocturnal hypoglycaemia
Insulin glargine	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Abasaglar®</b>		
Insulin glargine (biosimilar)	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Toujeo®</b>		
Insulin glargine (HIGH STRENGTH)	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Tresiba®</b>		<b>RESTRICTED</b> <b>3<sup>rd</sup> line after Levemir &amp; Lantus</b> <b>Diabetes Consultant only</b>
Insulin degludec	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
MHRA Drug Safety Update (Apr-13): Insulin degludec (Tresiba ▼): available in additional higher strength		
<b>Biphasic insulins</b>		
<b>Human</b>		
<b>Humalog® Mix 25</b>		
Biphasic insulin lispro	 <b>BNF</b> <b>emc</b>	
<b>Humalog® Mix 50</b>		
Biphasic insulin lispro	 <b>BNF</b> <b>emc</b>	
<b>Humulin M3®</b>		
Biphasic isophane insulin	 <b>BNF</b> <b>emc</b>	
<b>Insuman® Comb 25</b>		
Biphasic isophane insulin	 <b>BNF</b> <b>emc</b>	
<b>NovoMix® 30</b>		
Biphasic insulin aspart	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Animal</b>		
<b>Hypurin® Porcine 30/70 Mix Insulin</b>		
Biphasic isophane insulin	 <b>BNF</b> <b>emc</b>	
<b>6.1.2 Antidiabetic drugs</b>		
<b>6.1.2.1 Sulfonylureas</b>		
<b>Gliclazide</b>		
tablets	 <b>BNF</b> <b>emc</b>	
<b>Glipizide</b>		<b>RESTRICTED</b> <b>Not for initiation</b>
tablets	 <b>BNF</b> <b>emc</b>	
<b>6.1.2.2 Biguanides</b>		
<b>Metformin hydrochloride</b>		
 Green oral solution; tablets	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
MHRA Drug Safety Update (Jun-22): Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk		
MHRA Drug Safety Update (Mar-22): Metformin in pregnancy: study shows no safety concerns		

6.1.2.3 Other antidiabetic drugs		NICE NG28
<b>Alpha glucosidase inhibitors</b>		
<b>Acarbose</b>		
tablets	 	
<b>Dipeptidyl peptidase 4 (DPP 4) inhibitors</b>		
MHRA Drug Safety Update (Sep-12): Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis		
<b>Alogliptin</b>		
		
tablets	  	
<b>Linagliptin</b>		
		
tablets	  	
<b>Saxagliptin</b>		
		<b>2<sup>nd</sup> line</b> to improve glycaemic control in adults with metformin
tablets	  	
<b>Sitagliptin</b>		
		
tablets	  	
<b>Rapid acting insulin secretagogues (meglitinides)</b>		
<b>Nateglinide</b>		
tablets	  	<b>2<sup>nd</sup> line</b>
<b>Repaglinide</b>		
tablets	  	<b>2<sup>nd</sup> line</b>
<b>Glucagon-like peptide-1 (GLP-1) receptor agonists</b>		
MHRA Drug Safety Update (Oct-24): GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse		
MHRA Drug Safety Update (Jun-19): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued		
<b>Dulaglutide</b>		
		<b>RESTRICTED</b> <b>1<sup>st</sup> line weekly preparation</b> <b>Diabetes Consultants only</b>
injection	  	
<b>Exenatide</b>		
		<b>2<sup>nd</sup> line</b> patients with poor glycaemic control
injection	   	
<b>Bydureon®</b>		
		<b>3<sup>rd</sup> line</b> after failure / inadequate response to oral therapy
Exenatide prolonged release (once weekly injection)	  	
<b>Liraglutide (Victoza®)</b>		
		<b>2<sup>nd</sup> line</b> to achieve glycaemic control with metformin or a sulphonylurea <b>PRESCRIBE BY BRAND NAME</b>
6mg/mL pre-filled pen	   	
<b>Liraglutide (Saxenda®)</b>		
		<b>RESTRICTED</b> <b>in line with NICE TA664</b> <b>PRESCRIBE BY BRAND NAME</b>
6mg/mL pre-filled pen	   	
MHRA Drug Safety Update (Nov-23): Ozempic▼ (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
<b>Lixisenatide (Lyxumia®)</b>		
		<b>RESTRICTED</b> <b>3<sup>rd</sup> line</b> as per by GMMMG & NICE <b>Diabetes Consultants only</b>
injection	  	
<b>Semaglutide</b>		
		<b>1<sup>st</sup> line</b> weekly preparation
Ozempic® injection	  	
MHRA Drug Safety Update (Nov-23): Ozempic▼ (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
<b>Semaglutide</b>		
		<b>RESTRICTED</b> <b>as per by GMMMG</b>
Rybelsus® tablets	   	
<b>Tirzepatide</b>		
		<b>RESTRICTED</b> <b>as per NICE / GMMMG T2DM pathway</b>
Mounjaro® injection	   	



















**Sodium-glucose co-transporter 2 (SGLT2) inhibitors**

MHRA Drug Safety Update (Mar-20): SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness



MHRA Drug Safety Update (Feb-19): SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum)

MHRA Drug Safety Update (Mar-17): SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)









MHRA Drug Safety Update (Apr-16): SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis

<p><b>Canagliflozin</b></p> <p>tablets</p> <p>   </p>	<p><b>RESTRICTED</b> in line with NICE <b>Diabetes Consultants only</b></p>
<p>MHRA Drug Safety Update (Jun-16): Canagliflozin (Invokana ▼, Vokanamet ▼): signal of increased risk of lower extremity amputations in trial in high CV risk patients</p>	
<p><b>Dapagliflozin</b></p> <p></p> <p>tablets</p> <p>   </p>	<p><b>RESTRICTED</b> in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-16): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus</p>	
<p><b>Empagliflozin</b></p> <p></p> <p>tablets</p> <p>   </p>	<p><b>RESTRICTED</b> in line with NICE</p>
<p><b>Ertugliflozin</b></p> <p>tablets</p> <p>   </p>	<p><b>RESTRICTED</b> in line with NICE <b>Diabetes Consultants only</b></p>





**Thiazolidinediones**

<p><b>Pioglitazone</b></p> <p>tablets</p> <p>  </p>	<p><b>2<sup>nd</sup> line</b> add-on with metformin or a sulphonylurea</p>
<p>MHRA Drug Safety Update (Aug-11): Pioglitazone: risk of bladder cancer</p>	



**6.1.4 Treatment of hypoglycaemia**

<p><b>Glucagon</b></p> <p>1mg injection</p> <p> </p>	
<p><b>Glucose gel</b></p> <p>40% oral gel</p> <p> </p>	
<p><b>Diazoxide</b></p> <p></p> <p>tablets</p> <p>  </p>	<p><b>Hyperinsulinaemic Hypoglycaemia</b></p>

**6.1.5 Treatment of diabetic nephropathy and neuropathy**

<p><b>Diabetic nephropathy</b>  </p>	<p>(see also section 4.7.3 Neuropathic pain)</p>	<b>NICE NG3</b>
<b>Diabetic neuropathy</b>  		<b>NICE NG17</b>
		<b>NICE NG18</b>
		<b>NICE NG19</b>
		<b>NICE NG28</b>

**6.1.6 Diagnostic and monitoring agents for diabetes mellitus**

<p></p>	<p></p>
<p>MHRA Drug Safety Update (Oct-24): Insulin pumps &amp; CGM equipment: guidance for users on reporting suspected adverse incidents &amp; safety concerns to the MHRA's Yellow Card</p>	

## 6.2 Thyroid & antithyroid drugs



### 6.2.1 Thyroid hormones

#### Levothyroxine sodium

oral solution; tablets



MHRA Drug Safety Update (May-21): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products

#### Liothyronine sodium

Red Green

injection; tablets



**2<sup>nd</sup> line use (I.V. RESTRICTED to hypothyroid coma)**

### 6.2.2 Antithyroid drugs

#### Carbimazole

5mg; 20mg tablets (see also DNP below)



MHRA Drug Safety Update (Feb-19): Carbimazole: increased risk of congenital malformations; strengthened advice on contraception

MHRA Drug Safety Update (Feb-19): Carbimazole: risk of acute pancreatitis

#### Iodine (Aqueous Iodine Oral Solution)



Lugol's Iodine



#### Potassium iodide

tablets



#### Propylthiouracil

Green

tablets





## 6.3 Corticosteroids



MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

### 6.3.1 Replacement therapy

#### Fludrocortisone acetate

tablets



### 6.3.2 Glucocorticoid therapy

#### Prednisolone

**1<sup>st</sup> line:** standard tablets

**If 1<sup>st</sup> line not tolerated**

**2<sup>nd</sup> line:** dissolve standard tablets

**3<sup>rd</sup> line:** oral liquid

**4<sup>th</sup> line:** soluble tablets (££)



#### Dexamethasone



#### Hydrocortisone



MHRA Drug Safety Update (Dec-18): Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks

#### Hydrocortisone M/R

5mg tablets



**RESTRICTED**

**2<sup>nd</sup> line use in adrenal insufficiency**

#### Hydrocortisone

Green

Alkindi® granules in capsules



**RESTRICTED**

**2<sup>nd</sup> line use in adrenal insufficiency**

MHRA Drug Safety Update (Feb-21): Alkindi (granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules

#### Betamethasone



**RESTRICTED**  
**Specialist use only**

#### Methylprednisolone



MHRA Drug Safety Update (Oct-17): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows' milk allergy

#### Triamcinolone acetonide

(see also section 10.1.2.2)



**RESTRICTED**  
**Specialist use only**

## 6.4 Sex hormones



### 6.4.1 Female sex hormones and their modulators

#### 6.4.1.1 Oestrogens & HRT

##### Conjugated oestrogens with progestogen

**Premique®** (Conjugated oestrogens with medroxyprogesterone)

tablets



**2<sup>nd</sup> line use oral**  
(continuous combined HRT)

##### Estradiol with Progestogen

**Elleste-Duet®** (Estradiol with norethisterone)

tablets



**1<sup>st</sup> line use oral**  
(sequential HRT)

**Femoston®** (Estradiol with dydrogesterone)

tablets



**2<sup>nd</sup> line use oral**  
(sequential HRT)

**Kliovance®** (Estradiol with norethisterone)

tablets



**1<sup>st</sup> line use oral**  
(continuous combined HRT)

**Evorel Conti®** (Estradiol with norethisterone)

patch



**RESTRICTED**  
(Continuous combined HRT)  
when oral contraindicated

##### Estradiol only

**Elleste Solo®**

tablets



**1<sup>st</sup> line use oral**  
(oestrogen only HRT)

**Estradot®**

patch



**RESTRICTED**  
(Oestrogen only HRT)  
when oral contraindicated.

**Evorel®**

patch



**RESTRICTED**  
Paed. Endocrine Consultants

##### Ethinylestradiol, raloxifene & tibolone

**Ethinylestradiol**

tablets



2 microgram tablets (unlicensed)  
for amenorrhoea

**Raloxifene hydrochloride**

tablets



**RESTRICTED**  
Specialist Med. Consultant only  
NICE TA160 / TA161

**Tibolone**

tablets



**3<sup>rd</sup> line use oral**  
(continuous combined HRT)

#### 6.4.1.2 Progestogens and progesterone receptor modulators

**Dydrogesterone**

tablets



**Medroxyprogesterone acetate**

*Depo-Provera®* 150mg/mL injection



**Medroxyprogesterone acetate**

*Sayana Press®* 104mg/0.65 mL injection



**Norethisterone**

tablets



**Progesterone**

**Red** (suppositories in IVF)

pessaries; vaginal capsules; injection



**Ulipristal acetate**

**Red**

*Esmya®* 5mg tablets



**RESTRICTED**  
Specialist use only uterine fibroids

MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury

MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment

MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users

**6.4.2 Male sex hormones & antagonists****Testosterone & Esters****Oral****Testosterone**

Green Amber

injection &amp; implants only

BNF emc

**RESTRICTED**  
Specialist use only**Transdermal preparations****Androstanolone (aka Dihydrotestosterone (DHT))**

Andractim® 2.5% gel

MMC BNF emc

**RESTRICTED**  
Specialist use only - 3<sup>rd</sup> line

MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure

**Testosterone**

Tostran® 2% gel

MMC BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure

**Anti-androgens****Cyproterone acetate**

Green

tablets (see also section 8.3.4.2)

BNF emc

**RESTRICTED**  
Specialist use only**Finasteride**

Amber

tablets

BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Apr-24): Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation..)

MHRA Drug Safety Update (May-17): Finasteride: rare reports of depression and suicidal thoughts

# 6.5 Hypothalamic & pituitary hormones & anti-oestrogens



## 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

### Anti-oestrogens

**Clomifene citrate**

Red

tablets

BNF emc

### Anterior pituitary hormones (Corticotrophins)

**Tetracosactide**

Red

injection

BNF emc

**RESTRICTED**  
test for adrenocortical insufficiency

**Corticotropin releasing hormone**

Red

injection

emc

**RESTRICTED**  
Specialist use only

### Anterior pituitary hormones (Gonadotrophins)

**Human Chorionic Gonadotrophin (hCG)**

Red

Zivafert® injection

MMC emc

**RESTRICTED**  
Specialist use only

**Recombinant human follicle stimulating hormone (r-hFSH)**

Red

Ovaleap® injection

MMC BNF emc

**RESTRICTED**  
Specialist use only

### Anterior pituitary hormones (Growth Hormone)

**Somatropin**

Red

Amber

££

injection

PbR X NICE MMC BNF emc

**RESTRICTED**  
as per NICE TA64 / TA188

**Somatogon**

Red

££

Ngenla® injection

PbR X NICE MMC BNF emc

**RESTRICTED**  
as per NICE TA863

Growth hormone for primary and secondary hypopituitarism

Green

Growth hormone for children

Amber

Growth hormone for adults except in proven primary and secondary hypopituitarism

Red

### Anterior pituitary hormones (Growth Hormone receptor antagonists)

**Pegvisomant**

Red

££

injection

PbR X MMC BNF blue-teq emc

**RESTRICTED**  
acromegaly on named patient basis  
**NOT STOCKED**

### Hypothalamic hormones

**Gonadorelin (GnRH; LHRH)**

Red

injection

BNF emc

**RESTRICTED**  
Specialist use only

**Protirelin (TRH)**

Red

injection

BNF emc

**RESTRICTED**  
Specialist use only

## 6.5.2 Posterior pituitary hormones & antagonists

**Desmopressin**

injection; oral lyophilisates; nasal spray; solution; tablets (see also section 7.4.2)

MMC BNF emc

**RESTRICTED**  
Haematology Consultants only



**Terlipressin acetate**

injection

MMC BNF emc

**RESTRICTED**  
oesophageal varices / HRS-AKI

MHRA Drug Safety Update (Mar-23): Terlipressin: new recommendations to reduce risks of respiratory failure & septic shock in patients with type 1 hepatorenal syndrome

**Tolvaptan**

Red

££

tablets

PbR X NICE MMC BNF emc

**RESTRICTED Adult.**  
Endocrine / Renal Consultant only



**Vasopressin**

injection

BNF emc

**RESTRICTED**  
pituitary diabetes insipidus

### Antidiuretic hormone antagonists

**Demeclocycline hydrochloride**

Red

capsules (see also section 5.1.3)

MMC BNF emc

**RESTRICTED**  
SIADH only

## 6.6 Drugs affecting bone metabolism



### 6.6.1 Calcitonin & parathyroid hormone

#### Abaloparatide (Eladynos®)

Red 80 micrograms injection

PbR X NICE MMC BNF emc

**RESTRICTED** postmenopausal osteoporosis in line with NICE TA991

#### Calcitonin (salmon) / Salcatonin (Miacalcic®)

injection

MMC BNF emc

**RESTRICTED** osteoporosis patients with acute fracture pain.

MHRA Drug Safety Update (Aug-12): Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.

#### Parathyroid hormone

Red

injection

PbR X MMC BNF emc

**RESTRICTED** postmenopausal osteoporosis if failure or non-compliance with bisphosphonates

#### Teriparatide (Forsteo®)

Red

250 micrograms / mL injection

PbR X NICE MMC BNF emc

**RESTRICTED** as per NICE/NHSE

#### Teriparatide (Movymia®)

Red

250 micrograms / mL injection

PbR X NICE MMC BNF emc

Paeds. see decision tables  
**RESTRICTED** as per forsteo for new patients



### 6.6.2 Bisphosphonates & other drugs affecting bone metabolism

MHRA Guidance (Dec-14): Bisphosphonates: use and safety

MHRA Drug Safety Update (Dec-15): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update (Jun-11): Bisphosphonates: atypical femoral fractures

MHRA Drug Safety Update (Nov-09): Bisphosphonates: osteonecrosis of the jaw

#### Alendronic acid

tablets

NICE MMC BNF emc

**1<sup>st</sup> line use**

#### Risedronate sodium

tablets

NICE MMC BNF emc

**2<sup>nd</sup> line**  
Osteoporosis & Paget's disease

#### Strontium ranelate

Red

oral suspension

MMC BNF emc

**3<sup>rd</sup> line** osteoporosis patients unable to take bisphosphonates

#### Ibandronic acid

Red injection tablets

tablets; injection

NICE MMC BNF emc

**RESTRICTED** monthly treatment when daily/weekly dosing contraindicated; NICE TA464

#### Denosumab

Amber

Prolia® injection

NICE MMC BNF emc

**RESTRICTED** specialist use / NICE TA204

MHRA Drug Safety Update (May-22): Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia

MHRA Drug Safety Update (Aug-20): Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment

MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

#### Denosumab

Red

Xgeva® injection

NICE MMC BNF emc

**RESTRICTED** specialist use / NICE TA265

MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for advanced malignancies involving bone: study data show new 1ry malignancies reported more frequently...

MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

#### Zoledronic acid

Red

infusion

NICE MMC BNF emc

**RESTRICTED** see decision tables; also NICE TA464

#### Burosumab

Red

infusion

NICE MMC BNF emc

**RESTRICTED** specialist use only XLH / TIO  
NICE HST8 / TA993

#### Romosozumab

Red

Evenity® injection

NICE MMC BNF emc

**RESTRICTED** specialist use NICE TA791

## 6.7 Other endocrine drugs



### 6.7.1 Bromocriptine & other dopaminergic drugs

#### Bromocriptine

1mg; 2.5mg tablets

MMC BNF emc

MHRA Drug Safety Update (Oct-24): Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation

#### Cabergoline

500 microgram tablets

BNF emc

**RESTRICTED**  
Hyperprolactinaemia

### 6.7.2 Drugs affecting gonadotrophins

#### Danazol

capsules

BNF emc

#### Buserelin acetate

Red

injection (see also section 8.3.4.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**  
IVF

#### Buserelin acetate

Red

Suprecur® nasal spray

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**  
adult haem-oncology patients

#### Goserelin acetate

Amber Red

implant (also section 8.3.4.2)

BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

#### Leuprorelin acetate

Amber Red

injection (also section 8.3.4.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

#### Triptorelin acetate

Amber Red

injection (also section 8.3.4.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**

#### Cetrorelix acetate

Red

injection

MMC BNF emc

**RESTRICTED**  
IVF

#### Ganirelix

Red

injection

MMC BNF emc

**RESTRICTED**  
IVF

#### Linzagolix

Green

Yselyt® 100mg; 200mg tablets

NICE MMC BNF emc

**RESTRICTED**  
specialist use NICE TA996

#### Relugolix with estradiol & norethisterone acetate

Green

Ryeqo® 40mg/1mg/0.5mg tablets

NICE MMC BNF emc

**RESTRICTED**  
specialist use NICE TA832

Goserelin/Leuprorelin - Licensed Indications (Pre-op management prior to endometrial ablation/fibroid surgery)

Amber

Goserelin/Leuprorelin/Triptorelin - Licensed Indications (Prostate cancer for all and breast cancer for Goserelin)

Amber

Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin & leuprorelin)

Red

Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)

Red

### 6.7.3 Metyrapone

#### Metyrapone

Red

250mg capsules

BNF emc

**RESTRICTED**  
Specialist use only

### 6.7.4 Somatomedins

#### Mecasermin

£

10mg/mL injection

PbR x

BNF emc

blueiq

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex▼): risk of benign and malignant neoplasia

## Non-Formulary Items



### Carbimazole

DNP

10mg; 15mg tablets

MMC BNF emc

in line with  
GMMMG

### Hypurin® Bovine Isophane

Isophane insulin

emc

Discontinued  
July 2017

### Hypurin® Bovine Lente

Insulin zinc suspension

emc

Discontinued  
July 2017

### Hypurin® Bovine Neutral

Insulin bovine

emc

Discontinued  
July 2017

### Sotagliflozin

Zynquista® 200mg tablets

NICE MMC emc

Withdrawn August 2022

## Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the  
formulary ([click here](#))



### 7.1 Drugs used in Obstetrics

- 7.1.1 Prostaglandins & oxytocics
  - 7.1.1.1 Drugs affecting the ductus arteriosus
- 7.1.2 Mifepristone
- 7.1.3 Myometrial relaxants

### 7.2 Treatment of vaginal & vulval conditions

- 7.2.1 Preparations for vaginal & vulval changes
- 7.2.2 Vaginal & vulval infections

### 7.3 Contraceptives

- 7.3.1 Combined hormonal contraceptives
  - Ethinylestradiol with Desogestrel
  - Ethinylestradiol with Gestodene
  - Ethinylestradiol with Levonorgestrel
  - Ethinylestradiol with Norelgestromin
  - Ethinylestradiol with Norethisterone
  - Ethinylestradiol with Norgestimate
  - Mestranol with Norethisterone
- 7.3.2 Progestogen-only contraceptives
  - 7.3.2.1 Oral progestogen-only contraceptives
  - 7.3.2.2 Parenteral progestogen-only contraceptives
  - 7.3.2.3 Intra-uterine progestogen-only device
- 7.3.5 Emergency contraception

### 7.4 Drugs for genito-urinary disorders

- 7.4.1 Drugs for urinary retention
- 7.4.2 Drugs for urinary, enuresis & incontinence
- 7.4.3 Drugs used in urological pain
- 7.4.4 Bladder instillations & urological surgery
- 7.4.5 Drugs for erectile dysfunction
- 7.4.6 Drugs for premature ejaculation



## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Long-acting reversible contraception (CG30)  
Lower urinary tract symptoms (CG97)  
Nocturnal enuresis - the management of bedwetting in children and young people (CG111)  
Antenatal and postnatal mental health: clinical management and service guidance (CG192)  
Heavy menstrual bleeding: assessment and management (NG88)  
Urinary incontinence and pelvic organ prolapse in women: management (NG123)  
Caesarean birth (NG192)  
Antenatal care for uncomplicated pregnancies (NG201)  
Inducing labour (NG207)  
Intrapartum care for healthy women and babies (NG235)  
Overactive bladder - mirabegron (TA290)  
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)  
Vibegron for treating symptoms of overactive bladder syndrome (TA999)

## GMMMG Formulary

Formulary Homepage  
Chapter 7: Obstetrics, gynaecology & urinary tract disorders (v8.2 - Oct-24)  
GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List  
GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 7.1 Drugs used in Obstetrics



### 7.1.1 Prostaglandins & oxytocics

NICE NG207

#### Carbetocin

Red

*Pabal*® injection

MMC BNF emc

**RESTRICTED**  
Obs & Gynae Consultants only

#### Carboprost

Red

injection

BNF emc

#### Ergometrine maleate

Red

injection

BNF emc

#### Gemeprost

Red

pessaries

BNF emc

#### Oxytocin

Red

injection

BNF emc

#### Dinoprostone

Red

injection; pessaries; vaginal gel; vaginal tablet

MMC BNF emc

**RESTRICTED**  
Obs & Gynae Consultants only

### 7.1.1.1 Drugs affecting the ductus arteriosus

#### Maintenance of patency

#### Alprostadil

Red

*Prostin VR*® infusion

MMC BNF emc

#### Closure of the ductus arteriosus

#### Indometacin

Red

injection

BNF emc

### 7.1.2 Mifepristone

#### Mifepristone

Red

tablets

BNF emc

### 7.1.3 Myometrial relaxants

#### Nifedipine

Red



capsules; tablets

MMC BNF emc

**RESTRICTED (1<sup>st</sup> line)**  
Obs & Gynae Consultants only

#### Atosiban

Red

infusion; injection

MMC BNF emc

**RESTRICTED (2<sup>nd</sup> line)**  
Obs & Gynae Consultants only

#### Indometacin

Red



capsules; suppositories

MMC BNF emc

**RESTRICTED (3<sup>rd</sup> line)**  
Obs & Gynae Consultants only

### Beta<sub>2</sub> agonists

#### Salbutamol

Red

injection (see also section 3.1.1.1)

BNF emc

#### Terbutaline sulfate

Red

injection (see also section 3.1.1.1)

BNF emc

## 7.2 Treatment of vaginal & vulval conditions



### 7.2.1 Preparations for vaginal & vulval changes

#### Oestrogens, topical

##### Estradiol

Vagifem® 10 microgram pessaries



##### Estriol

0.01% cream



##### Estradiol (vaginal ring)

Estring® 7.5 microgram / 24 hours ring



**RESTRICTED**  
Obs & Gynae Consultants only

### 7.2.2 Vaginal & vulval infections

#### Preparations for vaginal & vulval candidiasis

##### Clotrimazole

cream; pessaries



##### Miconazole

vaginal cream



#### Preparations for other vaginal infections

##### Clindamycin

2% vaginal cream



##### Nystatin

vaginal cream; pessaries



##### Metronidazole

Zidoval® 0.75% vaginal gel



**RESTRICTED**  
Obs & Gynae Consultants only

##### Boric acid

Red vaginal pessary



**RESTRICTED**  
specialist use only for  
vulvovaginal candidiasis

## 7.3 Contraceptives



MHRA Drug Safety Update (Mar-19): Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?

### 7.3.1 Combined hormonal contraceptives

NICE CG30

MHRA Drug Safety Update (Mar-14): Combined hormonal contraceptives: risk of venous thromboembolism

#### Ethinylestradiol with desogestrel

**Munalea**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

**Mercilon**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

#### Ethinylestradiol with gestodene

**Femodene**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

**Aidulan**®

20microgram / 75 microgram tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

#### Ethinylestradiol with levonorgestrel

NICE NG88

**TriRegol**®

tablets



**Microgynon 30**®

tablets



**Ovranette**®

tablets



#### Ethinylestradiol with norelgestromin

**Evra**®

patch



**RESTRICTED**  
in line with GMMMG and SmPC

#### Ethinylestradiol with norethisterone

**Loestrin 20**®

tablets



**Loestrin 30**®

tablets



**Norimin**®

tablets



#### Ethinylestradiol with norgestimate

**Cilest**®

tablets



#### Mestranol with norethisterone

**Norinyl-1**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

### 7.3.2 Progestogen-only contraceptives

#### 7.3.2.1 Oral progestogen-only contraceptives

**Desogestrel**

Cerazette® 75 microgram tablets



**Levonorgestrel**

Norgeston® 35 microgram tablets



**Norethisterone**

Noriday® 350 microgram tablets



**7.3.2.2 Parenteral progestogen-only contraceptives**

**Injectable preparations**

**Medroxyprogesterone acetate**

*Depo-Provera*® 150mg/mL intramuscular injection



**Medroxyprogesterone acetate**

*Sayana Press*® 160mg/mL subcutaneous injection



**Implants**

**Etonogestrel**

*Nexplanon*® 68mg subdermal implant



**2<sup>nd</sup> line as per MMC**

MHRA Drug Safety Update (Feb-20): Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury & implant migration

MHRA Drug Safety Update (Jun-16): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung

**7.3.2.3 Intra-uterine progestogen-only device**

**Levonorgestrel**

*Mirena*® 20micrograms/24 hours IUD



MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name

**Levonorgestrel**

*Jaydess*® 13.5mg IUD



MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name

**RESTRICTED**  
Specialist use Tertiary Services only

**Levonorgestrel**

*Kyleena*® 19.5mg IUD



MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name

**RESTRICTED**  
Specialist use Tertiary Services only

**7.3.5 Emergency contraception**

**Levonorgestrel**

*Levonelle*® 1500 microgram tablets



MHRA Drug Safety Update (Sep-16): Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers...

MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women

**Ulipristal acetate**

*ellaOne*® 30mg tablets



MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women

**RESTRICTED**  
emergency contraception (SARC)

**Assisted Reproductive Technology (ART) cycles**

**Progesterone**

*Utrogestan*® 100mg; 200mg vaginal capsules

































**RESTRICTED**  
ART cycles  
**2<sup>nd</sup> line**

## 7.4 Drugs for genito-urinary disorders



7.4.1 Drugs for urinary retention		NICE CG97
Alpha blockers		NICE CG111
		NICE NG123
<b>Alfuzosin hydrochloride</b>		
tablets		
<b>Tamsulosin hydrochloride</b>		1 <sup>st</sup> line
capsules, tablets		
7.4.2 Drugs for urinary, enuresis & incontinence		NICE NG123
Urinary incontinence		NICE NG123
<b>Oxybutynin hydrochloride</b>		1 <sup>st</sup> line in OAB
oral solution; patch; tablets		
<b>Darifenacin hydrobromide</b>		1 <sup>st</sup> line in OAB
tablets		
<b>Tolterodine tartrate</b>		1 <sup>st</sup> line in OAB
capsules, tablets		
<b>Solifenacin succinate</b>		2 <sup>nd</sup> line in OAB
tablets		
<b>Duloxetine</b>		
capsules		
<b>Tropium chloride</b>		<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
capsules; tablets		
<b>Mirabegron</b>		<b>RESTRICTED</b> in line with TA290 / Paeds 3 <sup>rd</sup> line
tablets		
MHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga ▼): risk of severe hypertension and associated cerebrovascular and cardiac events		
<b>Vibegron</b>		<b>RESTRICTED</b> in line with TA999
 Obgemsa® 75 mg tablets		
Nocturnal enuresis		
<b>Amitriptyline hydrochloride</b>		
oral solution; tablets (see also section 4.3.1)		
<b>Desmopressin</b>		<b>RESTRICTED</b> Haematology Consultants only
injection; nasal spray; tablets (see also section 6.5.2)		
7.4.3 Drugs used in urological pain		
<b>Methionine</b>		<b>RESTRICTED</b> resistant calcium phosphate lithiasis
 tablets		European Association of Urology
<b>Pentosan polysulfate sodium</b>		<b>RESTRICTED</b> Urology Cons. in line with NICE
 capsules		
MHRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy		
<b>Potassium citrate</b>		
tablets		

**7.4.4 Bladder instillations & urological surgery**

<b>Chlorhexidine</b> 0.02% irrigation solution	 	
<b>Dimethyl sulfoxide</b>  50% solution		
<b>Glycine</b> 1.5% irrigation solution	 	
<b>Sodium chloride</b> 0.9% irrigation solution	 	
<b>Sodium citrate</b> 3% irrigation solution	 	
<b>Sodium hyaluronate</b>  Cystistat® 40mg/50mL bladder instillation	<b>MMC</b> 	<b>RESTRICTED</b> Urology Consultants only
<b>Sodium hyaluronate with sodium chondroitin sulfate</b>  iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation	<b>MMC</b> 	<b>RESTRICTED</b> Urology Consultants only
<b>7.4.5 Drugs for erectile dysfunction</b>		
<b>Alprostadil</b>  cream; injection; urethral sticks	<b>MMC</b>  	<b>RESTRICTED</b> Urology Consultants only
<b>Aviptadil with phentolamine mesilate</b>  Invicorp® injection	<b>MMC</b>  	<b>RESTRICTED</b> Urology Consultants only
<b>Sildenafil</b>  or  PAH injection; oral suspension; tablets (see also section 2.5.1)	<b>MMC</b>  	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
<b>Tadalafil</b>  or  PAH tablets (see also section 2.5.1)	<b>MMC</b>  	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
<b>Vardenafil</b> tablets	<b>MMC</b>  	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only

**7.4.6 Drugs for premature ejaculation****NOT STOCKED**

## Section 8: Malignant disease & immunosuppression

Supported by the  
formulary ([click here](#))



### 8.1 Cytotoxic drugs

Drugs for cytotoxic-induced side-effects

8.1.1 Alkylating drugs

8.1.2 Anthracyclines & other cytotoxic antibiotics

8.1.3 Antimetabolites

8.1.4 Vinca alkaloids & etoposide

8.1.5 Other antineoplastic drugs

### 8.2 Drugs affecting the immune response

8.2.1 Antiproliferative immunosuppressants

8.2.2 Corticosteroids & other immunosuppressants

8.2.3 Anti-lymphocyte monoclonal antibodies

8.2.4 Other immunomodulating drugs

### 8.3 Sex hormones & hormone antagonists in malignant disease

8.3.1 Oestrogens

8.3.2 Progestogens

8.3.3 Androgens

8.3.4 Hormone Antagonists

8.3.4.1 Breast Cancer

8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists

8.3.4.3 Somatostatin analogues

### 8.4 Miscellaneous preparations

#### Non-Formulary Items



## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Advanced breast cancer (CG81)  
 Familial breast cancer (CG164)  
 Hepatitis B (chronic) (CG165)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)  
 Early and locally advanced breast cancer: diagnosis and management (NG101)  
 Lung cancer: diagnosis and management (NG122)  
 Prostate cancer: diagnosis and management (NG131)  
 Colorectal cancer (NG151)  
 Temozolomide for malignant glioma (TA23)  
 Leukaemia (lymphocytic) - fludarabine (TA29)  
 Trastuzumab for advanced breast cancer (TA34)  
 Paclitaxel for ovarian cancer (TA55)  
 Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)  
 Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)  
 Docetaxel for prostate cancer (hormone-refractory) (TA101)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Paclitaxel for early breast cancer (TA108)  
 Docetaxel for early breast cancer (TA109)  
 Gemcitabine for Breast Cancer (TA116)  
 Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)  
 Leukaemia (lymphocytic) - fludarabine (TA119)  
 Carmustine implants and temozolomide for glioma (newly diagnosed & high grade) (TA121)  
 Pemetrexed for lung cancer (non small cell) (TA124)  
 Multiple sclerosis - natalizumab (TA127)  
 Bortezomib for relapsed multiple myeloma (TA129)  
 Pemetrexed for mesothelioma (TA135)  
 Rituximab for follicular non-Hodgkin's lymphoma (TA137)  
 Head and neck cancer - cetuximab (TA145)  
 Renal cell carcinoma - sunitinib (TA169)  
 Lenalidomide - multiple myeloma (TA171)  
 Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)  
 Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)  
 Renal Cell Carcinoma (TA178)  
 Sunitinib for gastrointestinal stromal tumours (TA179)  
 Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)  
 Cervical cancer (recurrent) - topotecan (TA183)  
 Lung cancer (small cell) - topotecan (TA184)  
 Soft tissue sarcoma - trabectedin (TA185)  
 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)  
 Gastric cancer (advanced) - capecitabine (TA191)  
 Lung cancer (non-small-cell, first line) - gefitinib (TA192)  
 Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)  
 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)  
 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)  
 Colorectal cancer (metastatic) - bevacizumab (TA212)  
 Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)  
 Renal cell carcinoma (1<sup>st</sup> line metastatic) - pazopanib (TA215)  
 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)  
 Myelodysplastic syndrome - azacitidine (TA218)  
 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)  
 Multiple myeloma (1<sup>st</sup> line) - bortezomib and thalidomide (TA228)  
 Osteosarcoma - mifamurtide (TA235)  
 Follicular lymphoma - rituximab (review TA110) (TA243)  
 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)  
 Bevacizumab in combination with paclitaxel & carboplatin for 1<sup>st</sup> line treatment of advanced ovarian cancer (TA284)  
 Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Multiple sclerosis (relapsing) - teriflunomide (TA303)  
 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Multiple myeloma - bortezomib (induction therapy) (TA311)

Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)  
 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)  
 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)  
 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)  
 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)  
 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)  
 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)  
 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)  
 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)  
 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)  
 Idelalisib for treating chronic lymphocytic leukaemia (TA359)  
 Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)  
 Bortezomib for previously untreated mantle cell lymphoma (TA370)  
 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)  
 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)  
 Nintedanib for treating idiopathic pulmonary fibrosis (TA379)  
 Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)  
 Olaparib for ovarian, fallopian tube and peritoneal cancer (TA381)  
 Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)  
 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)  
 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)  
 Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)  
 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)  
 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)  
 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)  
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)  
 Bosutinib for previously treated chronic myeloid leukaemia (TA401)  
 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)  
 Degarelix for treating advanced hormone-dependent prostate cancer (TA404)  
 Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)  
 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)  
 Pegaspargase for treating acute lymphoblastic leukaemia (TA408)  
 Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)  
 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)  
 Nivolumab for previously treated advanced renal cell carcinoma (TA417)  
 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)  
 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)  
 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)  
 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)  
 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)  
 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)  
 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)  
 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)  
 Everolimus for advanced renal cell carcinoma after previous treatment (TA432)  
 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)  
 Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)  
 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)  
 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)  
 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)  
 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)  
 Cabozantinib for previously treated advanced renal cell carcinoma (TA463)  
 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)  
 Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)  
 Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)  
 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)  
 Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)  
 Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)  
 Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)  
 Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)  
 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)  
 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)  
 Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)  
 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)  
 Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)  
 Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)  
 Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)  
 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)  
 Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)  
 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)  
 Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)  
 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)  
 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)  
 Tivozanib for treating advanced renal cell carcinoma (TA512)  
 Obinutuzumab for untreated advanced follicular lymphoma (TA513)  
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)  
 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)  
 Cabozantinib for treating medullary thyroid cancer (TA516)  
 Avelumab for treating metastatic Merkel cell carcinoma (TA517)  
 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)  
 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)  
 Midostaurin for untreated acute myeloid leukaemia (TA523)  
 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)  
 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)  
 Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)  
 Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)  
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)  
 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)  
 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)  
 Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)  
 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)  
 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)  
 Dinutuximab beta for treating neuroblastoma (TA538)  
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)  
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)  
 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)  
 Cabozantinib for untreated advanced renal cell carcinoma (TA542)  
 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)  
 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)  
 Padeliporfin for untreated localised prostate cancer (TA546)  
 Vandetanib for treating medullary thyroid cancer (TA550)  
 Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)  
 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)  
 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)  
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)  
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)  
 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)  
 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)  
 Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)  
 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)  
 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)  
 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)  
 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)  
 Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)  
 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)  
 Ocrelizumab for treating primary progressive multiple sclerosis (TA585)  
 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)  
 Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)  
 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)  
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)  
 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)  
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)  
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)  
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)  
 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)  
 Cladribine for treating relapsing–remitting multiple sclerosis (TA616)  
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)  
 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)  
 Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)  
 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)  
 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)  
 Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)  
 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)  
 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)  
 Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)  
 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)  
 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)  
 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)  
 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)  
 Entrectinib for treating NTRK fusion-positive solid tumours (TA644)  
 Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)  
 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)  
 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)  
 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)  
 Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)  
 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)  
 Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)  
 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)  
 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)  
 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)  
 Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)  
 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)  
 Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)  
 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)  
 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)  
 Pembrolizumab with pemtrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)  
 Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)  
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)

Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)  
 Avelumab for untreated metastatic Merkel cell carcinoma (TA691)  
 Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)  
 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)  
 Ofatumumab for treating relapsing multiple sclerosis (TA699)  
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)  
 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)  
 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)  
 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)  
 Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)  
 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)  
 Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)  
 Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)  
 Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)  
 Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)  
 Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)  
 Midostaurin for treating advanced systemic mastocytosis (TA728)  
 Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)  
 Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)  
 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)  
 Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)  
 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)  
 Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)  
 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)  
 Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)  
 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)  
 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)  
 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)  
 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)  
 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)  
 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)  
 Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)  
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)  
 Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)  
 Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)  
 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)  
 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)  
 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)  
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)  
 Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer.... (TA786)  
 Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)  
 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)  
 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)  
 Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)  
 Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)  
 Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)  
 Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)  
 Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)  
 Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802)  
 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)  
 Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)  
 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)  
 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)  
 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)  
 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)  
 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)  
 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)  
 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)  
 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)  
 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)  
 Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)  
 Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)  
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)  
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)  
 Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)  
 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)  
 Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)  
 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)  
 Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)  
 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)  
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)  
 Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)  
 Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)  
 Regorafenib for previously treated metastatic colorectal cancer (TA866)  
 Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)  
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)  
 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)  
 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)  
 Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)  
 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)  
 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)  
 Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia... (TA893)  
 Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)  
 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)  
 Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)  
 Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)  
 Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)  
 Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)  
 Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)  
 Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)  
 Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)  
 Ruxolitinib for treating polycythaemia vera (TA921)  
 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)  
 Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)  
 Targeted-release budesonide for treating primary IgA nephropathy (TA937)  
 Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)  
 Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)  
 Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)  
 Loncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)  
 Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)  
 Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)  
 Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)  
 Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)  
 Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)  
 Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)  
 Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)  
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA962)  
 Dostarlimab with platinum-based chemo for advanced / recurrent endometrial cancer with MSI-H or MMR deficiency (TA963)  
 Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)  
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)  
 Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)  
 Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)  
 Tisagenlecleucel for treating relapsed or refractory B-cell ALL in people 25 years and under (updates & replaces TA554) (TA975)  
 Dabrafenib for treating BRAF V600E mutation-positive glioma in children & young people aged 1 year & over (TA977)  
 Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)  
 Pembrolizumab for untreated locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma (TA983)  
 Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)  
 Relugolix for treating hormone-sensitive prostate cancer (TA995)  
 Pembrolizumab with platinum- and fluoropyrimidine-based chemo for untreated advanced HER2-negative gastric or GOJA (TA997)  
 Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)  
 Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)  
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)  
 Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)  
 Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)  
 Avapritinib for treating advanced systemic mastocytosis (TA1012)  
 Quizartinib for treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)  
 Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)  
 Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)  
 Pembrolizumab before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable NSCLC (TA1017)  
 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (updates & replaces TA756) (TA1018)  
 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (updates & replaces TA529) (TA1021)

## GMMMG Formulary

Formulary Homepage

Chapter 8: Malignant disease & immunosuppression (v12.9 - Jun-24)

GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List














































































































GMMMG Paediatric **Red/Amber/Green** Drug List
























































































































































## 8.1 Cytotoxic drugs



























































































































































## 8.1 Drugs for cytotoxic-induced side-effects




























<b>Dexrazoxane</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only 
<b>Disodium folinate</b>  <i>Sodiofolin</i> ® injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Folinic acid</b> (as calcium folinate)  tablets; injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Mesna</b>  tablets; injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Palifermin</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>8.1.1 Alkylating drugs</b>	
<b>Busulfan</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only
<b>Bendamustine</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Mar-21): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) MHRA Drug Safety Update (Jul-17): Bendamustine: increased mortality in recent clinical studies in off-label use; monitor for opportunistic infections, HBV reactivation	
<b>Carmustine</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only
<b>Chlorambucil</b>  tablets 	<b>RESTRICTED</b> Haematology Consultants only
<b>Cyclophosphamide</b>  injection; tablets; oral suspension 	<b>RESTRICTED</b> Haematology Consultants only
<b>Ifosfamide</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Lomustine</b>  capsules 	<b>RESTRICTED</b> Haematology Consultants only
<b>Melphalan</b>  injection; tablets 	<b>RESTRICTED</b> Haematology Consultants only
<b>Treosulfan</b>  injection 	<b>RESTRICTED</b> Adult Haematology / Paediatric Haematology / Oncology
<b>8.1.2 Anthracyclines &amp; other cytotoxic antibiotics</b>	
<b>Bleomycin</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Daunorubicin</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Doxorubicin hydrochloride</b>  infusion; injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Idarubicin hydrochloride</b>  capsules; injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Mitomycin</b>  injection 	<b>RESTRICTED</b> Consultants only
<b>Mitoxantrone</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only






















































































































































<b>Pixantrone</b>   infusion     	<b>RESTRICTED</b> Haematology Consultants only
<b>8.1.3 Antimetabolites</b>	
<b>Azacitidine</b>   injection     	<b>NICE CG81</b> <b>NICE NG151</b>
<b>Capecitabine</b>  tablets    	
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity MHRA Drug Safety Update (Dec-14): Capecitabine: risk of severe skin reactions - discontinue treatment	
<b>Cladribine</b>   infusion; injection      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Mar-22): Cladribine (Mavenclad): new advice to minimise risk of serious liver injury MHRA Drug Safety Update (Dec-17): Cladribine (Litak, Leustat) for leukaemia: reports of PML; stop treatment if PML is suspected	
<b>Clofarabine</b>   infusion    	<b>RESTRICTED</b> Haematology Consultants only
<b>Cytarabine</b>  injection   	<b>RESTRICTED</b> Haematology Consultants only
<b>Daunorubicin with cytarabine</b>   Vyxeos® 100mg/44mg infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Fludarabine phosphate</b>  injection; tablets   	<b>RESTRICTED</b> Haematology Consultants only
<b>Fluorouracil</b>  injection    	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity	
<b>Gemcitabine</b>  infusion    	<b>RESTRICTED</b> Haematology Consultants only 
<b>Mercaptopurine</b>  oral suspension; tablets (see also section 1.5.3)  	
<b>Methotrexate</b>  infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3)   	MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions
<b>Pemetrexed</b>   injection      	<b>RESTRICTED</b> Respiratory Consultants only in line with TA402
<b>8.1.4 Vinca alkaloids &amp; etoposide</b>	
<b>Etoposide</b>  capsules; infusion  	<b>RESTRICTED</b> Haematology Consultants only
<b>Vinblastine sulfate</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Vincristine sulfate</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>8.1.5 Other antineoplastic drugs</b>	
<b>Acalabrutinib</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Arsenic trioxide</b>   infusion      	<b>RESTRICTED</b> Haem. Consultants only / also in line with NICE TA526
<b>Asciminib</b>   Scemblix® 20mg/40mg tablets      	<b>RESTRICTED</b> Haem. Consultants in line with NICE TA813



































































<b>Asparaginase</b>  infusion   	<b>RESTRICTED</b> Haematology Consultants only
<b>Axicabtagene ciloleucel</b>   Yescarta® infusion      	<b>RESTRICTED</b> in line with NICE TA872
<b>Bevacizumab</b>   Avastin® 100mg in 4mL vial     	<b>RESTRICTED</b> Haematology Consultants only
<b>Bortezomib</b>   injection      	<b>RESTRICTED</b> Haematology Consultants only
<b>Brentuximab vedotin</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Brexucabtagene autoleucel</b>   Tecartus® infusion      	<b>RESTRICTED</b> Haem. Consultants only in line with NICE / CDF
<b>Cabozantinib</b>   tablets; capsules      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Carfilzomib</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ceritinib</b>   capsules      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Cetuximab</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Crisantaspase</b>   injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Dacarbazine</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Durvalumab</b>   infusion      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Entrectinib</b>   injection      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE
<b>Eribulin</b>   injection      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Erlotinib</b>   tablets      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Everolimus</b>   tablets      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Hydroxycarbamide</b> capsules; tablets (see GMMMG below)  	<b>RESTRICTED</b> Haematology Consultants only
<b>Hydroxycarbamide</b> Xromi® oral liquid   	<b>RESTRICTED</b> Paediatric patients with swallowing difficulties
<b>Ipilimumab</b>   infusion      	<b>RESTRICTED</b> Dermatology Consultants only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation	
<b>Ivosidenib</b>   Tibsovo® 250mg tablets      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ixazomib</b>   capsules      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE



<p><b>Lorlatinib</b>   </p> <p>Lorviqua® tablets</p> <p>     </p>	<p><b>RESTRICTED</b> Respiratory                      Consultants only in line with NICE</p>
<p><b>Midostaurin</b>   </p> <p>Rydapt® capsules</p> <p>     </p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line with NICE</p>
<p><b>Nintedanib esilate</b>   </p> <p>Ofev® capsules</p> <p>     </p>	<p><b>RESTRICTED</b> Respiratory                      Consultants only in line with NICE</p>
<p><b>Nintedanib esilate</b>   </p> <p>Vargatef® capsules</p> <p>     </p>	<p><b>RESTRICTED</b> Respiratory                      Consultants only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Niraparib</b>   </p> <p>Zejula® capsules</p> <p>     </p> <p>MHRA Drug Safety Update (Oct-20): Niraparib (Zejula ▼): reports of severe hypertension &amp; PRES, particularly in early treatment</p>	<p><b>RESTRICTED</b> Gynaecology                      Consultants only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Panitumumab</b>   </p> <p>infusion</p> <p>     </p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Panobinostat</b>   </p> <p>capsules</p> <p>    </p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line with TA380</p>
<p><b>Pegaspargase</b>   </p> <p>Oncaspar® injection</p> <p>    </p>	<p><b>RESTRICTED</b>                      Haematology Consultants only</p>
<p><b>Pembrolizumab</b>   </p> <p>infusion</p> <p>     </p> <p>MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection</p>	<p><b>RESTRICTED</b> Specialist use only in                      line with NICE / NHSE</p>
<p><b>Pentostatin</b>   </p> <p>infusion</p> <p> </p>	<p><b>RESTRICTED</b>                      Haematology Consultants only</p>
<p><b>Pertuzumab</b>   </p> <p>infusion</p> <p>     </p>	<p><b>RESTRICTED</b> Specialist Consultant                      use only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Procarbazine</b>   </p> <p>capsules</p> <p> </p>	<p><b>RESTRICTED</b>                      Haematology Consultants only</p>
<p><b>Sacituzumab govitecan</b>   </p> <p>Trodelyv® infusion</p> <p>     </p>	<p><b>RESTRICTED</b> Specialist Consultant                      use only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Selinexor</b>   </p> <p>Nexpovio® tablets</p> <p>     </p>	<p><b>RESTRICTED</b> Specialist Consultant                      use only in line with NICE</p>
<p><b>Sorafenib</b>   </p> <p>tablets</p> <p>     </p> <p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line NICE / NHSE</p>
<p><b>Sotorasib</b>   </p> <p>Lumykras® tablets</p> <p>     </p>	<p><b>RESTRICTED</b>                      PulmonaryOnc Consultants only                      in line with NICE TA781</p>
<p><b>Talimogene Laherparepvec</b>   </p> <p>injection</p> <p>     </p>	<p><b>RESTRICTED</b> Dermatology                      Consultants only in line with TA410</p>
<p><b>Tisagenlecleucel</b>   </p> <p>Kymriah® infusion</p> <p>     </p>	<p><b>RESTRICTED</b> in line with CDF criteria                      and NICE TA975</p>
<p><b>Trastuzumab</b>   </p> <p>infusion; injection</p> <p>     </p>	<p><b>RESTRICTED</b> Specialist use only in                      line with NICE</p>
<p><b>Venetoclax</b>   </p> <p>Venclyxto® tablets</p> <p>     </p> <p>MHRA Drug Safety Update (Dec-21): Venetoclax (Venclyxto ▼): updated recommendations on tumour lysis syndrome (TLS)</p>	<p><b>RESTRICTED</b> Specialist use only in                      line with NICE / NHSE</p>
<p>Hydroxycarbamide - Essential thrombocythaemia or polycythaemia with high risk of complications</p>	<p></p>
<p>Hydroxycarbamide - Sickle Cell Disease</p>	<p></p>

Other agents		
<b>Isotretinoin</b>   capsules; liquid (20mg/mL unlicensed preparation) (see also section 13.6.2)	  	<b>RESTRICTED</b> Specialist use only for the management of neuroblastoma
Platinum compounds		
<b>Cisplatin</b>  injection	 	<b>RESTRICTED</b> Haematology Consultants only
Protein kinase inhibitors		
<b>Abemaciclib</b>   Verzenios® tablets	     	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases		
<b>Alectinib</b>   Alecensa® capsules	     	<b>RESTRICTED</b> Specialist use only in line with NICE TA536 / TA1014
<b>Alpelisib</b>   Piqray® tablets	     	<b>RESTRICTED</b> Specialist use only in line with NICE TA816 <b>NOT STOCKED</b>
<b>Avapritinib</b>   Ayvakyt® tablets	     	<b>RESTRICTED</b> Specialist use only in line with NICE TA1012
<b>Axitinib</b>   Inlyta® tablets	     	<b>RESTRICTED</b> Haematology Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Bosutinib</b>   Bosulif® tablets	     	<b>RESTRICTED</b> Haematology Consultants only in line with TA401
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
<b>Brigatinib</b>   Alunbrig® tablets	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Crizotinib</b>   Xalkori® capsules	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Dabrafenib</b>   Tafinlar® capsules	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Dabrafenib</b>   Finlee® dispersible tablets	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Dacomitinib</b>   Vizimpro® tablets	     	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Dasatinib</b>   Sprycel® tablets; powder for oral suspension	     	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
<b>Encorafenib</b>   Braftovi® capsules	     	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Fedratinib</b>   Inrebic® capsules	     	<b>RESTRICTED</b> Haematology Consultants only
<b>Gefitinib</b>   tablets	     	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Gemtuzumab ozogamicin</b>   Mylotarg® injection	     	<b>RESTRICTED</b> Haematology Consultants only
<b>Gilteritinib fumarate</b>   Xospata® tablets	     	<b>RESTRICTED</b> Haematology Consultants only
<b>Ibrutinib</b>   Imbruvica® capsules; tablets	     	<b>RESTRICTED</b> Haem. Consultants only / also in line with NICE
MHRA Drug Safety Update (Nov-22): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations		
MHRA Drug Safety Update (Aug-17): Ibrutinib (Imbruvica ▼): reports of ventricular tachyarrhythmia; risk of HBV B reactivation & opportunistic infections		

<b>Idelalisib</b>   Zydelig® tablets     	<b>RESTRICTED</b> Specialist use only in line with NICE TA359
MHRA Drug Safety Update (Sep-16): Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection	
<b>Imatinib</b>   tablets     	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
<b>Inotuzumab ozogamicin</b>   Besponsa® 1mg solution for infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Larotrectinib sulfate</b>   Vitrakvi® 20mg/mL oral solution      	<b>RESTRICTED</b> Consultants only in line with NICE
<b>Lenvatinib</b>   Kisplyx® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE TA498 / 858
<b>Lenvatinib</b>   Lenvima® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE TA535 / 551 <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Loncastuximab tesirine</b>   Zynlonta® infusion      	<b>RESTRICTED</b> Specialist use only in line with NICE TA947
<b>Mobocertinib</b>   Exkivity® capsules      	<b>RESTRICTED</b> Specialist use only
<b>Momelotinib</b>   Omjara® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA957
<b>Neratinib</b>   Nerlynx® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA612 <b>NOT STOCKED</b>
<b>Nilotinib</b>   Tasisga® capsules      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
<b>Osimertinib</b>   Tagrisso® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Palbociclib</b>   Ibrance® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
<b>Ponatinib</b>   Iclusig® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA451
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome	
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events	
<b>Quizartinib dihydrochloride</b>   Vanflyta® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA1013
<b>Regorafenib</b>   Stivarga® 40mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA488 / TA555 <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Ribociclib</b>   Kisqali® 200mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
<b>Ruxolitinib</b>   Jakavi® tablets     	<b>RESTRICTED</b> Specialist use only in line with NICE / NHSE
<b>Selpercatinib</b>   Retsevmo® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE

<b>Selumetinib</b>   Koselugo® capsules     	<b>RESTRICTED</b> Specialist use only for NF1 in line with NICE HST20
<b>Sunitinib</b>   Sutent® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Tepotinib</b>   Tepmetko® 225mg tablets      	<b>RESTRICTED</b> Specialist use in line with NICE / NHSE
<b>Tivozanib</b>   Fotivda® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Trametinib</b>   Mekinist® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA396 <b>NOT STOCKED</b>
<b>Zanubrutinib</b>   Brukinsa® 80mg hard capsules      	<b>RESTRICTED</b> Specialist use in line with NICE / NHSE TA833 / TA931 / TA1001
<b>Topoisomerase I inhibitors</b>	
<b>Tretinoin</b>  capsules   	<b>RESTRICTED</b> Haematology Consultants only
<b>Taxanes</b>	
<b>Paclitaxel</b>  Infusion      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error	
<b>Cabazitaxel</b>   Jevtana® Infusion      	<b>RESTRICTED</b> Haematology Consultants only

## 8.2 Drugs affecting the immune response



### 8.2.1 Antiproliferative immunosuppressants

#### Azathioprine

Amber

tablets; oral solution; injection (see also sections 1.5.3; 10.1.3 & 13.5.3)



#### Mycophenolate mofetil

Amber

capsules; tablets; oral suspension; infusion



MHRA Drug Safety Update (Feb-18): Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients

MHRA Drug Safety Update (Dec-15): Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men

MHRA Drug Safety Update (Jan-15): Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

#### Belatacept

U ££

Nulojix® 25mg/mL injection



**RESTRICTED**  
Renal Transplant Consultants only  
**NOT STOCKED**

### 8.2.2 Corticosteroids & other immunosuppressants

#### Antithymocyte immunoglobulin (Rabbit)

££

injection



#### Basiliximab

Red ££

Simlect® injection



**RESTRICTED**  
Renal Consultants only

#### Ciclosporin (Dexamune®) & I.V. (Sandimmun®)

Amber ££

capsules; oral solution; injection (see also sections 10.1.3 and 13.5.3)



#### Sirolimus

Amber ££

oral solution; tablets (see also section 13.5.3)



**RESTRICTED**  
Renal Consultants only

#### Tacrolimus

Amber

capsules; tablets; ointment; oral suspension; infusion; sachets (see also section 13.5.3)



#### Voclosporin

Red ££

capsules



**RESTRICTED**  
Specialist use only in line with NICE

Immunosuppressants - e.g. ciclosporin, tacrolimus, sirolimus Amber Red if no SCP

### 8.2.3 Anti-lymphocyte monoclonal antibodies

#### Alemtuzumab

Red ££

Lemtrada® infusion



**RESTRICTED** Renal Consultants only  
under Patient Access Scheme

MHRA Drug Safety Update (Feb-20): Alemtuzumab: updated restrictions & monitoring requirements following review of serious CV & immune-mediated reactions

MHRA Drug Safety Update (May-19): Alemtuzumab and serious CV & immune-mediated adverse reactions: new restrictions to use & strengthened monitoring requirements

#### Atezolizumab

Red ££

Tecentriq® infusion; solution for injection



**RESTRICTED** Specialist Consultants  
in line with NICE / NHSE

MHRA Drug Safety Update (Jun-21): Atezolizumab (Tecentriq ▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)

#### Avacopan

Red ££

Tavneos® capsules



**RESTRICTED** Specialist Consultants  
in line with NICE

#### Avelumab

Red ££

Bavencio® infusion



**RESTRICTED** Specialist Consultants  
in line with NICE

#### Blinatumomab

Red ££

Blinicyto® infusion



**RESTRICTED** Haematology  
Consultants only in line with NICE

#### Burosumab

Red ££

Crysvita® injection



**RESTRICTED**  
X-linked hypophosphatemia

#### Daratumumab

Red ££

Darzalex® infusion



**RESTRICTED** Haematology  
Consultants only in line with  
NICE / NHSE

MHRA Drug Safety Update (Aug-19): Daratumumab (Darzalex ▼): risk of reactivation of hepatitis B virus

#### Glofitamab

Red ££

Columvi® infusion



**RESTRICTED** Haematology  
Consultants only in line with NICE



























































































#### Isatuximab

Red ££
















infusion



**RESTRICTED** Haematology  
Consultants only in line with EAMS

<b>Mogamulizumab</b>   <i>Poteligeo</i> ® infusion      	<b>RESTRICTED Haematology</b> Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Obinutuzumab</b>   <i>Gazyvaro</i> ® infusion      	<b>RESTRICTED Haematology</b> Consultants only in line with NICE
<b>Ofatumumab</b>   <i>Kesimpta</i> ® injection      	<b>RESTRICTED</b> Consultants only in line with NICE
MHRA Drug Safety Update (Aug-14): Ofatumumab▼: reminder of risk of serious and fatal infusion reactions MHRA Drug Safety Update (Jan-14): Ofatumumab: screen for hepatitis B virus before treatment	
<b>Pertuzumab</b>   <i>Perjeta</i> ® infusion      	<b>RESTRICTED Haematology</b> Consultants only in line with NICE
<b>Polatuzumab vedotin</b>   <i>Polivy</i> ® infusion      	<b>RESTRICTED Haematology</b> Consultants only in line with NICE
<b>Rituximab</b>   injection; infusion (see also section 10.1.3)       	<b>RESTRICTED Consultants only in line with NICE / NHSE</b>
MHRA Drug Safety Update (Dec-13): Rituximab: screen for hepatitis B virus before treatment	
<b>Teclistamab</b>   <i>Tecvayli</i> ® injection      	<b>RESTRICTED Haematology</b> Consultants only
<b>8.2.4 Other immunomodulating drugs</b>	
<b>Interferon alfa</b>	
<b>Peginterferon alfa-2a</b>   <i>Pegasys</i> ® injection   	<b>RESTRICTED</b> Gastro Consultants only
<b>Ropeginterferon alfa-2b</b>   <i>Besremi</i> ® injection   	<b>RESTRICTED myeloproliferative neoplasms</b>
<b>Interferon beta</b>	
MHRA Drug Safety Update (Oct-14): Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome	
<b>Interferon beta-1a</b>   injection      	<b>RESTRICTED Specialist use only in line with NICE TA527</b> <b>NOT STOCKED</b>
<b>Interferon beta-1b</b>   injection      	<b>RESTRICTED Specialist use only in line with NICE TA527</b> <b>NOT STOCKED</b>
<b>BCG bladder instillation</b>	
<b>Bacillus Calmette–Guérin</b>  <i>OncoTICE</i> ® bladder instillation  	<b>RESTRICTED</b> Specialist use only
<b>Bacillus Calmette–Guérin</b>  <i>BCG-medac</i> ® intravesical suspension   	<b>RESTRICTED</b> Specialist use only

Other Agents		
<b>Belumosudil</b>  Rezurock® 200mg tablets 	<b>RESTRICTED Specialist use in line with NICE</b>	
<b>Canakinumab</b>  Ilaris® 150mg/mL injection 	<b>RESTRICTED Specialist use in line with NHSE</b> 	
<b>Cemiplimab</b>  Libtayo® 50mg/mL injection 	<b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>	
<b>Dimethyl fumarate</b>  Tecfidera® capsules 	<b>RESTRICTED Specialist use only in line with NICE TA320</b>	
MHRA Drug Safety Update (Jan-21): Dimethyl fumarate (Tecfidera): updated advice on the risk of PML associated with mild lymphopenia MHRA Drug Safety Update (Apr-16): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy MHRA Drug Safety Update (Mar-15): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia		
<b>Dinutuximab beta</b>  Qarziba® 4.5mg/mL injection 	<b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>	
<b>Diroximel fumarate</b>  Vumerity® 231mg capsules 	<b>RESTRICTED Specialist use in line with NICE TA794</b> <b>NOT STOCKED</b>	
<b>Fingolimod hydrochloride</b>  Gilenya® capsules 	<b>RESTRICTED Specialist use only in line with NICE TA254</b>	
MHRA Drug Safety Update (Jan-21): Fingolimod (Gilenya ▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis		
<b>Glatiramer acetate</b>  injection 	<b>RESTRICTED Specialist use only in line with NICE TA527</b> <b>NOT STOCKED</b>	
<b>Imlifidase</b>  infusion 	<b>RESTRICTED Specialist use only in line with NICE TA809</b>	
<b>Lenalidomide</b>  Revlimid® capsules 	<b>RESTRICTED Haematology Consultants only</b>	
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (Jan-13): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions		
<b>Mifamurtide</b>  Mepact® Intravenous infusion 	<b>RESTRICTED Specialist use only in line with NICE TA235</b> <b>NOT STOCKED</b>	
<b>Natalizumab</b>  Tysabri® infusion 	<b>RESTRICTED Specialist use only in line with NICE TA127</b> <b>NOT STOCKED</b>	
MHRA Drug Safety Update (Apr-16): Natalizumab (Tysabri ▼): progressive multifocal leukoencephalopathy—updated advice to support early detection		
<b>Nivolumab</b>  Opdivo® 10mg/mL infusion 	<b>RESTRICTED Specialist use only in line with NICE</b>	
MHRA Drug Safety Update (Oct-19): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection		
<b>Ocrelizumab</b>  Ocrevus® 30mg/mL infusion 	<b>RESTRICTED Specialist use only in line with NICE TA533 / TA585</b> <b>NOT STOCKED</b>	
<b>Olaparib</b>  Lynparza® tablets 	<b>RESTRICTED Specialist use only in line with NICE</b> <b>NOT STOCKED</b>	
<b>Pomalidomide</b>  capsules 	<b>RESTRICTED Haematology only / also in line with NICE</b>	
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (May-16): Pomalidomide (Imnovid ▼): risk of hepatitis B reactivation MHRA Drug Safety Update (May-15): Pomalidomide (Imnovid ▼): risks of cardiac failure, interstitial lung disease and hepatotoxicity		
<b>Ponesimod</b>  Ponvory® tablets 	<b>RESTRICTED Specialist use only in line with NICE TA767</b> <b>NOT STOCKED</b>	
<b>Rucaparib</b>  tablets 	<b>RESTRICTED Specialist use only in line with NICE TA611</b> <b>NOT STOCKED</b>	
MHRA Drug Safety Update (Sep-22): Rucaparib (Rubraca ▼): withdrawal of third-line treatment indication		

<p><b>Teriflunomide</b>                         tablets       </p>	<p><b>RESTRICTED Specialist use only in line with NICE TA303</b>  <b>NOT STOCKED</b></p>
<p><b>Thalidomide</b>                         capsules      </p>	<p><b>RESTRICTED Haematology Consultants only</b></p>
<p>MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)                      MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years                      MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies</p>	



## 8.3 Sex hormones & hormone antagonists in malignant disease



### 8.3.1 Oestrogens

#### Diethylstilbestrol

tablets



**RESTRICTED**  
Specialist use only

### 8.3.2 Progestogens

#### Medroxyprogesterone acetate

tablets



**RESTRICTED**  
Specialist use only

#### Megestrol acetate

tablets



**RESTRICTED**  
Specialist use only

### 8.3.3 Androgens

#### Testolactone

tablets



**RESTRICTED**  
Specialist use only

### 8.3.4 Hormone Antagonists

#### 8.3.4.1 Breast Cancer

##### Aminoglutethimide

tablets



**NICE NG101**

**RESTRICTED**  
Specialist use only

##### Anastrozole

Green

tablets



**RESTRICTED**  
Specialist use only

##### Exemestane

Green

tablets



**RESTRICTED**  
Specialist use only

##### Letrozole

Green

tablets



**RESTRICTED**  
Specialist use only

##### Tamoxifen

Green

tablets; oral solution



**RESTRICTED**  
Specialist use only

#### 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists

##### Gonadorelin analogues

##### Buserelin acetate

Red

injection (see also section 6.7.2)



**RESTRICTED**  
Specialist use only

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

##### Goserelin acetate

Amber

Red

implant (also section 6.7.2)



**RESTRICTED**  
Specialist use only

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

##### Leuprorelin acetate

Amber

Red

injection (also section 6.7.2)



**RESTRICTED**  
Specialist use only

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

##### Triptorelin acetate

Amber

Red

injection (also section 6.7.2)



**RESTRICTED**  
Specialist use only

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

Goserelin/Leuprorelin - Licensed Indications (pre-op management prior to endometrial ablation/fibroid surgery)

Amber

Goserelin/Leuprorelin/Triptorelin - Licensed Indications (prostate cancer (all), breast cancer (goserelin))
















































Amber

Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)

Red

Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)

Red

<b>Anti-androgens</b>	
<b>Bicalutamide</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets  	<b>RESTRICTED</b> Specialist use only
<b>Cyproterone acetate</b> <span style="background-color: orange; color: white; padding: 2px;">Amber</span> tablets (see also section 6.4.2) MHRA Drug Safety Update (Jun-20): Cyproterone acetate: new advice to minimise risk of meningioma MHRA Drug Safety Update (Apr-20): Cyproterone acetate: restrictions in use of due to risk of meningioma  	<b>RESTRICTED</b> Specialist use only
<b>Darolutamide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> 300mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Flutamide</b> tablets  	<b>RESTRICTED</b> Specialist use only
<b>Enzalutamide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> tablets      	<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
<b>Abiraterone acetate</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Zytiga® tablets      	<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
<b>Gonadotrophin-releasing hormone antagonists</b>	
<b>Degarelix</b> <span style="background-color: orange; color: white; padding: 2px;">Amber</span> Firmagon® 80mg; 120mg injection    	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Other</b>	
<b>Radium-223 dichloride</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Xofigo® 1,100 kBq/mL injection     	<b>RESTRICTED</b> Specialist use only in line with NICE
MHRA Drug Safety Update (Sep-18): Xofigo ▼: new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial MHRA Drug Safety Update (Dec-17): ▼ Xofigo: Increased risk of death and fractures in RCT with abiraterone acetate & prednisolone/prednisone	
<b>8.3.4.3 Somatostatin analogues</b>	
<b>Lanreotide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection    	<b>RESTRICTED</b> Consultant only - acromegaly
<b>Octreotide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection     	<b>RESTRICTED</b> 3 <sup>rd</sup> line use Gastro. Consultant only
<b>Lutetium (<sup>177</sup>Lu) oxodotretotide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Lutathera® injection     	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>

## 8.4 Miscellaneous preparations



### Glucarpidase



Voraxaze © 1,000 unit injection (see also sections 1.10, 10.4 & 13.14)



**RESTRICTED**  
2<sup>nd</sup> line rescue therapy



### Trifluridine / Tipiracil hydrochloride



tablets



**RESTRICTED** Specialist use only in line with NICE  
**NOT STOCKED**

# Non-Formulary Items



<p><b>Belzutifan</b>  </p> <p>tablets     </p>	<p><b>MFT not a commissioned centre</b>                  Patients referred to Christie Hospital</p>
<p><b>Disodium levofolinate</b>  </p> <p>injection   </p>	<p><b>Not MMC approved</b></p>
<p><b>Interferon alfa-2a</b>  </p> <p><i>Roferon-A</i>® injection   </p>	<p><b>DISCONTINUED</b>                  Sep-19</p>
<p><b>Interferon alfa-2b</b>  </p> <p><i>IntronA</i>®    </p>	<p><b>DISCONTINUED</b>                  Dec-18</p>
<p><b>Peginterferon alfa-2b</b>  </p> <p><i>ViraferonPeg</i>®    </p>	<p><b>DISCONTINUED</b>                  Dec-16</p>

## Section 9: Nutrition & blood

Supported by the  
formulary ([click here](#))



### 9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells

### 9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

### 9.3 Intravenous nutrition

### 9.4 Oral nutrition

- 9.4.1 Nutrition in special diets

### 9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

### 9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

### 9.7 Bitters & tonics

### 9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)  
 Nutrition support in adults (CG32)  
 Coeliac disease: recognition, assessment and management (NG20)  
 Chronic kidney disease: assessment and management (NG203)  
 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)  
 Migalastat for treating Fabry disease (HST4)  
 Eliglustat for treating type 1 Gaucher disease (HST5)  
 Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)  
 Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)  
 Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)  
 Lumasiran for treating primary hyperoxaluria type 1 (HST25)  
 Hyperparathyroidsism - cinacalcet (TA117)  
 Thrombocytopenic purpura - romiplostim (TA221)  
 Thrombocytopenic purpura - eltrombopag (TA293)  
 Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)  
 Etelcalcetide for treating secondary hyperparathyroidism (TA448)  
 Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)  
 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)  
 Patiromer for treating hyperkalaemia (TA623)  
 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)  
 Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)  
 Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)  
 Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)  
 Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)  
 Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)  
 Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)  
 Avalglucosidase alfa for treating Pompe disease (TA821)  
 Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)  
 Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)  
 Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)  
 Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)  
 Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)  
 Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)  
 Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)  
 Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)

## GMMMG Formulary

Formulary Homepage  
 Chapter 9: Nutrition & Blood (v7.3 - Oct-24)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

## 9.1 Anaemias and some other blood disorders



### 9.1.1 Iron deficiency anaemias

#### 9.1.1.1 Oral iron

##### Ferrous sulfate

tablets

1<sup>st</sup> line use**STANDARD PREPARATIONS ONLY**

##### Ferrous fumarate

tablets; oral solution



##### Ferric maltol

Green

capsules



##### Sodium feredetate

oral solution

**LIQUID PREPARATIONS ONLY**

#### Iron & folic acid

##### Ferrous sulfate

M/R tablets



##### Ferrous fumarate

capsules; tablets



#### 9.1.1.2 Parenteral iron

##### Ferric carboxymaltose

Red

Ferinject® injection

**RESTRICTED**

MHRA Drug Safety Update (Nov-20): Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures

##### Ferric derisomaltose

Red

Monofer® injection

**RESTRICTED**

MHRA: Monofer and Diafer name change (Nov-20)

MHRA Drug Safety Update (Sep-13): Intravenous iron and serious hypersensitivity reactions

##### Iron sucrose

Red

Venofer® injection

**RESTRICTED**

#### 9.1.2 Drugs used in megaloblastic anaemias

MHRA Drug Safety Update (Dec-23): Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions

##### Hydroxocobalamin

Intramuscular injection; sachets

1<sup>st</sup> line use

##### Cyanocobalamin

Green

50microgram; 1mg tablets



See BSH guidance



#### 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias

##### Erythropoietins

MHRA Drug Safety Update (Jan-18): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)

##### Darbepoetin alfa

Red

injection

**RESTRICTED**  
Renal Consultants only

##### Epoetin alfa

Red

injection

**RESTRICTED**  
Renal Consultants only

##### Epoetin beta

Red

injection

**RESTRICTED**  
Renal Consultants only

MHRA Drug Safety Update (May-15): Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded


























































































































#### Sickle-cell disease

##### Hydroxycarbamide

Amber


























oral solution; capsules

**RESTRICTED**  
Haematology Consultants only

<b>Iron overload</b>		
<b>Deferasirox</b>   tablets    	<b>RESTRICTED</b> Haematology Consultants only	
<b>Deferiprone</b>   tablets    	<b>RESTRICTED</b> Haematology Consultants only	
<b>Desferrioxamine mesilate</b>   injection   	<b>RESTRICTED</b> Haematology Consultants only	
<b>Exagamglogene autotemcel</b>   Casgevy® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE TA1003 / NHSE	
<b>Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI)</b>		
<b>Roxadustat</b>   Evrenzo® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>Paroxysmal nocturnal haemoglobinuria &amp; atypical haemolytic uraemic syndrome</b>		
<b>Eculizumab</b>   Soliris® 300mg/30mL infusion       	<b>RESTRICTED</b> Haematology Consultants only	
<b>Eculizumab</b>   Bekemv® 300mg/30mL infusion       	<b>RESTRICTED</b> Haem Consultants only - new patients	
<b>Eculizumab</b>   Epysqli® 300mg/30mL infusion       	<b>RESTRICTED</b> Haem Consultants only new patients < 2years old & patients with HFI	
<b>Ravulizumab</b>   infusion      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>9.1.4 Drugs used in autoimmune thrombocytopenic purpura</b>		
<b>Anagrelide</b>   capsules   	<b>RESTRICTED</b> Haematology Consultants only	
<b>Avatrombopag</b>   Doptelet® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>Caplacizumab</b>   Cablivi® injection      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>	
<b>Eltrombopag</b>   Revolade® tablets      	<b>RESTRICTED</b> Haematology Consultants only	
MHRA Drug Safety Update (Jul-18): Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results		
<b>Fostatinib</b>   Tavlesse® tablets      	<b>RESTRICTED</b> Specialist use only	
<b>Lusutrombopag</b>   Mulpleo® tablets      	<b>RESTRICTED</b> Specialist use only	
<b>Romiplostim</b>   Nplate® injection      	<b>RESTRICTED</b> Haematology Consultants only	



**9.1.6 Drugs used in neutropenia**

<p><b>Filgrastim</b>   </p> <p>injection    </p> <p>MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome</p>		<p><b>RESTRICTED</b>                  Haematology Consultants only</p>
<p><b>Lenograstim</b>   </p> <p>injection   </p>		<p><b>RESTRICTED</b>                  Haematology Consultants only</p>
<p><b>Pegfilgrastim</b>   </p> <p>injection    </p> <p>MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome</p>		<p><b>RESTRICTED</b>                  Haematology Consultants only</p>
<p><b>9.1.7 Drugs used to mobilise stem cells</b></p>		
<p><b>Plerixafor</b>   </p> <p>injection     </p>		<p><b>RESTRICTED - initiation on advice of Haematology Consultant only</b></p> <p></p>

## 9.2 Fluids and electrolytes



### 9.2.1 Oral preparations for fluid & electrolyte imbalance

#### 9.2.1.1 Oral potassium

##### Potassium chloride

Sando-K® effervescent tablets; Kay-Cee-L® syrup



##### Potassium removal

##### Calcium polystyrene sulfonate

Calcium Resonium® powder; enema (unlicensed)



##### Sodium zirconium cyclosilicate

Red

Lokelma® powder sachets



#### 9.2.1.2 Oral sodium and water

##### Sodium chloride (Slow Sodium®)

600mg M/R tablets



##### Oral Rehydration Therapy (ORT)

##### Oral Rehydration Salts (ORS)

DNP

oral powder



#### 9.2.1.3 Oral bicarbonate

##### Sodium bicarbonate

500mg capsules; 8.4% (1mmol/mL) oral solution



##### Sodium hydrogen carbonate

Nephrotrans® 50mg gastro-resistant capsules



**RESTRICTED**  
2<sup>nd</sup> line patients with severe GI side effects

### 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

#### 9.2.2.1 Electrolytes & water

##### Intravenous sodium

##### Sodium chloride

infusion; injection



##### Sodium chloride with other ingredients

##### Sodium chloride & glucose

infusion



##### Sodium chloride, calcium chloride & potassium chloride (Ringer's solution)

infusion



##### Sodium chloride, calcium chloride, potassium chloride & sodium lactate

infusion



##### Intravenous glucose

##### Glucose

infusion



MHRA Drug Safety Update (May-23): Glucose solutions: recommendations to minimise the risks associated with the accidental use instead of saline solutions in arterial lines

MHRA Drug Safety Update (Jul-12): Glucose solutions: false blood glucose readings when used to flush arterial lines

##### Intravenous potassium

##### Potassium chloride and glucose

infusion



##### Potassium chloride and sodium chloride










infusion



##### Potassium chloride, sodium chloride & glucose

infusion



<b>Bicarbonate and lactate</b>	
<b>Sodium bicarbonate</b>  1.26%, 2.74%, 4.2% & 8.4% injection; infusion	 
<b>Sodium lactate compound</b>  (Hartmann's solution) infusion	 
<b>Water</b>	
<b>Water for Injections</b>  injection	
<b>9.2.2.2 Plasma &amp; plasma substitutes</b>	
<b>Dextran</b>  Dextran 40 - 10% in sodium chloride 0.9% infusion	
<b>Dextrose Acid Citrate ACDA</b>  solution	
<b>Gelatin</b>  Gelofusine® infusion	 

## 9.3 Intravenous nutrition



**Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)**

**NICE CG32**

## 9.4 Oral nutrition



**Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)**

**NICE CG32**

### 9.4.1 Nutrition in special diets

#### Sapropterin dihydrochloride



Kuvan® 100mg soluble tablets



**RESTRICTED**  
Tetrahydrobiopterin deficiency



#### LaBiNIC® probiotic drops



LaBiNIC® probiotic drops



**RESTRICTED**  
prevention of NEC

# 9.5 Minerals



## 9.5.1 Calcium and magnesium

### 9.5.1.1 Calcium supplements

#### Oral preparations

##### Calcium carbonate

Green

*Cacit*® effervescent tablets; *Calcichew*® chewable tablets (see also section 9.5.2.2)



##### Calcium carbonate & calcium lactate gluconate

Green

*Calvive*® 1000 effervescent tablets



#### Parenteral preparations

##### Calcium gluconate

10% injection



MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia

##### Calcium chloride

10% injection



MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia

#### with vitamin D

see section 9.6.4



#### with risedronate sodium & colecalciferol

see section 6.6.2



### 9.5.1.2 Hypercalcaemia & hypercalciuria

##### Cinacalcet

Red 2<sup>nd</sup> HPT Amber 1<sup>st</sup> HPT ££

tablets



**RESTRICTED**  
as per NICE TA117

##### Etelcalcetide

Red ££

injection



**RESTRICTED**  
as per NICE TA448

### 9.5.1.3 Magnesium

##### Magnesium aspartate dihydrate

*Magnaspartate*® sachets



**NICE ESUOM4**

**1<sup>st</sup> line use**

##### Magnesium glycerophosphate

chewable tablets; capsules; oral solution; tablets



##### Magnesium sulfate

injection; infusion



MHRA Drug Safety Update (May-19): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy

### 9.5.2 Phosphorus

#### 9.5.2.1 Phosphate supplements

##### Phosphate supplements (*Phosphate-Sandoz*®)

effervescent tablets



**Effervescent tabs**

##### Phosphates (*Polyfusor*®)

Red

infusion



**I.V. preparation**

#### 9.5.2.2 Phosphate-binding agents

##### Aluminium hydroxide

Green

capsules



##### Calcium carbonate

Green

tablets (see also section 9.5.1.1)



##### Calcium acetate

Green

tablets













##### Calcium acetate with magnesium carbonate

Green

*Osvaren*® 435mg/235mg tablets



**RESTRICTED**  
Renal Consultants only

<p><b>Lanthanum</b>                        chewable tablets; oral powder  </p>	<p><b>RESTRICTED</b>                      Renal Consultants only</p>
<p><b>Patiromer calcium</b>                        Veltassa® oral powder  </p>	<p><b>RESTRICTED</b> Consultants only                      in line with NICE TA623</p>
<p><b>Sevelamer carbonate</b>                        tablets  </p>	<p><b>RESTRICTED</b>                      Renal Consultants only</p>
<p><b>Sucroferric oxyhydroxide</b>                        chewable tablets  </p>	<p><b>RESTRICTED</b>                      Renal Consultants only - 3<sup>rd</sup> line</p>
<p><b>9.5.3 Fluoride</b></p>	
<p><b>Sodium fluoride</b>                      tablets, paediatric drops, dental rinse  </p>	
<p><b>9.5.4 Zinc</b></p>	
<p><b>Zinc sulfate</b>                      Solvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules  </p>	

## 9.6 Vitamins



### 9.6.1 Vitamin A

#### Vitamin A

150,000units/mL drops



#### Vitamin A palmitate

100,000units/2mL injection



#### Vitamins A & D

capsules



### 9.6.2 Vitamin B group

#### Pyridoxine hydrochloride

tablets



#### Thiamine

tablets



#### Vitamin B compound



#### Vitamin B compound Strong

tablets



#### Vitamins B & C

*Pabrinex*® Intramuscular (IM) & Intravenous (IV) injection



### 9.6.3 Vitamin C (ascorbic acid)

#### Ascorbic acid

tablets



### 9.6.4 Vitamin D

#### Alfacalcidol

Green

capsules; injection; oral drops



#### Calcitriol

capsules; oral solution



#### Ergocalciferol

*Sterogy*® 600,000 IU / 1.5mL ampoule



#### Vitamin D and calcium

#### Colecalciferol

1<sup>st</sup> line use

*Calcichew D3*® Forte tablets / *Adcal D3*® chewable tablets



#### Calcium & Ergocalciferol

calcium 97mg/vitamin D 400units



#### Colecalciferol with calcium carbonate

*Cacit*® D3 effervescent granules; 800 IU capsules



### 9.6.5 Vitamin E (tocopherols)

#### Alpha tocopheryl acetate (Vitamin E)

500mg/5mL liquid















#### Alpha tocopheryl acetate (Vitamin E)

75 unit capsules





9.6.6 Vitamin K		
<b>Phytomenadione</b>		
<i>Konakion® MM &amp; Konakion® MM Paediatric</i> injection	  	
<b>Menadiol sodium phosphate</b>		
oral solution; tablets	  	
9.6.7 Multivitamin preparations		
<b>Vitamins B,C</b>		<b>RESTRICTED</b>
<i>Renavit®</i> tablets	  	
<b>Vitamins A,D,E,K</b>		<b>RESTRICTED</b> Paediatric CF patients
<i>Paravit-CF®</i> capsules; liquid	  	

## 9.7 Bitters & tonics



Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use

# 9.8 Metabolic disorders



## 9.8.1 Drugs used in metabolic disorders

### Serine deficiency

**L-Serine**

(Nutricia L-Serine) powder

MMC

**RESTRICTED**  
Specialist use only

### Wilson's Disease

**Penicillamine**

tablets (see also section 10.1.3)

**Trientine dihydrochloride**

capsules

MMC

3<sup>rd</sup> line use



### Carnitine Deficiency

**Levocarnitine**

injection; oral solution

**RESTRICTED**  
Specialist use only

### Fabry's disease

**Agalsidase alfa**

Replagal® infusion

MMC

**RESTRICTED**  
Specialist use only  
**NOT STOCKED**

**MigALastat**

Galafold® capsules

MMC

**RESTRICTED**  
Specialist use only (NICE HST4)

### Mucopolysaccharidosis

**Elosulfase alfa**

Vimizim® infusion

MMC

**RESTRICTED**  
Specialist use only (NICE HST19)

**Galsulfase**

Naglazyme® infusion

MMC

**RESTRICTED**  
Specialist use only  
**NOT STOCKED**

**Idursulfase**

Elaprase® infusion

MMC

**RESTRICTED**  
Specialist use only

**Laronidase**

Aldurazyme® infusion

MMC

**RESTRICTED**  
Specialist use only  
**NOT STOCKED**

**Vestronidase alfa**

Mepsevii® infusion

MMC

**RESTRICTED**  
Specialist use only



### Nephropathic cystinosis

**Cystagon® (Mercaptamine)**

capsules (NB: prescribe as CYSTAGON®)

**RESTRICTED**  
Specialist use only

### Pompe disease

**Avalglucosidase alfa**

Nexviadyme® infusion

MMC

**RESTRICTED**  
Specialist use only (NICE TA821)

### Tyrosinaemia type I

**Nitisinone**

capsules; oral suspension

MMC

**RESTRICTED**  
Specialist use only

### Urea cycle disorders



**Arginine**

infusion; oral solution

MMC

**RESTRICTED**  
Specialist use only

**Carglumic acid**

dispersible tablets

MMC

**RESTRICTED**  
Specialist use only

**Citrulline**

powder

MMC















































































**RESTRICTED**  
Specialist use only

**Glycerol phenylbutyrate**

Ravicti® 1.1g/mL oral liquid

MMC

**RESTRICTED**  
Specialist use only

<p><b>Sodium phenylbutyrate</b>                         tablets; injection; oral liquid; granules (discontinued)</p>	   	<p><b>RESTRICTED</b> Specialist use only</p>
<b>Homocystinuria</b>		
<p><b>Betaine</b>                         tablets; oral powder</p>	  	<p><b>RESTRICTED</b> Specialist use only</p>
<p><b>Sodium benzoate</b>                      injection; oral solution; tablets; powder</p>	  	<p><b>RESTRICTED</b> Specialist use only</p>
<p><b>Uridine</b></p>	 	<p><b>RESTRICTED</b> Specialist use only</p>
<b>Other metabolic disorders</b>		
<p><b>Asfotase alfa</b>                         Strensiq® injection</p>	     	<p><b>RESTRICTED</b> Specialist use only (NICE HST23)</p>
<p><b>Cerliponase alfa</b>                         Brineura® 150mg solution for infusion</p>	    	<p><b>RESTRICTED</b> Specialist use only (NICE HST12)</p>
<p><b>Eliglustat</b>                         Cerdelga® 84mg capsules</p>	     	<p><b>RESTRICTED</b> Specialist use only (NICE HST5)</p>
<p><b>Lumasiran</b>                         Oxlumio® injection</p>	     	<p><b>RESTRICTED</b> Specialist use only (NICE HST25)</p>
<p><b>MigLUstat</b>                         100mg capsules</p>	   	<p><b>RESTRICTED</b> Specialist use only</p>
<p><b>Sebelipase alfa</b>                         Kanuma® 2mg/mL solution for infusion</p>	     	<p><b>RESTRICTED</b> Specialist use only (NICE HST30)</p>
<p><b>Sodium dichloroacetate</b>                          50 mg/mL powder for reconstitution for oral solution (200 mL)</p>	  	<p><b>RESTRICTED</b> Specialist use only Primary lactic acidosis / PDHC deficiency</p>
<p><b>Velaglucerase alfa</b>                         VPRIV® 400 units vial</p>	   	<p><b>RESTRICTED</b> Specialist use only</p>
<b>9.8.2 Acute porphyrias</b>		
<p><b>Haem Arginate</b>                         infusion</p>	  	

# Non-Formulary Items



<p><b>Cipaglucosidase alfa</b>  </p> <p><i>Pombiliti</i>® infusion  </p>	<p><b>MFT not a commissioned centre</b>                  Patients referred to NCA</p>
<p><b>Crizanlizumab</b>  </p> <p><i>Adakveo</i>® 10mg/mL injection  </p>	<p><b>MA Withdrawn January 2024</b></p>
<p>MHRA Class 2 Medicines Recall: Novartis Pharmaceuticals UK Limited, Adakveo 10 mg/ml concentrate for solution for infusion, EL(24)A/06</p>	
<p><b>Crovalimab</b>  </p> <p><i>PiaSky</i>® infusion  </p>	<p><b>MFT not a commissioned centre</b>                  Patients referred to Leeds</p>
<p><b>Danicopan</b>  </p> <p><i>Voydeya</i>® tablets  </p>	<p><b>MFT not a commissioned centre</b>                  Patients referred to Leeds</p>
<p><b>Iptacopan hydrochloride monohydrate</b>  </p> <p><i>Fabhalta</i>® 200mg hard capsules  </p>	<p><b>MFT not a commissioned centre</b>                  Patients referred to Leeds</p>
<p><b>Pegcetacoplan</b>  </p> <p><i>Aspavelli</i>® 1080mg injection  </p>	<p><b>MFT not a commissioned centre</b>                  Patients referred to Leeds</p>
<p><b>Voxelotor</b>  </p> <p><i>Oxbryta</i>® 500mg tablets  </p>	<p><b>MA Withdrawn September 2024</b></p>

## Section 10: Musculoskeletal & Joint Diseases

Supported by the  
formulary ([click here](#))



### 10.1 Drugs used in rheumatic diseases & gout

- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs that suppress the rheumatic disease process
  - Gold
  - Penicillamine
  - Antimalarials
  - Drugs affecting the immune response
  - Cytokine modulators
- 10.1.4 Gout and cytotoxic induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases

### 10.2 Drugs used in neuromuscular disorders

- 10.2.1 Drugs that enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants
  - Nocturnal leg cramps
- 10.2.3 Drugs used in neuromuscular disorders

### 10.3 Drugs for the relief of soft-tissue inflammation

- 10.3.1 Enzymes
- 10.3.2 Rubefacients & other topical antirheumatics

### 10.4 Miscellaneous preparations

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Rheumatoid arthritis in adults: management (NG100)  
 Osteoarthritis in over 16s: diagnosis and management (NG226)  
 Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)  
 Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)  
 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)  
 Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)  
 Hyperuricaemia - febuxostat (TA164)  
 Psoriasis - ustekinumab (TA180)  
 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)  
 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)  
 Psoriatic arthritis - golimumab (TA220)  
 Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)  
 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)  
 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)  
 Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)  
 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)  
 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)  
 Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Baricitinib for moderate to severe rheumatoid arthritis (TA466)  
 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)  
 Tofacitinib for moderate to severe rheumatoid arthritis (TA480)  
 Sarilumab for moderate to severe rheumatoid arthritis (TA485)  
 Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)  
 Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)  
 Tocilizumab for treating giant cell arteritis (TA518)  
 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)  
 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)  
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)  
 Nusinersen for treating spinal muscular atrophy (TA588)  
 Upadacitinib for treating severe rheumatoid arthritis (TA665)  
 Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)  
 Anakinra for treating Still's disease (TA685)  
 Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)  
 Ixekizumab for treating axial spondyloarthritis in adults (TA718)  
 Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)  
 Tofacitinib for treating juvenile idiopathic arthritis (TA735)  
 Upadacitinib for treating moderate rheumatoid arthritis (TA744)  
 Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)  
 Risdiplam for treating spinal muscular atrophy (TA755)  
 Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)  
 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)  
 Upadacitinib for treating active ankylosing spondylitis (TA829)  
 Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)  
 Bimekizumab for treating axial spondyloarthritis (TA918)  
 Tofacitinib for treating active ankylosing spondylitis (TA920)

## GMMMG Formulary





































Formulary Homepage  
 Chapter 10: Musculoskeletal & Joint Diseases (v8.4 - Dec-24)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List
























































































































# 10.1 Drugs used in rheumatic diseases & gout



















































10.1 Drugs used in rheumatic diseases & gout		NICE CG177
10.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs)		NICE NG100
<p>MHRA Drug Safety Update (Oct-12): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks            MHRA Drug Safety Update (May-09): Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment            MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks</p>		
<p><b>Ibuprofen (oral)</b></p> <p>200mg; 400mg; 600mg tablets; 5% gel</p> <p>MMC  </p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk</p>		<b>1<sup>st</sup> line use</b>
<p><b>Ibuprofen (IV)</b></p> <p>200mg in 50mL solution for infusion</p> <p>MMC  </p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk</p>		<b>short-term symptomatic treatment of acute moderate pain</b>
<p><b>Naproxen</b></p> <p>250mg; 500mg tablets</p> <p> </p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy</p>		
<p><b>Celecoxib</b></p> <p>100mg; 200mg capsules</p> <p>MMC  </p> <p>MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks</p>		<b>RESTRICTED - osteoarthritis in line with NICE NG226</b>
<p><b>Diclofenac sodium</b></p> <p>50mg tablets; suppositories; injection (restricted post-op pain)</p> <p>MMC  </p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription            MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings</p>		<b>RESTRICTED - acute post-operative pain (injection)</b>
<p><b>Flurbiprofen</b></p> <p>50mg tablets</p> <p> </p>		
<p><b>Indometacin</b></p> <p>capsules; suppositories</p> <p>MMC  </p>		<b>RESTRICTED 3<sup>rd</sup> line (off-label) for tocolysis</b>
<p><b>Mefenamic acid</b></p> <p>250mg; 500mg tablets</p> <p> </p>		
<p><b>Meloxicam</b></p> <p>7.5mg; 15mg tablets</p> <p> </p>		
<p><b>Sulindac</b></p> <p>100mg; 200mg tablets</p> <p>MMC  </p>		
<p><b>Etodolac</b></p> <p>600mg tablets</p> <p>MMC  </p>		<b>RESTRICTED Consultant Anaesthetist use only</b>
<p><b>Phenylbutazone</b></p> <p>100mg; 200mg tablets</p> <p> </p>		<b>RESTRICTED Specialist use only, ankylosing spondylitis</b>



<b>10.1.2 Corticosteroids</b>		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
<b>10.1.2.1 Systemic corticosteroids</b>		<b>NICE NG100</b>
<b>Prednisolone</b>		
	 	
<b>10.1.2.2 Local corticosteroid injections</b>		<b>NICE NG100</b>
<b>Hydrocortisone acetate</b>		
25mg/mL injection	 	
<b>Methylprednisolone acetate</b>		
40mg/mL injection	 	
<b>Triamcinolone acetonide</b>		
10mg/mL; 40mg/mL injection	 	
<b>Triamcinolone hexacetonide</b>		<b>RESTRICTED Paediatric Rheumatology Consultants only</b>
20mg/mL injection	  	
<b>10.1.3 Drugs that suppress the rheumatic disease process</b>		
<b>Gold</b>		<b>NICE NG100</b>
<b>Auranofin</b>		<b>RESTRICTED Rheumatology Consultants only</b>
Amber tablets	 	
<b>Sodium aurothiomalate</b>		<b>RESTRICTED Rheumatology Consultants only</b>
Amber injection	 	
<b>Penicillamine</b>		<b>RESTRICTED Rheumatology Consultants only</b>
Amber tablets (see also section 9.8.1)	 	
<b>Antimalarials</b>		
<b>Hydroxychloroquine sulfate</b>		<b>RESTRICTED Rheumatology Consultants only</b>
Amber tablets	  	
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions		
MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
<b>Mepacrine hydrochloride</b>		<b>RESTRICTED Rheumatology Consultants only</b>
Red 100mg tablets	  	
<b>Drugs affecting the immune response</b>		<b>NICE NG100</b>
<b>Azathioprine</b>		<b>RESTRICTED Rheumatology Consultants only</b>
Amber tablets; injection; oral solution (see also sections 1.5.3, 8.2.1 & 13.5.3)	  	
<b>Ciclosporin</b>		<b>RESTRICTED Consultants only</b>
Amber capsules; oral solution; injection (see also sections 8.2.2 & 13.5.3)	   	
<b>Leflunomide</b>		<b>RESTRICTED Rheumatology Consultants only</b>
Amber tablets	  	
<b>Methotrexate</b>		<b>RESTRICTED Consultants only</b>
Amber oral Red parenteral tablets; injections (see also sections 1.5.3, 8.1.3 & 13.5.3)	  	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions		
MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose		

Cytokine modulators		
<b>Abatacept</b>   injection; infusion       	<b>RESTRICTED</b> Rheum. Consultants only in line with NICE / NHSE	
<b>Adalimumab</b>   injection (see also sections 1.5.3, 11.4.2 & 13.5.3)       	<b>RESTRICTED</b> Consultants only in line with NICE	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
<b>Anakinra</b>   injection       	<b>RESTRICTED</b> Consultants only in line with NICE / NHSE	
<b>Apremilast</b>   10mg; 20mg; 30mg tablets (see also section 13.5.3)     	<b>RESTRICTED</b> 3 <sup>rd</sup> / 4 <sup>th</sup> line as per NICE/GMMMG	
<b>Baricitinib</b>   2mg; 4mg tablets       	<b>RESTRICTED</b> Rheumatology Consultants only in line with NICE	
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality MHRA Drug Safety Update (Aug-20): Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors MHRA Drug Safety Update (Mar-20): Baricitinib (Olumiant▼): risk of venous thromboembolism		
<b>Belimumab</b>   Benlysta® 120mg; 400mg infusion; 200mg/1mL pre-filled pen      	<b>RESTRICTED</b> Consultants only	
MHRA Drug Safety Update (Apr-19): Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials		
<b>Bimekizumab</b>   Bimzelx® injection (see also section 13.5.3)      	<b>RESTRICTED</b> in line with NICE	
<b>Certolizumab pegol</b>   Cimzia® 200mg/1mL injection (see also section 13.5.3)     	<b>RESTRICTED</b> Rheumatology Consultants in line with NICE	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
<b>Etanercept</b>   injection (see also section 13.5.3)       	<b>RESTRICTED</b> Consultants only; in line with NICE	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
<b>Filgotinib</b>   Jyseleca® 100mg; 200mg tablets (see also section 1.5.3)      	<b>RESTRICTED</b> Consultants only in line with NICE	
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
<b>Golimumab</b>   injection (see also section 1.5.3)     	<b>RESTRICTED</b> Consultants only in line with NICE	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
<b>Guselkumab</b>   100mg/mL injection (see also section 13.5.3)     	<b>RESTRICTED</b> in line with NICE	
<b>Infliximab</b>   Remicade® infusion; Remsima® infusion (see also section 13.5.3)       	<b>RESTRICTED</b> Consultants only <b>MMC Remsima</b>	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
<b>Ixekizumab</b>   80mg/1mL injection (see also section 13.5.3)     	<b>RESTRICTED</b> Consultants only in line with NICE	
<b>Rituximab</b>   injection; infusion (see also section 8.2.3)      	<b>RESTRICTED</b> Consultants only in line with NICE / NHSE	
<b>Sarilumab</b>   Kevzara® 150mg/1.14mL injection      	<b>RESTRICTED</b> Rheumatology Consultants only in line with NICE	
<b>Secukinumab</b>   Cosentyx® 150mg/1mL injection (see also section 13.5.3)      	<b>RESTRICTED</b> Rheumatology Consultants only in line with NICE	
<b>Tocilizumab</b>   infusion      	<b>RESTRICTED</b> Consultants only in line with NICE	
MHRA Drug Safety Update (Jul-19): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation		

<p><b>Tofacitinib</b>   </p> <p>Xeljanz® 5mg; 10mg tablets (see also section 1.5.3)</p> <p>     </p> <p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality                  MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies                  MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections                  MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing</p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p><b>Upadacitinib</b>   </p> <p>MR tablet (see also sections 1.5.3 &amp; 13.5.3)</p> <p>     </p> <p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality</p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p><b>Ustekinumab</b>   </p> <p>Stelara® injection; infusion (see also sections 1.5.3 &amp; 13.5.3)</p> <p>     </p> <p>MHRA Drug Safety Update (Jan-15): Ustekinumab (Stelara): risk of exfoliative dermatitis</p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p><b>Ustekinumab</b>   </p> <p>Wezenla® injection; infusion (see also sections 1.5.3 &amp; 13.5.3)</p> <p>     </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p><b>10.1.4 Gout and cytotoxic induced hyperuricaemia</b></p>	
<p><b>Acute attacks of gout</b></p>	
<p><b>Colchicine</b></p> <p>tablets</p> <p> </p>	
<p><b>Long-term control of gout</b></p>	
<p><b>Allopurinol</b></p> <p>tablets</p> <p> </p>	<p><b>1<sup>st</sup> line use</b></p>
<p><b>Febuxostat</b>  </p> <p>tablets</p> <p>   </p> <p>MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease                  MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease                  MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity</p>	<p><b>RESTRICTED</b>                  Rheumatology Consultants only</p>
<p><b>Hyperuricaemia associated with cytotoxic drugs</b></p>	
<p><b>Rasburicase</b>   </p> <p>Fasturtec® infusion</p> <p>    </p>	<p><b>RESTRICTED</b>                  Haematology Consultants only</p>
<p><b>10.1.5 Other drugs for rheumatic diseases</b></p>	
	<p><b>NICE CG177</b></p> <p><b>NICE TA477</b></p> <p><b>NICE TA508</b></p>

## 10.2 Drugs used in neuromuscular disorders



## 10.2.1 Drugs that enhance neuromuscular transmission

## Anticholinesterases

## Pyridostigmine bromide

tablets

1<sup>st</sup> line use

## Neostigmine metisulfate

tablets; injection (see also section 15.1.6)



## Edrophonium chloride

injection



**RESTRICTED**  
diagnosis of myasthenia gravis  
Licensed product discontinued

## 10.2.2 Skeletal muscle relaxants

## Baclofen

10mg tablets; 5mg/mL oral solution

1<sup>st</sup> line use

## Dantrolene sodium

25mg; 100mg capsules; *Ryanodex*® 250mg/20mL vial (see also section 15.1.8)

## Diazepam

tablets; liquid; injection; rectal tube (see also sections 4.1.2, 4.8.2 &amp; 15.1.4.1)



## Tizanidine

Amber

2mg; 4mg tablets



**RESTRICTED**  
Consultant Neurologist only

## Nocturnal leg cramps

## Quinine sulfate

tablets (see also section 5.4.1)



MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions

MHRA Drug Safety Update (Jun-10): Quinine: not to be used routinely for nocturnal leg cramps

## 10.2.3 Drugs used in neuromuscular disorders

## Ataluren

Red ££

oral suspension sachets



**Specialist use only**  
in line with NICE HST22

## Atidarsagene autotemcel

Red ££

Libmeldy® infusion



**Specialist use only**  
in line with NICE HST18

## Nusinersen

Red ££

injection



**Specialist use only**  
in line with NICE TA588 / NHSE  
**Named patient access**

MHRA Drug Safety Update (Sep-18): Nusinersen (Spinraza ▼): reports of communicating hydrocephalus; discuss symptoms with patients &amp; carers - investigate urgently

## Onasemnogene abeparvovec

Red ££

*Zolgensma*® infusion

**RESTRICTED Paediatric Neurology**  
Consultants only NICE / NHSE

## Risdiplam

Red ££

oral solution



**Specialist use only**  
in line with NICE TA755

## 10.3 Drugs for the relief of soft-tissue inflammation



### 10.3.1 Enzymes

#### Hyaluronidase

Red

injection



**RESTRICTED**  
extravasation

### 10.3.2 Rubefacients & other topical antirheumatics

#### Piroxicam

0.5% gel



#### Capsaicin

DNP

cream, patch



Patch restricted to peripheral  
neuropathic pain specialists at TGH

## 10.4 Miscellaneous preparations



### Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 13.14)

PbR X



**RESTRICTED**  
2<sup>nd</sup> line rescue therapy



### Dibotermin alfa



InductOs®

PbR X



**RESTRICTED**  
NHSE CCP 16063/P



## Section 11: Eye

Supported by the  
formulary ([click here](#))



### 11.3 Anti-infective eye preparations

11.3.1 Antibacterials

11.3.3 Antivirals

### 11.4 Corticosteroid & other anti-inflammatory preparations

11.4.1 Corticosteroids

11.4.2 Other anti-inflammatory preparations

### 11.5 Mydriatics & cycloplegics

### 11.6 Treatment of glaucoma

Beta-blockers

Prostaglandin analogues and prostamides

Combination products (prostaglandin analogue with beta-blocker)

Combination products (prostaglandin analogue with Rho kinase inhibitor)

Sympathomimetics

Carbonic anhydrase inhibitors

Miotics

### 11.7 Local anaesthetics

### 11.8 Miscellaneous ophthalmic preparations

11.8.1 Tear deficiency, ocular lubricants & astringents

11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment

11.8.3 Other preparations

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Glaucoma: diagnosis and management (NG81)  
 Age-related macular degeneration (NG82)  
 Diabetic retinopathy: management and monitoring (NG242)  
 Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)  
 Macular degeneration (age related) ranibizimab & pegaptanib (TA155)  
 Macular oedema (retinal vein occlusion) - dexamethasone (TA229)  
 Macular oedema (diabetic) - ranibizumab (TA274)  
 Macular oedema (retinal vein occlusion) - ranibizumab (TA283)  
 Macular degeneration (wet age-related) - aflibercept (1<sup>st</sup> line) (TA294)  
 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)  
 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)  
 Aflibercept for treating diabetic macular oedema (TA346)  
 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)  
 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Holoclar for treating limbal stem cell deficiency after eye burns (TA467)  
 Aflibercept for treating choroidal neovascularisation (TA486)  
 Cenegeermin for treating neurotrophic keratitis (TA532)  
 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)  
 Brolucizumab for treating wet age-related macular degeneration (TA672)  
 Faricimab for treating diabetic macular oedema (TA799)  
 Faricimab for treating wet age-related macular degeneration (TA800)  
 Brolucizumab for treating diabetic macular oedema (TA820)  
 Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)  
 Fluocinolone acetonide intravitreal implant for treating chronic DMO (updates & replaces TA301 / TA613) (TA953)  
 Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)  
 Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)  
 Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

## GMMM Formulary

Formulary Homepage  
 Chapter 11: Eye (v6.3 - Dec-24)  
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red/Amber/Green](#) Drug List



## 11.3 Anti-infective eye preparations



### 11.3.1 Antibacterials

#### Chloramphenicol

0.5% eye drops, 1% eye ointment



MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years

#### Fusidic acid (ophthalmic)

1% eye drops



#### Amikacin (ophthalmic)

**U** **Red**

2.5% eye drops



**RESTRICTED** microbial keratitis.  
Consultant Ophthalmologist only  
**NOT STOCKED**

#### Amphotericin

**U**

0.15% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

#### Azithromycin (ophthalmic)

**Red**

Azzyter® 1.5% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

#### Ceftazidime (ophthalmic)

**U**

5% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only  
**NOT STOCKED**

#### Cefuroxime (ophthalmic)

**U** **Red**

5% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

#### Cefuroxime (intracameral injection)

**Red**

Ximaract® 50mg in 5mL intracameral injection



**RESTRICTED** Consultant  
Ophthalmologist only

#### Chlorhexidine (ophthalmic)

**U** **Red**

0.02% eye drops



**RESTRICTED** acanthamoeba  
keratitis. Consultant only

#### Ciprofloxacin (ophthalmic)

0.3% eye drops



**RESTRICTED** microbial keratitis.  
Consultant Ophthalmologist only

MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...

#### Erythromycin (ophthalmic)

**U**

0.5% eye ointment



**RESTRICTED** superficial eye  
infections

#### Gentamicin (ophthalmic)

**U** **Red**

1.5% eye drops (Use with cefuroxime eye drops)



**RESTRICTED** Consultant  
Ophthalmologist only

#### Levofloxacin (ophthalmic)

**Red**

0.5% eye drops



**RESTRICTED** Consultant only corneal  
ulcers/ keratitis

MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...

#### Natamycin

**U**

5% eye drops



**RESTRICTED** fungal keratitis,  
conjunctivitis, fungal blepharitis

#### Ofloxacin

**Red**

0.3% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...

#### Penicillin (ophthalmic)

**U** **Red**

2,500 units/mL eye drops



**RESTRICTED** microbial keratitis.  
Consultant Ophthalmologist only









#### Polyhexamethylene biguanide (PHMB)

**U** **Red**

0.02% eye drops



**NOT STOCKED**

<p><b>Propamide isetionate</b>  <span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>0.1% eye drops</p>	 	<p><b>RESTRICTED</b> Consultant                  Ophthalmologist only</p>
<p><b>Vancomycin (ophthalmic)</b>  <span style="background-color: red; color: white; padding: 2px;">U</span></p> <p>5% eye drops</p>	 	<p><b>RESTRICTED</b> gram positives,                  including MRSA but not VRE  <b>NOT STOCKED</b></p>
<p><b>11.3.3 Antivirals</b></p>		
<p><b>Ganciclovir</b>  <span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>0.15% eye gel</p>	 	
<p><b>Trifluorothymidine</b>  <span style="background-color: red; color: white; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">Red</span></p> <p>1% eye drops</p>	 	

## 11.4 Corticosteroid & other anti-inflammatory preparations



### 11.4.1 Corticosteroids

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

<b>Betamethasone</b> 0.1% eye drops & ointment 	
<b>Dexamethasone</b> 0.1% eye drops & minims 	
<b>Dexamethasone (intravitreal implant)</b>  Ozurdex® 700micrograms intravitreal implant 	<b>RESTRICTED</b> as per NICE TA229; TA460 & TA824
<b>Fluocinolone acetonide</b>  Iluvien® 190micrograms intravitreal implant 	<b>RESTRICTED</b> as per NICE TA590 & TA953
<b>Prednisolone</b> 0.5% & 1% eye drops; 0.5% minims 	
<b>Fluorometholone</b>  0.1% eye drops 	
<b>Hydrocortisone sodium phosphate</b> Softacort® 3.35 mg/mL PF single use eye drops 	
<b>Triamcinolone acetonide</b>  Kenalog® 40mg/mL injectable suspension 	<b>RESTRICTED</b> intralesional injection in skin grafts
<b>Triamcinolone acetonide</b>  Triesence® 40mg/mL injectable suspension 	<b>RESTRICTED</b> uveitis; sympathetic ophthalmia
<b>Triamcinolone acetonide</b>  Intracinol® 40mg/mL ophthalmic suspension 	<b>RESTRICTED</b> opacification of the vitreous humour
<b>Corticosteroids preparations with antibiotics</b>	
<b>Betamethasone with neomycin sulphate</b> 0.1% / 0.5% eye drops (Betnesol-N®) 	
<b>Dexamethasone with hypromellose, neomycin and polymyxin B sulfate</b> 1 mg/mL : 3500 IU/mL : 6000 IU/mL (Maxitrol® eye drops & ointment) 	
<b>11.4.2 Other anti-inflammatory preparations</b>	
<b>Sodium cromoglicate</b> 2% eye drops 	
<b>Adalimumab</b>  Amgevita® injection (see also sections 1.5.3, 10.1.3 & 13.5.3) 	<b>RESTRICTED Consultant Ophthalmologist only</b> Non-infectious Uveitis
<b>Antazoline with xylometazoline</b> 0.5% eye drops 	
<b>Azelastine hydrochloride</b> 0.05% eye drops 	<b>RESTRICTED</b> allergic conjunctivitis, children only
<b>Ketotifen hydrogen fumarate</b> Ketofall® 0.25mg/mL PF eye drops 	
<b>Lodoxamide</b> 0.1% eye drops 	<b>RESTRICTED</b> allergic conjunctivitis
<b>Olopatadine</b> 1mg/mL eye drops 	<b>RESTRICTED</b> Seasonal allergic conjunctivitis
<b>Potassium ascorbate</b>  10% eye drops 	<b>RESTRICTED</b> management of chemical burns to the cornea

## 11.5 Mydriatics & cycloplegics



### Antimuscarinics

#### Atropine sulphate

1% minims



#### Cyclopentolate hydrochloride

1% eye drops, 0.5% &amp; 1% minims



#### Tropicamide

0.5% &amp; 1% eye drops, 0.5% &amp; 1% minims



### Sympathomimetics

#### Phenylephrine hydrochloride

2.5% &amp; 10% minims



**10% contraindicated in children & the elderly**

### Sympathomimetics with tropicamide

#### Phenylephrine hydrochloride with tropicamide

Mydriaser® 5.4mg / 280micrograms ophthalmic insert



**RESTRICTED Pre-operative mydriasis in cataract patients**

## 11.6 Treatment of glaucoma



Beta-blockers	NICE NG81	
<b>Timolol maleate</b>		
0.25% & 0.5% eye drops		
<b>Timolol once-daily</b>		
0.25% eye drops, <i>Tiopex</i> ® 0.1% gel, 0.5% long-acting ophthalmic gel		
<b>Betaxolol</b>		
0.25% & 0.5% eye drops, 0.25% minims		
<b>Levobunolol hydrochloride</b>		
0.5% eye drops		
Prostaglandin analogues and prostamides		
<b>Bimatoprost</b>		
100 micrograms/mL eye drops		
<b>Latanoprost</b>		
50 micrograms/mL eye drops		
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
<b>Latanoprost (preservative free)</b>		
50 micrograms/mL preservative free eye drops		
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
<b>Travoprost</b>		
40 micrograms/mL eye drops		
Combination products (prostaglandin analogue with beta-blocker)		
<b>Latanoprost with timolol</b>		
50micrograms/mL / 5mg/mL eye drops; preservative free eye drops		
Combination products (prostaglandin analogue with Rho kinase inhibitor)		
<b>Latanoprost with netarsudil</b>		<b>RESTRICTED use in line with NICE TA1009</b>
<i>Roclanda</i> ® 50micrograms/mL / 5mg/mL + 200micrograms/mL eye drops		<b>NOT for 1ry care recommendation at present</b>
Sympathomimetics		
<b>Brimonidine tartrate</b>		
0.2% eye drops		
<b>Apraclonidine</b>		<b>RESTRICTED to delay laser treatment / surgery in uncontrolled glaucoma</b>
or		
0.5%; 1% eye drops		
Carbonic anhydrase inhibitors & systemic drugs		
<b>Acetazolamide</b>		
250mg tablets; <i>Diamox SR</i> ® 250mg capsules		
<b>Brinzolamide</b>		
10mg/mL eye drops		
<b>Brinzolamide with brimonidine</b>		<b>RESTRICTED glaucoma patients in whom monotherapy provides insufficient IOP reduction</b>
<i>Simbrinza</i> ® 2% eye drops		
<b>Dorzolamide</b>		
2% eye drops; also preservative free		
<b>Dorzolamide with timolol</b>		
<i>Cosopt</i> ® 2% eye drops; also preservative free		

**Miotics****Pilocarpine**

1%, 2% &amp; 4% eye drops, 2% minims

**Pilocarpine**

4% ophthalmic gel



## 11.7 Local anaesthetics



### Ocular Local anaesthetics

#### Fluorescein with lidocaine (minims)

4% / 0.25% eye drops



#### Oxybuprocaine hydrochloride (minims)

0.4% eye drops



#### Proxymetacaine hydrochloride (minims)

0.5% eye drops



#### Tetracaine (Amethocaine) (minims)

1% &amp; 2% eye drops



# 11.8 Miscellaneous ophthalmic preparations



## Other preparations

<p><b>Botulinum toxin type A</b></p> <p><i>Xeomin</i>® injection</p> <p>MMC BNF emc</p>	<p><b>RESTRICTED</b> Consultant Ophthalmologist only blepharospasm &amp; strabismus</p>
<p><b>Ciclosporin (eye)</b></p> <p>U</p> <p>2% eye drops</p> <p>BNF emc</p>	<p><b>RESTRICTED</b> Consultant Ophthalmologist only</p>
<p><b>Ciclosporin (<i>Ikervis</i>®)</b></p> <p>Green</p> <p>1mg/mL eye drops</p> <p>NICE MMC BNF emc</p>	<p><b>RESTRICTED</b> Consultant Ophthalmologist only in line with NICE TA369</p>
<p><b>Ciclosporin (<i>Verkazia</i>®)</b></p> <p>Green</p> <p>1mg/mL eye drops</p> <p>MMC BNF emc</p>	<p><b>RESTRICTED Paediatrics</b> for vernal keratoconjunctivitis / severe allergic eye disease</p>
<p><b>Mercaptamine</b></p> <p>Red EF</p> <p>Cystadrops® eye drops</p> <p>PbR x MMC BNF blueiteq emc</p>	<p><b>RESTRICTED</b> Specialist use only <b>NHSE</b></p> <p>NHS England</p>
<p><b>Sodium chloride</b></p> <p>U Red</p> <p>5% eye drops</p> <p>BNF emc</p>	
<p><b>Allogeneic Serum eye drops</b></p> <p>U Red</p> <p>eye drops (minims) (from NHS Blood &amp; Transplant Service) (not a medicine)</p> <p>MMC blueiteq</p>	<p><b>RESTRICTED</b> Consultant Ophthalmologist only</p> <p>NHS England</p>
<p><b>11.8.1 Tear deficiency, ocular lubricants &amp; astringents</b></p>	
<p><b>Acetylcysteine</b></p> <p>U</p> <p><i>Ilube</i>® 5% eye drops</p> <p>BNF emc</p>	
<p><b>Alteplase</b></p> <p>25micrograms in 0.1mL intravitreal injection</p> <p>MMC BNF emc</p>	<p><b>RESTRICTED</b> Consultant Ophthalmologist only</p>
<p><b>Carbomers</b></p> <p><i>Viscotears</i>® 0.2% eye drops</p> <p>MMC BNF emc</p>	
<p><b>Carmellose sodium</b></p> <p><i>Celluvisc</i>® 0.5% eye drops</p> <p>BNF emc</p>	
<p><b>Glycerol and mineral oils (<i>Cationorm</i>®)</b></p> <p>preservative free eye drops</p> <p>MMC emc</p>	
<p><b>Hydroxyethylcellulose</b></p> <p><i>Minims</i>® Artificial Tears preservative free eye drops</p> <p>BNF emc</p>	
<p><b>Hypromellose</b></p> <p>0.3% eye drops</p> <p>MMC BNF emc</p>	
<p><b>Liquid Paraffin</b></p> <p><i>Lacri-Lube</i>® ointment</p> <p>BNF emc</p>	
<p><b>Polyvinyl alcohol</b></p> <p><i>Liquifilm Tears</i>® 1.4% eye drops</p> <p>MMC BNF emc</p>	
<p><b>Sodium chloride (minims)</b></p> <p>0.9% eye drops</p> <p>BNF emc</p>	
<p><b>Sodium hyaluronate</b></p> <p><i>Hyla-Forte</i>® 0.2% eye drops</p> <p>MMC BNF emc</p>	



**11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment****Ocular diagnostic preparations****Fluorescein sodium**

1% &amp; 2% preservative free eye drops

**Fluorescein sodium**

Red

100mg/mL injection

**RESTRICTED**  
Specialist use only  
fundus fluorescein angiography**Indocyanine green (ICG)**

Red

Verdye® 5mg/mL injection

**RESTRICTED**  
Specialist use only**Ocular peri-operative drugs****Acetylcholine chloride**

1% intraocular irrigation

**RESTRICTED** Consultant  
Ophthalmologist only**Apraclonidine**

Iopidine® 0.5% eye drops; 1% preservative free eye drops

**RESTRICTED** Consultant  
Ophthalmologist only**Bromfenac**

Yellox® 0.9 mg/mL eye drops

**RESTRICTED** Consultant only for  
pseudophakic CMO**Ketorolac trometamol**

Red

Acular® 0.5% eye drops

**RESTRICTED** Consultant  
Ophthalmologist only**Nepafenac**

Nevanac® 1 mg/mL eye drops

**RESTRICTED. 1<sup>st</sup> line post cataract  
surgery in diabetics. 2<sup>nd</sup> line CMO****Povidone-Iodine**

5% eye drops

**RESTRICTED** Consultant  
Ophthalmologist only**Heavy Silicone oil**

Densiron® 68 - 10mL syringe

**RESTRICTED** intraocular tamponade  
of inferior retinal breaks**Subfoveal choroidal neovascularisation****Aflibercept**

Red ££

Eylea® 40mg in 1mL injection

**RESTRICTED** Consultant  
Ophthalmologist only**Bevacizumab**

Red ££ U

Avastin® 100mg in 4mL vial

**RESTRICTED** Consultant  
Ophthalmologist only**Brolucizumab**

Red ££

Beovu® 120mg in 1mL injection

**RESTRICTED** Consultant  
Ophthalmologist only

MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu ▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals

**Faricimab**

Red ££

Vabysmo® 120mg/mL injection

**RESTRICTED** Consultant  
Ophthalmologist in line with NICE  
TA799 / TA800 / TA1004**Ranibizumab**

Red ££

Lucentis® / Ongavia® 10mg/mL injection

**RESTRICTED** Consultant  
Ophthalmologist onlyNHS  
England**Verteporfin**

Red ££

Visudyne® 15mg vial

**RESTRICTED** Consultant  
Ophthalmologist only**Vitreomacular traction****11.8.3 Other preparations****Voretigene****Voretigene neparvec**

Red ££

Luxturna® 2mL vial

**RESTRICTED** Consultant  
Ophthalmologist in line with NICE**Insulin eye drops****Insulin (soluble) eye drops**

Red U

Humulin S® in Systane® lubricant eye drops

**RESTRICTED**  
Consultant Ophthalmologist

# Non-Formulary Items



## Ocriplasmin



Jetrea® 0.5 mg/0.2mL injection



**RESTRICTED** Consultant  
Ophthalmologist only

**DISCONTINUED May-20**

## Polymyxin B sulfate

Polyfax® eye ointment



**RESTRICTED** gram negative  
bacteria, including pseudomonas

**DISCONTINUED Nov-17**

## Poly (carboxymethylglucose sulfate)

Cacical® eye drops (0.33mL)



**RESTRICTED** Consultant  
Ophthalmologist only

**DISCONTINUED Dec-19**

## Section 12: Ear, nose & oropharynx

Supported by the  
formulary ([click here](#))



### 12.1 Drugs acting on the ear

- 12.1.1 Otitis externa
- 12.1.3 Removal of ear wax

### 12.2 Drugs acting on the nose

- 12.2.1 Drugs used in nasal allergy
- 12.2.2 Topical nasal decongestants
- 12.2.3 Nasal preparations for infection

### 12.3 Drugs acting on the oropharynx

- 12.3.1 Drugs for oral ulceration & inflammation
- 12.3.2 Oropharyngeal anti-infective drugs
- 12.3.4 Mouthwashes, gargles & dentifrices
- 12.3.5 Treatment of dry mouth

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79)  
Sore throat (acute): antimicrobial prescribing (NG84)  
Otitis media (acute): antimicrobial prescribing (NG91)  
Tinnitus: assessment and management (NG155)  
Otitis media with effusion in under 12s (NG233)  
Allergic rhinitis (CKS)

## GMMM Formulary

Formulary Homepage  
Chapter 12: Ear, nose & oropharynx (v6.0 - May-24)  
GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List  
GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 12.1 Drugs acting on the ear



### 12.1.1 Otitis externa

#### Astringent preparations

##### Aluminium acetate

ear drops



#### Anti-inflammatory preparations

##### Betamethasone sodium phosphate

Betnesol® 0.1% ear drops



##### Prednisolone sodium phosphate

Predsol® 0.5% ear drops



#### Anti-inflammatory with antibacterial preparations

##### Dexamethasone with glacial acetic acid and neomycin sulfate

Otomize® 0.1% / 3250u per mL ear spray



##### Dexamethasone with framycetin sulfate and gramicidin

Sofradex® 0.05% / 0.5% / 0.005% ear/eye drops



##### Flumetasone pivalate with clioquinol

Locorten-Vioform® 0.02% / 1% ear drops



##### Gentamicin with hydrocortisone

1% / 0.3% ear drops



##### Hydrocortisone with neomycin and polymyxin B sulfate

Otosporin® 1% : 3400u/mL : 10,000u/mL ear drops



#### Analgesic / Anti-inflammatory / local anaesthetic preparations

##### Phenazone with lidocaine

Otigo® 40mg/g / 10mg/g ear drops



**RESTRICTED**  
paeds in line with NICE NG91

#### Anti-infective preparations

##### Ciprofloxacin

Green

Cetralax® 0.2% ear drops



MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling &amp; potentially long-lasting or irreversible side effects

##### Clotrimazole

1% ear drops



### 12.1.3 Removal of ear wax

#### Chlorobutanol / Arachis oil

Cerumol® ear drops



#### Olive oil ear drops

DNP

ear drops



#### Sodium bicarbonate

DNP

5% ear drops



## 12.2 Drugs acting on the nose



### 12.2.1 Drugs used in nasal allergy

#### Antihistamines

##### Azelastine hydrochloride

Rhinolast® 40micrograms nasal spray



##### Azelastine hydrochloride

Azelair® 0.15% nasal spray



#### Corticosteroids

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

##### Beclometasone dipropionate

50micrograms nasal spray



**1<sup>st</sup> line use**

##### Betamethasone sodium phosphate

0.1% nose drops



##### Mometasone furoate

50micrograms nasal spray



**1<sup>st</sup> line use nasal polyps**

##### Fluticasone furoate

Avamys® 27.5micrograms nasal spray



##### Fluticasone propionate with azelastine hydrochloride

Green

Dymista® 50micrograms / 137micrograms nasal spray



**RESTRICTED 3<sup>rd</sup> line use**

#### Cromoglicate

##### Sodium cromoglicate

4% nasal spray



### 12.2.2 Topical nasal decongestants

#### Sympathomimetics

##### Ephedrine hydrochloride

0.5%; 1% nasal drops



**1<sup>st</sup> line use**

##### Sodium chloride

0.9% nasal drops



##### Xylometazoline hydrochloride

0.1% nasal drops



#### Antimuscarinics

##### Ipratropium bromide

0.03% nasal spray



Rhinorrhoea associated with allergic & non-allergic rhinitis

### 12.2.3 Nasal preparations for infection

##### Chlorhexidine dihydrochloride with neomycin

Naseptin® 0.1% / 0.5% nasal cream



**1<sup>st</sup> line use staphylococcal infections**

##### Mupirocin

2% nasal ointment



**RESTRICTED MRSA / post nasal cautery**

## 12.3 Drugs acting on the oropharynx



### 12.3.1 Drugs for oral ulceration & inflammation

#### Local Analgesics

##### Benzylamine hydrochloride

Green

0.15% oral rinse; 0.15% spray



##### Carmellose sodium

30g protective paste



#### Corticosteroids

##### Hydrocortisone

muco-adhesive buccal tablets



### 12.3.2 Oropharyngeal anti-infective drugs

#### Oropharyngeal fungal infections

##### Miconazole

DNP

2% oral gel



MHRA Drug Safety Update (Sep-17): Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin

##### Nystatin

DNP

100,000 units/mL oral suspension



### 12.3.4 Mouthwashes, gargles & dentifrices

##### Chlorhexidine gluconate

0.2% mouthwash; 1% dental gel



### 12.3.5 Treatment of dry mouth

#### Local treatment

##### AS Saliva Orthana®

spray; lozenges



##### BioXtra®

oral gel



#### Systemic treatment

##### Pilocarpine

5mg tablets



**RESTRICTED** Consultant use only  
following irradiation for head & neck  
cancer

#### Treatment of Dental Caries

##### Silver diamine fluoride (SDF) 38%

liquid



## Section 13: Skin

Supported by the  
formulary (click here)



### 13.2 Emollient & barrier preparations

13.2.1 Emollients

13.2.2 Barrier preparations

### 13.3 Topical local anaesthetics & antipruritics

### 13.4 Topical corticosteroids

### 13.5 Preparations for eczema & psoriasis

13.5.1 Preparations for eczema

13.5.2 Preparations for psoriasis

13.5.3 Drugs affecting the immune response

Cytokine Modulators

### 13.6 Acne & Rosacea

13.6.1 Topical preparations for acne

13.6.2 Oral preparations for acne

### 13.7 Preparations for warts & calluses

### 13.8 Sunscreens & camouflagers

13.8.1 Sunscreen preparations

### 13.9 Shampoos & other preparations for scalp/hair conditions

### 13.10 Anti-infective skin preparations

13.10.1 Antibacterial preparations

13.10.2 Antifungal preparations

13.10.3 Antiviral preparations

13.10.4 Parasitocidal preparations

13.10.5 Preparations for minor cuts & abrasions

### 13.11 Skin cleansers, antiseptics & desloughing agents

13.11.1 Alcohols & saline

13.11.2 Chlorhexidine salts

13.11.4 Iodine

13.11.6 Oxidisers & dyes

13.11.7 Desloughing agents

### 13.12 Antiperspirants

### 13.13 Topical circulatory preparations

### 13.14 Miscellaneous preparations

### Non-Formulary Items



## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Atopic eczema in children (CG57)  
 Psoriasis: assessment and management (CG153)  
 Pressure Ulcers (CG179)  
 Pubic lice CKS (2011)  
 Scabies CKS (2011)  
 Acne vulgaris CKS (2014)  
 Head lice CKS (2015)  
 Surgical site infections: prevention and treatment (NG125)  
 Atopic dermatitis (eczema) - topical steroids (TA81)  
 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)  
 Psoriasis - efalizumab and etanercept (TA103) **EMA (efalizumab)**  
 Psoriasis - infliximab (TA134)  
 Psoriasis - adalimumab (TA146)  
 Alitretinoin for the treatment of severe chronic hand eczema (TA177)  
 Psoriasis - ustekinumab (TA180)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Secukinumab for treating moderate to severe plaque psoriasis (TA350)  
 Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)  
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)  
 Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Ixekizumab for treating moderate to severe plaque psoriasis (TA442)  
 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)  
 Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)  
 Brodalumab for treating moderate to severe plaque psoriasis (TA511)  
 Guselkumab for treating moderate to severe plaque psoriasis (TA521)  
 Dupilumab for treating moderate to severe atopic dermatitis (TA534)  
 Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)  
 Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)  
 Risankizumab for treating moderate to severe plaque psoriasis (TA596)  
 Baricitinib for treating moderate to severe atopic dermatitis (TA681)  
 Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)  
 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)  
 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)  
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)  
 Bimekizumab for treating active psoriatic arthritis (TA916)  
 Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)  
 Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)  
 Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)  
 Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

## GMMMG Formulary

Formulary Homepage  
 Chapter 13: Skin (v7.5 - Dec-24)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

# 13.2 Emollient & barrier preparations



## 13.2.1 Emollients

### Non-Proprietary emollient preparations

MHRA Drug Safety Update (Aug-20): Emollients and risk of severe and fatal burns: new resources available  
 MHRA Drug Safety Update (Jul-20): Safe use of emollient skin creams to treat dry skin conditions  
 MHRA Drug Safety Update (Dec-18): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients  
 MHRA Patient Info Leaflet (Jul-20): Skin creams - risk of fire and burns

<b>Aqueous cream BP</b>		
cream		
<b>Emulsifying ointment BP</b>		
ointment		
<b>Liquid &amp; white soft paraffin</b>		
ointment		
<b>Paraffin, white soft BP</b>		
white petroleum jelly		
<b>Paraffin, yellow soft BP</b>		
yellow petroleum jelly		

### Proprietary emollient preparations

MHRA Drug Safety Update (Jul-24): Epimax Ointment and Epimax Paraffin-Free Ointment: reports of ocular surface toxicity & ocular chemical injury

<b>Diprobase®</b>		
cream; ointment		
<b>Doublebase®</b>		
gel		
<b>Hydromol®</b>		
cream; ointment		
<b>Oilatum®</b>		
<b>Preparations containing urea</b>		
<b>Balneum® Plus</b>		
<b>With antimicrobials</b>		
<b>Dermol® &amp; Dermol® 500</b>		<b>RESTRICTED patients unable to tolerate 1<sup>st</sup> / 2<sup>nd</sup> line antimicrobial washes</b>

#### 13.2.1.1 Emollient bath and shower preparations

DNP

#### Emollient bath and shower preparations without antimicrobials

When used for the management of eczema in children or adults. This recommendation does not apply to the use of standard emollients when used in the bath or shower as a soap substitute

DNP

#### With antimicrobials

<b>Dermol® 600</b>		
bath emollient		
<b>Oilatum® Plus</b>		<b>2<sup>nd</sup> line MRSA decolonisation therapy</b>
bath emollient		

## 13.2.2 Barrier preparations

### Proprietary barrier preparations

<b>Metanium®</b>		<b>2<sup>nd</sup> line only at parental request</b>
ointment		
<b>Sudocrem®</b>		<b>2<sup>nd</sup> line only at parental request</b>
cream		

## 13.3 Topical local anaesthetics & antipruritics



### 13.3 Topical local anaesthetics & antipruritics

#### Crotamiton

cream; lotion



#### Mepyramine maleate

2% w/w cream



## 13.4 Topical corticosteroids



### Corticosteroid only preparations

**NICE TA81**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

#### HYDROCORTISONE

**Potency**
**Canesten HC®**

Mild

hydrocortisone 1% plus clotrimazole 1% cream


**Daktacort®**

Mild

hydrocortisone 1%, miconazole nitrate 2% cream; ointment


**Eurax-hydrocortisone®**

Mild

hydrocortisone 0.25%, crotamiton 10% cream


**Fucidin H®**

Mild

hydrocortisone 1%, fusidic acid 1% cream



#### BETAMETHASONE ESTERS

**Potency**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

**Betamethasone valerate**

Moderate

betamethasone valerate 0.025% ointment, cream


**Betnovate-RD®**

Moderate

betamethasone valerate 0.025% cream; ointment



#### CLOBETASONE BUTYRATE

**Potency**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

**Eumovate®**

Moderate

Clobetasone butyrate 0.05% cream; ointment



#### BETAMETHASONE ESTERS

**Potency**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

**Betamethasone valerate**

Potent

betamethasone valerate 0.1% ointment; cream; lotion; scalp lotion


**Betnovate®**

Potent

Betamethasone valerate 0.1% cream; ointment; scalp application; lotion


**Betamethasone valerate with clioquinol**

Potent

betamethasone valerate 0.1% / clioquinol 3% ointment; cream


**Betamethasone valerate with neomycin sulfate**

Potent

betamethasone valerate 0.1% / neomycin sulfate 0.5% cream; ointment


**Diprosalic®**

Potent

Betamethasone dipropionate 0.05%, salicylic acid 3% ointment


**Fucibet®**

Potent











betamethasone valerate 0.1% plus fusidic acid 2% cream


**Betnovate®**

Potent

betamethasone valerate ointment 25% in coal tar


**DERMATOLOGY ONLY**

<b>CLOBETASOL PROPIONATE</b>		<b>Potency</b>
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions		
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
<b>Dermovate®</b> clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	 	Very potent
<b>Dermovate NN®</b> clobetasol propionate 0.05% / neomycin sulfate / nystatin cream	 	Very potent
<b>Etrivex®</b> clobetasol propionate 500micrograms/g shampoo	  	Very potent <b>RESTRICTED - 1<sup>st</sup> Care referral</b>
<b>DIFLUCORTOLONE VALERATE</b>		<b>Potency</b>
<b>Diflucortolone valerate</b>  diflucortolone valerate 0.3% oily cream	 	Very potent <b>RESTRICTED Consultant Gynaecologist</b>

# 13.5 Preparations for eczema & psoriasis



## 13.5.1 Preparations for eczema

### Alitretinoin

Red ££

10mg; 30mg capsules

PbR X NICE MMC BNF emc

MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic

MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women

**RESTRICTED**  
Dermatology Consultants only

## 13.5.2 Preparations for psoriasis

### Topical preparations for psoriasis

NICE CG153

#### Calcipotriol

Dovonex® ointment; with Betamethasone (*Dovobet*® 0.05% ointment)

BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Dithranol

Green Red (unlicensed preps)

Dithocream® 0.1% & 0.25% cream

BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Salicylic acid

Zinc & Salicylic acid paste BP (*Lassar's Paste*)

BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Tacalcitol

Curatoderm® lotion; ointment

BNF emc

**RESTRICTED**  
Dermatology Consultants only

### Tars

#### Coal tar paste BP

paste

BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Coal tar with salicylic acid and precipitated sulfur

Cocois® scalp ointment

BNF emc

**RESTRICTED**  
Dermatology Consultants only

### Oral retinoids for psoriasis

#### Acitretin

Red

10mg; 25mg capsules

BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Dimethyl fumarate

#### Dimethyl fumarate

Red ££

30mg; 120mg tablets

PbR X NICE MMC BNF emc bluefeq

**RESTRICTED**  
3<sup>rd</sup>/4<sup>th</sup> line as per NICE/GMMMG  
Referral to SRFT

### 13.5.3 Drugs affecting the immune response

#### Abrocitinib

Red ££

Cibingo® 50mg; 100mg; 200mg tablets

PbR X NICE MMC BNF emc bluefeq

**RESTRICTED**  
Dermatology Consultants only  
in line with NICE

MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality

#### Azathioprine

Amber

25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3)

BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Ciclosporin

Amber

25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2)

PbR X MMC BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Methotrexate

Amber

2.5mg tablets (see also sections 8.1.3 & 10.1.3)

MMC BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Pimecrolimus

Green

1% cream

NICE MMC BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Sirolimus

Green

Hyfor® 0.2% gel (see also section 8.2.2)

MMC BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Tacrolimus (specially made by SRFT)

Green

0.03%; 0.1% ointment (see also section 8.2.2)

PbR X NICE MMC BNF emc

**RESTRICTED**  
Dermatology Consultants only

#### Upadacitinib










































































































































Red ££

Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3)

PbR X NICE MMC BNF emc bluefeq

**RESTRICTED**  
Dermatology Consultants only  
in line with NICE

MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality

<b>Cytokine Modulators</b>		(see also section 10.1.3)
<b>Adalimumab</b>   injection (see also sections 1.5.3, 10.1.3 & 11.4.2)	     	<b>RESTRICTED</b> Dermatology Consultants only
<b>Apremilast</b>   10mg; 20mg; 30mg tablets (see also section 10.1.3)	    	<b>RESTRICTED</b> 3 <sup>rd</sup> /4 <sup>th</sup> line as per NICE/GMMMG
<b>Bimekizumab</b>   <i>Bimzelx</i> ® injection (see also section 10.1.3)	     	<b>RESTRICTED</b> in line with NICE
<b>Brodalumab</b>   <i>Kyntheum</i> ® 140mg/mL injection	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Certolizumab pegol</b>   <i>Cimzia</i> ® 200mg/1mL injection (see also section 10.1.3)	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Dupilumab</b>   <i>Dupixent</i> ® 150mg/mL injection (see also section 3.4.2)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Etanercept</b>   injection (see also section 10.1.3)	     	<b>RESTRICTED</b> Dermatology Consultants only
<b>Guselkumab</b>   100mg/mL injection (see also section 10.1.3)	    	<b>RESTRICTED</b> in line with NICE
<b>Infliximab</b>   100mg injection (see section 10.1.3)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Ixekizumab</b>   80mg/1mL injection (see also section 10.1.3)	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Lebrikizumab</b>   <i>Ebglyss</i> ® 250mg in 2mL injection	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Risankizumab</b>   <i>Skyrizi</i> ® 75mg; 150mg injection (see also section 1.5.3)	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Ritlecitinib</b>   <i>Litfulo</i> ® 50mg capsules	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Secukinumab</b>   <i>Cosentyx</i> ® 150mg/1mL injection (see also section 10.1.3)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Tildrakizumab</b>   100mg injection	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Tralokinumab</b>   <i>Adtralza</i> ® 150mg; 300mg injection	    	<b>RESTRICTED</b> Dermatology only in line with NICE / NHSE
<b>Ustekinumab</b>   <i>Stelara</i> ® injection (see also sections 1.5.3 & 10.1.3)	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Ustekinumab</b>   <i>Wezenla</i> ® injection (see also sections 1.5.3 & 10.1.3)	     	<b>RESTRICTED</b> Specialist use only in line with NICE

## 13.6 Acne & Rosacea



### 13.6.1 Topical preparations for acne

NICE CKS: Acne

**For mild to moderate acne, use topical benzyl peroxide or a topical retinoid 1<sup>st</sup> line. Topical antibiotic should be reserved for patients who have not responded to other topical preparations.**

#### Benzyl peroxide & azelaic acid

##### Benzoyl peroxide

DNP

4% cream; 5% gel



1<sup>st</sup> line

##### Azelaic acid

Skinoren® 20% cream



2<sup>nd</sup> line

#### Topical antibacterials for acne

##### Clindamycin

Dalacin T® 1% topical lotion



2<sup>nd</sup> / 3<sup>rd</sup> line

##### Erythromycin with zinc acetate

Zineryt® 40mg/mL erythromycin; zinc acetate 12mg/mL lotion



2<sup>nd</sup> / 3<sup>rd</sup> line

#### Topical retinoids & related preparations for acne

##### Adapalene

Differin® 0.1% cream; 0.1% gel



1<sup>st</sup> line

#### Topical retinoids with antibacterial

##### Isotretinoin with erythromycin

Isotrexin® 500micrograms/1g : 20mg/1g gel



**RESTRICTED**  
Dermatology Consultants only

### 13.6.2 Oral preparations for acne

NICE CKS: Acne

**Oral antibiotics should be reserved for moderate to severe acne or where topical preparations have failed. Please refer to Chapter 5.**

##### Lymecycline

408mg capsules (see also section 5.1.3)



**RESTRICTED**  
GP referral only

#### Hormone treatment for acne

##### Co-cyprindiol

Cyproterone acetate 2mg / ethinylestradiol 35micrograms tablets



**RESTRICTED**  
GP referral only

#### Oral retinoid for acne

##### Isotretinoin

Red

5mg; 10mg; 20mg; 40mg capsules (see also section 8.1.5)



**RESTRICTED**  
Dermatology Consultants only

MHRA Drug Safety Update (Oct-23): Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight on initiation of treatment in under 18s

MHRA Drug Safety Update (Apr-23): Isotretinoin (Roaccutane ▼): new safety measures, including additional oversight on initiation of treatment in under 18s

MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼, and acitretin ▼): temporary monitoring advice during COVID-19 pandemic

MHRA Drug Safety Update (Nov-20): Isotretinoin (Roaccutane ▼): contribute to expert review

MHRA Drug Safety Update (Aug-20): Isotretinoin (Roaccutane ▼): reminder of important risks and precautions

MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women

MHRA Drug Safety Update (Oct-17): Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido

MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders



## 13.7 Preparations for warts & calluses



### 13.7 Preparations for warts & calluses

<b>Salicylic acid</b> DNP ointment; liquid	 	
<b>Silver nitrate</b> pencil	 	<b>RESTRICTED</b> Dermatology Consultants only
<b>Silver nitrate</b> 75% applicator	  	<b>RESTRICTED</b> ENT - nasal cauterly
<b>Anogenital warts</b>		
<b>Podophyllotoxin</b> 0.15% cream	 	<b>1<sup>st</sup> line</b>
<b>Imiquimod</b> Green 5% cream	  	<b>RESTRICTED</b> GUM Consultant only

## 13.8 Sunscreens & camouflagers



### 13.8.1 Sunscreen preparations

#### Photodamage

##### Methyl-5-aminolevulinate



160mg/g cream

MMC BNF emc

**RESTRICTED** Dermatology  
Consultants & Vulval Intraepithelial  
Neoplasia (VIN) only

##### Diclofenac sodium

Solaraze® 3% gel

BNF emc

**RESTRICTED**  
Dermatology Consultants

##### Fluorouracil with salicylic acid

Actikerall® 5mg/g / 100mg/1g cutaneous solution

MMC BNF emc

**RESTRICTED** Dermatology  
Consultants as per MMC

## 13.9 Shampoos &amp; other preparations for scalp / hair conditions

**Shampoos****Ketoconazole**

Nizoral® 2% shampoo

**RESTRICTED** persistent / severe  
seborrhoeic dermatitis / dandruff**Capasal®**

coal tar 1%, coconut oil 1% &amp;, salicylic acid 0.5% shampoo

**RESTRICTED**  
Dermatology Consultants only**Ceanel Concentrate®**

cetrimide 10%, undecenoic acid 1% &amp; phenylethyl alcohol 7.5% shampoo

**RESTRICTED**  
Dermatology Consultants only**Other scalp preparations****Polytar®**

40mg/mL coal tar scalp shampoo

**Hirsutism****Eflornithine hydrochloride monohydrate**

Vaniqa® 11.5% cream

**RESTRICTED**  
Dermatology Consultants only

## 13.10 Anti-infective skin preparations



### 13.10.1 Antibacterial preparations

**Topical antibacterials should generally be avoided for the treatment of infections**

#### 13.10.1.1 Antibacterial preparations only used topically

<b>Mupirocin</b>		
2% cream; ointment	MMC BNF emc	
<b>Fusidic acid</b>		<b>RESTRICTED</b> superficial impetigo
2% cream; ointment	BNF emc	
<b>Metronidazole</b>		<b>RESTRICTED</b> topical treatment of rosacea
0.75% topical gel; cream	BNF emc	
<b>Silver sulfadiazine</b>		<b>RESTRICTED</b> Treatment/prophylaxis of burns
1% w/w cream	BNF emc	
<b>13.10.2 Antifungal preparations</b>		
<b>Amorolfine</b>		<b>1<sup>st</sup> line</b> antifungal for nail infections
5% nail lacquer	MMC BNF emc	
<b>Benzoic acid with salicylic acid</b>		<b>1<sup>st</sup> line</b> treatment of ringworm
benzoic acid 6% / salicylic acid 3% / in emulsifying ointment	BNF emc	
<b>Clotrimazole</b>		<b>1<sup>st</sup> line</b> fungal skin infections
1% cream	BNF emc	
<b>Miconazole</b>		<b>2<sup>nd</sup> line</b> fungal skin infections
2% cream	BNF emc	
<b>Terbinafine</b>		<b>2<sup>nd</sup> line</b> fungal skin infections
1% cream	BNF emc	
<b>13.10.3 Antiviral preparations</b>		
<b>Aciclovir</b>		<b>1<sup>st</sup> line</b>
5% cream (see also section 5.3.2.1)	BNF emc	
<b>13.10.4 Parasitocidal preparations</b>		
		<b>NICE CKS: Head lice</b>
		<b>NICE CKS: Pubic lice</b>
		<b>NICE CKS: Scabies</b>
<b>Ivermectin</b>		
<b>U</b> tablets	MMC BNF emc	
<b>Malathion</b>		
0.5% aqueous solution	BNF emc	
<b>Permethrin</b>		
1% crème rinse; 5% dermal cream	BNF emc	
MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition...		
<b>13.10.5 Preparations for minor cuts &amp; abrasions</b>		
<b>Brulidine</b>		<b>RESTRICTED</b> Theatres only
0.15% w/w cream	emc	
<b>Preparations for boils</b>		
<b>Magnesium sulfate</b>		
paste, BP	BNF emc	
<b>Skin tissue adhesive</b>		
<b>Histoacryl®</b>		<b>RESTRICTED</b> Theatres only
0.5mL skin adhesive	BNF emc	

## 13.11 Skin cleansers, antiseptics & desloughing agents



### 13.11.1 Alcohols & saline

Isopropyl alcohol 70%



Sodium chloride

0.9% irrigation solution



### 13.11.2 Chlorhexidine salts

Chlorhexidine gluconate



### 13.11.4 Iodine

Alcoholic iodine solution BP



Iodine weak solution



Povidone-iodine



### 13.11.6 Oxidisers & dyes

Hydrogen peroxide solution, BP

3% solution; 6% solution



**RESTRICTED**  
Specialist use only

Potassium permanganate

400mg tablets for cutaneous solution



**RESTRICTED**  
Specialist use only

National Patient Safety Alert (Apr-22): Inadvertent oral administration of potassium permanganate

### 13.11.7 Desloughing agents

**CONTACT THE TISSUE VIABILITY TEAM on x64042**

## 13.12 Antiperspirants



### Aluminium salts

#### Aluminium chloride hexahydrate

20% cutaneous solution



### Glycopyrronium bromide

#### Glycopyrronium bromide (glycopyrrolate)

Robinul®



#### Glycopyrronium bromide (glycopyrrolate)



0.5% cream



**RESTRICTED**  
Diabetes Consultants only  
(gustatory sweating)

# 13.13 Topical circulatory preparations



## Topical circulatory preparations

### Heparinoid

Hirudoid® 0.3% cream; 0.3% gel



## 13.14 Miscellaneous preparations



<b>8-Methoxypsoralen</b>	MMC	<b>RESTRICTED</b> Dermatology Consultants only
 10mg tablets		
<b>Fumaric acid esters</b>	MMC	<b>RESTRICTED</b> Dermatology Consultants only
 Fumaderm® tablets		
<b>Glucarpidase</b>	PbR X MMC	<b>RESTRICTED</b> 2 <sup>nd</sup> line rescue therapy
 Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 10.4)		
<b>Hyaluronic acid with lidocaine</b>	MMC	<b>RESTRICTED</b> vocal cord paralysis
 Juvederm® / Belotero® injection		



## Non-Formulary Items



### Ingenol mebutate

**WITHDRAWN**  
**Feb-20**

*Picato*® 150 micrograms/g gel (face & scalp); 500 micrograms/g gel (trunk & extremities)



MHRA Drug Safety Update (Feb-20): Ingenol mebutate gel (*Picato* ▼): suspension of the licence due to risk of skin malignancy

MHRA Drug Safety Update (Oct-19): Ingenol mebutate gel (*Picato* ▼): increased incidence of skin tumours seen in some clinical studies

### Proflavine cream, BPC

**DISCONTINUED**  
**Jul-18**

0.1% cream



## Section 14: Immunological products & vaccines

Supported by the  
formulary ([click here](#))



### 14.4 Vaccines & antisera

- Bacillus Calmette-Guérin (BCG) vaccines
- Botulism antitoxin
- COVID-19 vaccine
- Diphtheria vaccines (children under 10yrs old)
- Diphtheria vaccines (children over 10yrs old & adults)
- Haemophilus type B conjugate vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Human papilloma virus vaccine
- Influenza vaccine
- Measles, Mumps & Rubella (MMR) vaccine
- Meningococcal vaccines
- Pneumococcal vaccines
- Poliomyelitis vaccines
- Rabies vaccines
- Respiratory syncytial virus (RSV) vaccine
- Tetanus vaccines
- Typhoid vaccines
- Varicella-zoster vaccines

### 14.5 Immunoglobulins

- 14.5.1 Normal immunoglobulin
- 14.5.2 Disease-specific immunoglobulins
- 14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin  
Immunoglobulin follow up form  
Immunoglobulin Prescribing and Administration Guidelines  
Immunoglobulin Prescribing Flow Chart  
Immunoglobulin request form  
National Demand Programme for Immunoglobulin - Clinical Info  
[Non-formulary Conversion Table](#)

## NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

## GMMM Formulary





















Formulary Homepage  
Chapter 14: Immunological products & vaccines **(ON HOLD)**  
GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List  
GMMM Paediatric **Red/Amber/Green** Drug List







## Other Links

National Immunoglobulin Database  
DH: Clinical guidelines for immunoglobulin use (2<sup>nd</sup> edition update)  
Immunoglobulin handbook (HPA)

## 14.4 Vaccines & antisera

MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunosuppressed

<b>Bacillus Calmette-Guérin (BCG) vaccines</b>		<b>Tuberculosis: the Green Book, ch.32</b>
<b>Bacillus Calmette-Guérin (BCG) vaccine</b>		
injection	 	
<b>BCG vaccine diagnostic agent</b> (Tuberculin purified protein derivative (PPD))		
injection	 	
<b>Botulism antitoxin</b>		
<b>Botulism antitoxin</b>		<b>RESTRICTED Emergencies only</b>
injection	 	
<b>COVID-19 vaccine</b>		<b>Covid19: the Green Book, ch.14a</b>
<b>Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)</b>		<b>12 years of age and older pending availability of XBB1.5</b>
Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)	 	
<b>Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)</b>		<b>12 years of age and older</b>
Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)	 	
<b>Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)</b>		<b>5 to 11 year olds</b>
Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)	 	
<p>MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023            MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023            MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023            MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022            MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022            MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022            MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022            MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022            MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022            MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022            MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022            MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022            MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022            MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022            MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022            MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021            MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021            MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021            MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021            MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021            MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021            MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021            MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021            MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021            MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice            MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19</p>		
<b>Diphtheria vaccines (children under 10yrs old)</b>		<b>Diphtheria: the Green Book, ch.15</b>
<b>Infanrix hexa®</b>		
injection	 	
<b>Infanrix-IPV®</b>		
injection	 	
<b>Repevax®</b>		
injection	 	
<b>Diphtheria vaccines (children over 10yrs old &amp; adults)</b>		<b>Diphtheria: the Green Book, ch.15</b>
<b>Revaxis®</b>		
injection	 	

<b>Haemophilus type B conjugate vaccine</b>		<b>Hib: the Green Book, ch.16</b>
<b>Haemophilus Influenzae B &amp; Meningitis C vaccine</b>		
Menitorix® injection	 	
<b>Hepatitis A vaccine</b>		<b>Hepatitis A: the Green Book, ch.17</b>
<b>Hepatitis A vaccine single component</b>		
Havrix Monodose®; Havrix Junior Monodose®; Vaqta® Paediatric injection	 	
<b>Hepatitis B vaccine</b>		<b>Hepatitis B: the Green Book, ch.18</b>
<b>Hepatitis B single component</b>		
Engerix B®; Engerix B® Paediatric injection	 	
<b>Hepatitis B single component</b>		
HBvaxPRO®; HBvaxPRO® Paediatric injection	 	
<b>Human papilloma virus (HPV) vaccine</b>		<b>HPV: the Green Book, ch.18a</b>
<b>Human Papilloma Virus (HPV) quadrivalent vaccine</b>		<b>RESTRICTED</b> <b>Paediatric Immunology Consultant</b>
Gardasil® injection	  	
<b>Influenza vaccine</b>		<b>Influenza: the Green Book, ch.19</b>
<b>Influenza vaccine</b>		
injection, intranasal	 	
<b>Measles, Mumps &amp; Rubella (MMR) vaccine</b>		<b>Measles: the Green Book, ch.21</b>
<b>Measles, Mumps &amp; Rubella vaccine</b>		<b>Mumps: the Green Book, ch.23</b>
		<b>Rubella: the Green Book, ch.28</b>
injection	 	
<b>Meningococcal vaccines</b>		<b>Meningococcal: the Green Book, ch.22</b>
<b>Meningococcal Polysaccharide A, C, W135 &amp; Y vaccine</b>		
injection	 	
<b>Meningococcal group B vaccine</b>		<b>RESTRICTED</b> <b>childhood immunisation schedule</b> <b>&amp; high risk patients</b>
Bexsero® injection	  	
<b>Meningococcal group C vaccine</b>		
injection	 	
<b>Pneumococcal vaccines</b>		<b>Pneumococcal: the Green Book, ch.25</b>
<b>Pneumococcal Polysaccharide vaccine</b>		
injection	 	
<b>Poliomyelitis vaccines</b>		<b>Polio: the Green Book, ch.26</b>
<b>Poliomyelitis vaccine inactivated</b>		
	 	
<b>Rabies vaccines</b>		<b>Rabies: the Green Book, ch.27</b>
<b>Rabies vaccine inactivated</b>		<b>RESTRICTED</b> <b>Not Stocked</b>
Rabipur® injection	 	
<b>Respiratory syncytial virus (RSV) vaccine</b>		<b>RSV: the Green Book, ch.27a</b>
<b>Respiratory syncytial virus (RSV) vaccine (bivalent, recombinant)</b>		
Abrysvo® injection	   	
<b>Tetanus vaccines</b>		<b>Tetanus: the Green Book, ch.30</b>
<b>Tetanus vaccine adsorbed</b>		
injection	 	
<b>Typhoid vaccines</b>		<b>Typhoid: the Green Book, ch.33</b>
<b>Typhoid polysaccharide vaccine</b>		
Typhim Vi® injection	 	
<b>Varicella-Zoster vaccines</b>		<b>Varicella: the Green Book, ch.34</b>
<b>Varicella-Zoster live attenuated vaccine</b>		
Varivax® injection	 	

## 14.5 Immunoglobulins

1.) All Immunoglobulin requests should follow [NHSE Clinical Commissioning Policy for the use of therapeutic immunoglobulin \(Ig\) England \(2024\)](#).

2.) MFT have adopted a 'no form, no immunoglobulin' policy. All IVIg requests must have an Immunoglobulin Request Form completed via Hive.

3.) All immunoglobulin use **MUST** be recorded on the [National Immunoglobulin Database](#).

### 14.5.1 Normal immunoglobulin Red (for ITP & home treatment programmes)

#### For intramuscular use

##### Normal immunoglobulin injection

Red ££

injection

PbR X




**RESTRICTED**  
Specialist use only

#### For subcutaneous use

##### Normal immunoglobulin injection

Red ££

injection

PbR X





**RESTRICTED**  
Specialist use only

#### For intravenous use

##### Human normal immunoglobulin

Red ££

injection

PbR X





**RESTRICTED**  
Specialist use only

### 14.5.2 Disease-specific immunoglobulins

#### Hepatitis B immunoglobulin

##### Hepatitis B immunoglobulin

injection




**RESTRICTED**  
Not Stocked

#### Tetanus immunoglobulin

##### Tetanus immunoglobulin

injection




#### Varicella-Zoster immunoglobulin

##### Varicella-Zoster immunoglobulin

Green

injection




**RESTRICTED**  
Not Stocked

#### Cytomegalovirus (CMV) immunoglobulin

##### Human normal immunoglobulin (CMV)

injection





**RESTRICTED**  
Specialist use only

### 14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin

#### Anti-D (Rh<sub>0</sub>) immunoglobulin



















Red

injection






## Non-Formulary Items

<p><b>AstraZeneca COVID-19 vaccine</b></p> <p><i>Vaxzevria</i>® injection</p>	   	<p><b>DISCONTINUED</b> May-24</p>
<p><b>Moderna Biotech COVID-19 vaccine</b></p> <p><i>Spikevax</i>® injection</p>	   	<p><b>DISCONTINUED</b></p>
<p><b>Novavax COVID-19 vaccine</b></p> <p><i>Nuvaxovid</i>® injection</p>	   	<p><b>PAUSED by JCVI</b></p>
<p><b>Pediacel</b>®</p> <p>injection</p>	  	<p><b>REPLACED by</b> <b>Infanrix hexa</b>®</p>
<p><b>Infanrix-IPV+Hib</b>®</p> <p>injection</p>	  	<p><b>REPLACED by</b> <b>Infanrix hexa</b>®</p>

## Section 15: Anaesthesia

Supported by the  
formulary ([click here](#))



### 15.1 General anaesthesia

- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative & analgesic post-operative drugs
  - 15.1.4.1 Benzodiazepines
  - 15.1.4.2 Non-opioid analgesics
  - 15.1.4.3 Opioid analgesics
  - 15.1.4.4 Other drugs for sedation
- 15.1.5 Neuromuscular blocking drugs
  - Non-depolarising neuromuscular blocking drugs
  - Depolarising neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
  - Anticholinesterases
  - Other drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central & respiratory depression
- 15.1.8 Drugs for malignant hyperthermia

### 15.2 Local anaesthesia

- Lidocaine
- Bupivacaine
- Levobupivacaine
- Prilocaine
- Ropivacaine
- Tetracaine
- Local Anaesthetic Toxicity
- Other agents



## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
Paediatric Anaesthesia Website  
Children's Pain Management Website  
PICU Emergency Drugs Calculator  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

## GMMMG Formulary

Formulary Homepage  
Chapter 15: Anaesthesia (**ON HOLD**)  
GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List  
GMMMG Paediatric **Red/Amber/Green** Drug List

## 15.1 General anaesthesia

### 15.1.1 Intravenous anaesthetics

#### Etomidate

injection



#### Ketamine

Red

injection



#### Propofol

injection; infusion



#### Thiopental sodium

injection



### 15.1.2 Inhalational anaesthetics

#### Volatile liquid anaesthetics

#### Desflurane

anaesthetic agent



**RESTRICTED**  
Theatres only

#### Isoflurane

anaesthetic agent



#### Methoxyflurane

Penthrox® inhalation vapour



**RESTRICTED**  
ED only

#### Sevoflurane

anaesthetic agent



#### Nitrous oxide

#### Nitrous oxide



#### Nitrous oxide 50% & oxygen 50%

Entonox®



### 15.1.3 Antimuscarinic drugs

#### Atropine sulfate

600microgram/1mL injection



**Adults 600microgram/1mL**  
**I.M. or I.V.**

#### Glycopyrronium bromide

200micrograms/1mL; 600micrograms/3mL injection



**Adults 200-400microgram I.V.**

#### Hyoscine hydrobromide

400microgram/mL injection



### 15.1.4 Sedative & analgesic post-operative drugs

#### 15.1.4.1 Benzodiazepines

**NICE CG112**

#### Diazepam

tablets; liquid; injection; rectal tube (see also sections 4.1.2; 4.8.2 &amp; 10.2.2)



#### Lorazepam

tablets; injection (see also sections 4.1.2 &amp; 4.8.2)



#### Midazolam

Green

oromucosal solution; injection; infusion (see also section 4.8.2)



#### Temazepam

tablets; oral solution (see also section 4.1.1)



### 15.1.4.2 Non-opioid analgesics

#### Ketorolac trometamol

injection



#### Parecoxib

injection



**RESTRICTED**  
Theatres only - acute postop. pain

**15.1.4.3 Opioid analgesics****Alfentanil**

injection

**Fentanyl**

injection (see also section 4.7.2)

**Remifentanyl**

injection

**RESTRICTED**  
Specialist use only**15.1.4.4 Other drugs for sedation****Dexmedetomidine hydrochloride**

infusion

**RESTRICTED**  
Specialist use only**15.1.5 Neuromuscular blocking drugs****Non-depolarising neuromuscular blocking drugs****Atracurium besilate**

injection

**Cisatracurium**

injection

**RESTRICTED**  
Consultant only**Mivacurium**

injection

**Rocuronium bromide**

injection

**Vecuronium bromide**

injection

**Depolarising neuromuscular blocking drugs****Suxamethonium chloride**

injection

**15.1.6 Drugs for reversal of neuromuscular blockade****Anticholinesterases****Neostigmine metilsulfate**

injection (see also section 10.2.1)

**Neostigmine metilsulfate with glycopyrronium bromide**

injection

**Other drugs for reversal of neuromuscular blockade****Sugammadex**

Bridion® injection

**RESTRICTED - Consultant**  
(Emergency) use in Theatres only  
Complete Trust incident & audit forms**15.1.7 Antagonists for central & respiratory depression****Doxapram hydrochloride**

injection (see also section 3.5.1)

**Flumazenil**

injection

**Naloxone hydrochloride**

injection

**15.1.8 Drugs for malignant hyperthermia****Dantrolene sodium**

injection (see also section 10.2.2)



MHRA Drug Safety Update (Jul-14): Intravenous dantrolene: risk of undissolved crystals

# 15.2 Local anaesthesia

## AAGBI SAFETY GUIDELINE

### 15.2 Local anaesthesia

#### Lidocaine hydrochloride

##### Lidocaine

0.5%, 1% & 2% injection (see also section 2.3.2)



##### with adrenaline

##### Lidocaine with adrenaline

1%, 2% injection



##### for surface anaesthesia

##### Lidocaine with chlorhexidine

Instillagel® 2% gel



##### Lidocaine

OptiLube Active CHG Free® 2% gel



##### Lidocaine with phenylephrine

Co-phenylcaine® 5% / 0.5% spray



##### Lidocaine with prilocaine

EMLA® 5% cream



##### Lidocaine

4% topical solution



##### Lidocaine

Laryngojet® 4% (160mg/4mL) jet spray



##### Lidocaine

5% ointment



##### Lidocaine

Xylocaine® 10% spray



##### Lidocaine

Green  DNP

Versatis® 700mg medicated plaster



**RESTRICTED**  
Consultant / specialist pain team only

#### Bupivacaine hydrochloride

##### Bupivacaine hydrochloride

0.25% Infusion (500mL)



##### Bupivacaine hydrochloride with glucose

Marcaïn Heavy® 0.5% Injection



##### with adrenaline

##### Bupivacaine and adrenaline

0.25% with 1:200,000 injection



##### Bupivacaine and adrenaline

0.5% with 1:200,000 injection



##### with other ingredients

##### Bupivacaine and fentanyl



0.125% with 1mg/500mL infusion



##### Bupivacaine and sodium chloride

























0.08% in 0.9%



##### Bupivacaine hydrochloride with glucose

20mg with 320mg/4mL spinal injection



<b>Levobupivacaine</b>		
<b>Levobupivacaine</b>		
<i>Chirocaine</i> ® 25mg/10mL; 50mg/10mL; 75mg/10mL injection; epidural 250mg/200mL	MMC  	
<b>Levobupivacaine with fentanyl</b>		
 0.1% with 2microgram/mL epidural	 	
<b>Prilocaine hydrochloride</b>		
<b>Prilocaine hydrochloride</b>		
<i>Citanest</i> ® 1% injection	 	
<b>Prilocaine hydrochloride</b>		
<i>Prilotekal</i> ® 2% injection	MMC  	
<b>Prilocaine with felypressin</b>		
<i>Octapressin</i> ® 3% cartridges (30mg/mL Citanest with 0.54micrograms/mL)	 	
<b>Ropivacaine hydrochloride</b>		
<b>Ropivacaine hydrochloride</b>		For Consultant use on CDU (elective CS), Theatre 1 (ortho) & wards 1 & 2 (following surgery in Th. 1)
injection; infusion	MMC  	
<b>Tetracaine (amethocaine)</b>		
<b>Tetracaine</b>		RESTRICTED children under 1yr by specific doctor request or IV team
<i>Ametop</i> ® 4% gel	MMC  	
<b>Local Anaesthetic Toxicity</b>		<b>AAGBI SAFETY GUIDELINE</b>
<b>Intralipid 20%</b>		
20% injection	 	
<b>Other agents</b>		
<b>Cocaine</b>		
 5% solution	 	
<b>Ethyl chloride</b>		
<i>Cryogesic</i> ® spray	MMC 	
<b>Mepivacaine hydrochloride</b>		
3% injection	 	
<b>Neomycin sulfate with fluocinolone acetonide &amp; lidocaine hydrochloride</b>		RESTRICTED Paediatrics. Intra-urethral steroid ointment
<i>Nefluan</i> ® 10g gel	MMC 	

## Section 16: Miscellaneous

Supported by the  
formulary ([click here](#))



### 16.1 Organ Perfusion Fluids

16.1.1 Cardiac Perfusion Fluids

16.1.2 Kidney / Pancreas / Liver perfusion fluids

16.1.3 Contrast Agents

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

## GMMMG Formulary

Formulary Homepage  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#) Drug List

## 16.1 Organ Perfusion fluids

### 16.1.1 Cardiac perfusion fluids

Aspartate / Glutamate solution



100mL

MMC

Bretschneiders Histidine-Tryptophan-Ketoglutarate (HTK)

*Custodiol Cardioplegia*® solution (1000mL)

MMC

emc<sup>+</sup>

Cardioplegia in Ringer's solution



1000mL

MMC

emc<sup>+</sup>

Cardioplegic ULTH Formula A



500mL

MMC

Cardioplegic ULTH Formula B



500mL

MMC

Sterile Concentrate for Cardioplegia infusion

20mL

MMC

emc<sup>+</sup>

### 16.1.2 Kidney / Pancreas / Liver perfusion fluids

Cold Storage Solution (UW solution)

*Belzer UW*® (1000mL)

MMC

Kidney Perfusion Fluid

*Soltran*® (1000mL)

MMC

Lung Perfusion solution

*Perfadex*® (1000mL)

MMC

Machine Perfusion solution

*Belzer MPS*® UW machine perfusion solution (1000mL)

MMC

### 16.1.3 Contrast Agents

Gadobutrol

*Gadovist*® (1.0mmol/mL) injection

MMC

emc<sup>+</sup>

Gadoteric acid

*Dotarem*® (0.5mmol/mL) injection

MMC

emc<sup>+</sup>

Gadoxetic acid

*Primovist*® (0.25mmol/mL) injection

MMC

emc<sup>+</sup>

Perflutren

*Luminity*® (150microlitres/mL) lipid microspheres for injection

MMC

emc<sup>+</sup>

Sulphur hexafluoride

*SonoVue*® (8microlitre/mL) injection

MMC

emc<sup>+</sup>